PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
20919951-1	2011	Growth factor (basic fibroblast growth factor or vascular endothelial growth factor)-immobilized polycaprolactone (PCL)/Pluronic F127 porous beads were prepared as an injectable bulking agent for effective treatment of urinary incontinence.	polycaprolactone	97-113	vascular endothelial growth factor A	Homo sapiens	49-83
20919951-1	2011	Growth factor (basic fibroblast growth factor or vascular endothelial growth factor)-immobilized polycaprolactone (PCL)/Pluronic F127 porous beads were prepared as an injectable bulking agent for effective treatment of urinary incontinence.	polycaprolactone	115-118	vascular endothelial growth factor A	Homo sapiens	49-83
21248694-0	2011	Tri-layered electrospinning to mimic native arterial architecture using polycaprolactone, elastin, and collagen: a preliminary study.	polycaprolactone	72-88	tRNA-Ile (anticodon AAT) 9-1	Homo sapiens	0-3
21115281-5	2011	The initial fast releases of TGF-beta1 from different microspheres could be significantly decreased with increasing polycaprolactone content in CPCs, and some microspheres were able to maintain sustained releases of TGF-beta1 by mainly controlling their composition.	polycaprolactone	116-132	transforming growth factor beta 1	Homo sapiens	29-38
20951603-3	2011	Photosensitive scaffolds such as composite poly (3-hexylthiophene)/polycaprolactone (P3HT/PCL) nanofibers are fabricated by electrospinning process in our lab for skin regeneration in presence of applied photocurrent.	polycaprolactone	67-83	PHD finger protein 1	Homo sapiens	85-93
21250636-4	2011	This strategy, termed "shape memory assisted self-healing (SMASH)", is demonstrated in a blend system consisting of cross-linked poly(epsilon-caprolactone) network (n-PCL) with linear poly(epsilon-caprolactone) (l-PCL) interpenetrating the network, and exhibits a combination of SM response from the network component and SH capacity from the linear component.	polycaprolactone	129-155	PHD finger protein 1	Homo sapiens	167-170
20886548-1	2011	In this study, we fabricated non-woven matrices using blends of polycaprolactone and gelatin with various spinning volumes to control the immobilized heparin content, which was ultimately intended to increase the immobilization efficiency of bFGF.	polycaprolactone	64-80	fibroblast growth factor 2	Homo sapiens	242-246
20412027-5	2010	In the present study, we examined Runx2-modified BMSCs, delivered via polycaprolactone scaffolds loaded with type I collagen meshes, in critical-sized segmental defects in rats compared to unmodified cells, cell-free scaffolds, and empty defects.	polycaprolactone	70-86	RUNX family transcription factor 2	Rattus norvegicus	34-39
20656079-9	2011	Tropoelastin was subsequently incorporated into a synthetic elastin/polycaprolactone conduit with mechanical properties optimized to mimic the human internal mammary artery, including permeability, compliance, elastic modulus and burst pressure.	polycaprolactone	68-84	elastin	Homo sapiens	0-12
20656079-9	2011	Tropoelastin was subsequently incorporated into a synthetic elastin/polycaprolactone conduit with mechanical properties optimized to mimic the human internal mammary artery, including permeability, compliance, elastic modulus and burst pressure.	polycaprolactone	68-84	elastin	Homo sapiens	5-12
22114498-3	2011	METHODS: A novel PCL-Tween 80 copolymer was synthesized from e-caprolactone and Tween 80 in the presence of stannous octoate as a catalyst via ring opening polymerization.	polycaprolactone	61-75	PHD finger protein 1	Homo sapiens	17-20
22216144-7	2011	Interestingly, ESCs on the most compliant substrate, 4%PEG-86%PCL-10%CPCL, exhibited the highest alpha-MHC expression as well as the most mature Ca(2+) signaling dynamics.	polycaprolactone	62-65	myosin, heavy polypeptide 6, cardiac muscle, alpha	Mus musculus	97-106
19691971-2	2010	We have developed a novel heparinized basic fibroblast growth factor (bFGF)-incorporating tubular stent by polymer materials of poly D, L-lactic/glycolic acid (PLGA) and polycaprolactone (PCL) with preferable biocompatibility and mechanical elasticity.	polycaprolactone	170-186	fibroblast growth factor 2	Homo sapiens	38-68
19691971-2	2010	We have developed a novel heparinized basic fibroblast growth factor (bFGF)-incorporating tubular stent by polymer materials of poly D, L-lactic/glycolic acid (PLGA) and polycaprolactone (PCL) with preferable biocompatibility and mechanical elasticity.	polycaprolactone	170-186	fibroblast growth factor 2	Homo sapiens	70-74
19691971-2	2010	We have developed a novel heparinized basic fibroblast growth factor (bFGF)-incorporating tubular stent by polymer materials of poly D, L-lactic/glycolic acid (PLGA) and polycaprolactone (PCL) with preferable biocompatibility and mechanical elasticity.	polycaprolactone	188-191	fibroblast growth factor 2	Homo sapiens	38-68
19691971-2	2010	We have developed a novel heparinized basic fibroblast growth factor (bFGF)-incorporating tubular stent by polymer materials of poly D, L-lactic/glycolic acid (PLGA) and polycaprolactone (PCL) with preferable biocompatibility and mechanical elasticity.	polycaprolactone	188-191	fibroblast growth factor 2	Homo sapiens	70-74
20133067-9	2010	Extracapsular extension status was associated with the highest hazard ratio, 3.04; 5-year PSA relapse rates were 7% for no ECE, 20% for unilateral ECE, and 48% for bilateral ECE.	polycaprolactone	123-126	kallikrein related peptidase 3	Homo sapiens	90-93
20933540-2	2011	Firstly, amino-remained chitosan-graft-poly (e-caprolactone) (CS-g-PCL) was synthesized with a facile one-step manner by grafting e-caprolactone oligomers onto the hydroxyl groups of CS via ring-opening polymerization by using methanesulfonic acid as solvent and catalyst.	polycaprolactone	45-59	polycystic kidney disease 2-like 1	Mus musculus	67-70
21499434-2	2011	In the present study, cationic chitosan-graft-poly(e-caprolactone)/polycaprolactone (CS-PCL/PCL) hybrid scaffolds were successfully prepared by electrospinning.	polycaprolactone	67-83	polycystic kidney disease 2-like 1	Mus musculus	85-95
22073379-2	2011	We report the electrospinning of Poly(epsilon-caprolactone) (PCL) to form a 3-dimensional scaffold for use as a synthetic BGS.	polycaprolactone	33-59	PHD finger protein 1	Homo sapiens	61-64
21076184-2	2010	In this study we have prepared and evaluated porous poly(epsilon-caprolactone) (PCL) integrated with fibrin composite (FC) to get a biomimetic hybrid scaffold (FC PCL) with the biological properties of fibrin, fibronectin (FN), gelatin, growth factors and glycosaminoglycans.	polycaprolactone	80-83	fibronectin 1	Homo sapiens	210-221
21076184-2	2010	In this study we have prepared and evaluated porous poly(epsilon-caprolactone) (PCL) integrated with fibrin composite (FC) to get a biomimetic hybrid scaffold (FC PCL) with the biological properties of fibrin, fibronectin (FN), gelatin, growth factors and glycosaminoglycans.	polycaprolactone	80-83	fibronectin 1	Homo sapiens	223-225
20560772-0	2010	Chemically-conjugated bone morphogenetic protein-2 on three-dimensional polycaprolactone scaffolds stimulates osteogenic activity in bone marrow stromal cells.	polycaprolactone	72-88	bone morphogenetic protein 2	Homo sapiens	22-50
20560772-6	2010	Conjugated BMP-2 release from the PCL scaffolds was significantly slower than that from BMP-2-adsorbed PCL scaffolds over 15 days, which resulted in more BMP-2 locally retained on the conjugated scaffold.	polycaprolactone	34-37	bone morphogenetic protein 2	Homo sapiens	11-16
20560772-8	2010	Finally, gene expression of osteogenic markers (alkaline phosphatase, osteoclacin, and type I collagen) was upregulated in bone marrow stromal cells cultured on the PCL scaffolds with BMP-2 conjugation, but not on PCL scaffolds after BMP-2 adsorption.	polycaprolactone	165-168	bone morphogenetic protein 2	Homo sapiens	184-189
20560772-8	2010	Finally, gene expression of osteogenic markers (alkaline phosphatase, osteoclacin, and type I collagen) was upregulated in bone marrow stromal cells cultured on the PCL scaffolds with BMP-2 conjugation, but not on PCL scaffolds after BMP-2 adsorption.	polycaprolactone	165-168	bone morphogenetic protein 2	Homo sapiens	234-239
20542561-2	2010	Hence, we have functionalized polycaprolactone (PCL) films by peptides derived from the bone sialoprotein containing RGD sequence (pRGD), to increase their ability to interact with murine MC3T3-E1 preosteoblasts, and favour cell response to recombinant human bone morphogenetic protein-2 (rhBMP-2).	polycaprolactone	30-46	bone morphogenetic protein 2	Homo sapiens	259-287
20542561-2	2010	Hence, we have functionalized polycaprolactone (PCL) films by peptides derived from the bone sialoprotein containing RGD sequence (pRGD), to increase their ability to interact with murine MC3T3-E1 preosteoblasts, and favour cell response to recombinant human bone morphogenetic protein-2 (rhBMP-2).	polycaprolactone	48-51	bone morphogenetic protein 2	Homo sapiens	259-287
19913115-1	2010	This paper describes a study on the preparation and characterisation of partially biodegradable microparticles of poly(epsilon-caprolactone)/poly(ethyl methacrylate) (PCL/PEMA) as carriers of synthetic glycolipids with antimitotic activity against brain tumour cells.	polycaprolactone	114-140	PHD finger protein 1	Homo sapiens	167-170
20144913-6	2010	In terms of the endothelial cells grown on CDHA-PCL nanocomposites with 24% PCL, an increased expression of the endothelial marker vWF compared to CDHA-PCL with 11% PCL was observed in real-time polymerase chain reaction analysis.	polycaprolactone	48-51	von Willebrand factor	Homo sapiens	131-134
20144913-6	2010	In terms of the endothelial cells grown on CDHA-PCL nanocomposites with 24% PCL, an increased expression of the endothelial marker vWF compared to CDHA-PCL with 11% PCL was observed in real-time polymerase chain reaction analysis.	polycaprolactone	76-79	von Willebrand factor	Homo sapiens	131-134
20214450-9	2010	Our results suggest that CD34 antibody conjugation significantly improved the hemocompatibility of PAAc-conjugated PCL.	polycaprolactone	115-118	CD34 molecule	Homo sapiens	25-29
20422025-7	2010	Poly-epsilon-caprolactone nanoparticles (PCL-NPs) were used to incorporate anandamide, which could thus enter the cell and activate TRPV1 channels bypassing any possible specific protein(s) involved in the uptake process.	polycaprolactone	0-25	transient receptor potential cation channel subfamily V member 1	Homo sapiens	132-137
20615294-1	2010	The effect of molecular weight on the thermal degradation of poly(epsilon-caprolactone) (PCL) was investigated by thermogravimetric analysis in combination with differential thermal analysis and Fourier transform infrared spectroscopy (TGA/DTA/FT-IR).	polycaprolactone	61-87	T-box transcription factor 1	Homo sapiens	236-239
20615294-1	2010	The effect of molecular weight on the thermal degradation of poly(epsilon-caprolactone) (PCL) was investigated by thermogravimetric analysis in combination with differential thermal analysis and Fourier transform infrared spectroscopy (TGA/DTA/FT-IR).	polycaprolactone	89-92	T-box transcription factor 1	Homo sapiens	236-239
20034769-1	2010	In this work, porous poly(epsilon-caprolactone) (PCL)/Eudragit RS 100 (ERS-100) microcapsules containing tulobuterol base as a model drug were prepared by a solvent evaporation method and the effect of the quaternary ammonium groups of ERS-100 on the release behaviors of the microcapsules was investigated.	polycaprolactone	21-47	PHD finger protein 1	Homo sapiens	49-52
20129661-0	2010	The effects of Runx2 immobilization on poly (epsilon-caprolactone) on osteoblast differentiation of bone marrow stromal cells in vitro.	polycaprolactone	39-66	RUNX family transcription factor 2	Homo sapiens	15-20
20047821-2	2010	In particular, cationic chitosan-graft-polycaprolactone (CS-g-PCL) copolymers were synthesized with a facile one-pot manner via ring-opening polymerization of epsilon-CL onto the hydroxyl groups of CS by using methanesulfonic acid as solvent and catalyst.	polycaprolactone	39-55	polycystic kidney disease 2-like 1	Mus musculus	62-65
19756968-1	2010	The objective of this study was to improve the efficacy of polycaprolactone/bioglass (PCL/BG) bone substitute using demineralized bone matrix (DBM) or calcium sulfate (CS) as a third component.	polycaprolactone	59-75	PHD finger protein 1	Homo sapiens	86-89
19353561-7	2010	Acute monocyte interaction with scaffolds of PCL (120 mg/mL) resulted in the lowest amount of TF expressed (4 ng/disc), whereas scaffolds of 160 mg/mL PDO elicited the highest amount of TF expressed (51 ng/disc).	polycaprolactone	45-48	coagulation factor III, tissue factor	Homo sapiens	94-96
19353561-7	2010	Acute monocyte interaction with scaffolds of PCL (120 mg/mL) resulted in the lowest amount of TF expressed (4 ng/disc), whereas scaffolds of 160 mg/mL PDO elicited the highest amount of TF expressed (51 ng/disc).	polycaprolactone	45-48	coagulation factor III, tissue factor	Homo sapiens	186-188
19878025-1	2009	OBJECTIVE: To determine elution characteristics of bone morphogenetic protein (BMP)-2 from a polycaprolactone coating applied to orthopedic implants and determine effects of this coating on osseointegration.	polycaprolactone	93-109	BMP2	Ovis aries	51-85
19557487-0	2009	Starch-poly-epsilon-caprolactone microparticles reduce the needed amount of BMP-2.	polycaprolactone	7-32	bone morphogenetic protein 2	Homo sapiens	76-81
19557487-2	2009	We developed and tested a novel injectable drug delivery system consisting of starch-poly-epsilon-caprolactone microparticles for inducing osteogenesis and requiring smaller amounts of BMP-2.	polycaprolactone	85-110	bone morphogenetic protein 2	Homo sapiens	185-190
19919526-1	2009	In this contribution, a biodegradable and injectable thermosensitive poly(ethylene glycol)-poly(epsilon-caprolactone)-poly(ethylene glycol) (PEG-PCL-PEG, PECE) hydrogel system was successfully prepared for basic fibroblastic growth factor (bFGF) antigen delivery.	polycaprolactone	91-117	fibroblast growth factor 2	Homo sapiens	206-238
19919526-1	2009	In this contribution, a biodegradable and injectable thermosensitive poly(ethylene glycol)-poly(epsilon-caprolactone)-poly(ethylene glycol) (PEG-PCL-PEG, PECE) hydrogel system was successfully prepared for basic fibroblastic growth factor (bFGF) antigen delivery.	polycaprolactone	91-117	fibroblast growth factor 2	Homo sapiens	240-244
19878025-3	2009	PROCEDURES: An in vitro study was conducted to determine BMP-2 elution from polycaprolactone-coated implants.	polycaprolactone	76-92	BMP2	Ovis aries	57-62
19878025-4	2009	An in vivo study was conducted to determine the effects on osseointegration when the polycaprolactone with BMP-2 coating was applied to bone screws.	polycaprolactone	85-101	BMP2	Ovis aries	107-112
19878025-11	2009	CONCLUSIONS AND CLINICAL RELEVANCE: BMP-2 within the polycaprolactone coating did not stimulate osteogenesis.	polycaprolactone	53-69	BMP2	Ovis aries	36-41
18985781-0	2009	Effects of nerve growth factor from genipin-crosslinked gelatin in polycaprolactone conduit on peripheral nerve regeneration--in vitro and in vivo.	polycaprolactone	67-83	nerve growth factor	Rattus norvegicus	11-30
19426840-9	2009	The levels of both alkaline phosphatase activity and osteocalcin were found to be higher in the coated PCL nanofibers than in the uncoated PCL nanofibers, indicating that biomimetic calcium phosphate on PCL nanofibers supports osteoblastic differentiation.	polycaprolactone	103-106	bone gamma-carboxyglutamate protein	Homo sapiens	53-64
19743842-4	2009	Incorporation of chitosan in PCL nanofibers not only improved the adhesion and proliferation of MC 3T3-E1 cells but also elevated calcium deposition, alkaline phosphatase (ALP) activity, and the expression of osteopontin (OPN) compared to PCL alone nanofibers.	polycaprolactone	239-242	secreted phosphoprotein 1	Mus musculus	209-220
19736995-1	2009	Biodegradable poly(epsilon-caprolactone)/poly(ethylene glycol) (PCL/PEG) copolymer nanoparticles showed potential application in drug delivery systems.	polycaprolactone	14-40	polycystic kidney disease 2-like 1	Mus musculus	64-67
19736995-2	2009	In this article, monodisperse poly(epsilon-caprolactone)/poly(ethylene glycol)/poly(epsilon-caprolactone) (PCL/PEG/PCL, PCEC) nanoparticles, approximately 40 nm, were prepared by solvent extraction method using acetone as the organic solvent.	polycaprolactone	30-56	polycystic kidney disease 2-like 1	Mus musculus	107-110
19736995-2	2009	In this article, monodisperse poly(epsilon-caprolactone)/poly(ethylene glycol)/poly(epsilon-caprolactone) (PCL/PEG/PCL, PCEC) nanoparticles, approximately 40 nm, were prepared by solvent extraction method using acetone as the organic solvent.	polycaprolactone	79-105	polycystic kidney disease 2-like 1	Mus musculus	107-110
19269907-2	2009	The change in the ratio of CO/C-O bonds is a significant factor influencing the wettability of PCL.	polycaprolactone	95-98	DAN domain BMP antagonist family member 5	Homo sapiens	27-33
18563819-6	2009	The n-CS/PCL composites exhibit excellent in vitro bioactivity, with surface apatite formation for 40% (w/w) n-CS (C40) exceeding that of 20% (w/w) n-CS (C20) at 7 and 14 days.	polycaprolactone	9-12	CCR4-NOT transcription complex, subunit 11	Mus musculus	115-118
19491030-1	2009	Microporous polycaprolactone (PCL) matrices containing lysozyme, collagenase and catalase respectively with molecular weight covering a wide range from 14.3 to 240kDa were produced by a novel method involving rapid cooling of particle suspensions in dry ice.	polycaprolactone	12-28	catalase	Homo sapiens	81-89
19491030-1	2009	Microporous polycaprolactone (PCL) matrices containing lysozyme, collagenase and catalase respectively with molecular weight covering a wide range from 14.3 to 240kDa were produced by a novel method involving rapid cooling of particle suspensions in dry ice.	polycaprolactone	30-33	catalase	Homo sapiens	81-89
18977026-2	2009	OEC cultured on starch polycaprolactone fiber meshes (SPCL) in monoculture retained their endothelial functionality and responded to angiogenic stimulation by VEGF (vascular endothelial growth factor) in fibrin gel-assays in vitro.	polycaprolactone	23-39	vascular endothelial growth factor A	Homo sapiens	159-163
19319413-1	2009	Highly crystalline directional poly(epsilon-caprolactone) based on a tetrahydroxymethyl resorcin[4]arene initiator core was synthesized by a "core first" method via ring-opening polymerization catalyzed by Sn(Oct)(2) in bulk at 120 degrees C.	polycaprolactone	31-56	plexin A2	Homo sapiens	209-212
18925830-0	2009	The effect of pulse-released nerve growth factor from genipin-crosslinked gelatin in schwann cell-seeded polycaprolactone conduits on large-gap peripheral nerve regeneration.	polycaprolactone	105-121	nerve growth factor	Rattus norvegicus	29-48
19249261-3	2009	This work, for the first time, reports the use of polyurethane/polycaprolactone (PU/PCL) blend as a proposed material for shape memory stents.	polycaprolactone	63-79	PHD finger protein 1	Homo sapiens	84-87
19339628-5	2009	EPC were cultured on fibronectin-coated supramolecular films of oligocaprolactone under angiogenic conditions to determine their angiogenic capacity and future use in regenerative medicine.	polycaprolactone	64-81	fibronectin 1	Homo sapiens	21-32
19337085-10	2009	BMP-2 was released from polycaprolactone over 2 weeks, with 86 percent remaining covalently bound, in contrast to 93 percent retained by poly(lactic-co-glycolic acid).	polycaprolactone	24-40	bone morphogenetic protein 2	Mus musculus	0-5
18977026-2	2009	OEC cultured on starch polycaprolactone fiber meshes (SPCL) in monoculture retained their endothelial functionality and responded to angiogenic stimulation by VEGF (vascular endothelial growth factor) in fibrin gel-assays in vitro.	polycaprolactone	23-39	vascular endothelial growth factor A	Homo sapiens	165-199
19209424-1	2009	This work deals with the self-assembly in water of ABC miktoarm star terpolymers consisting of hydrophobic poly(-caprolactone), hydrophilic poly(ethylene oxide) (PEO), and pH-sensitive poly(2-vinylpyridine) (P2VP).	polycaprolactone	107-126	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	51-54
18721077-0	2009	The role of lipase and alpha-amylase in the degradation of starch/poly(epsilon-caprolactone) fiber meshes and the osteogenic differentiation of cultured marrow stromal cells.	polycaprolactone	66-92	lipase G, endothelial type	Rattus norvegicus	12-18
18318528-2	2008	The PPR macroinitiator for ATRP was prepared by the inclusion complexation of biodegradable poly(epsilon-caprolactone) (PCL) with alpha-cyclodextrin (alpha-CD), in which the crystalline PCL segments were included into the hydrophobic alpha-CD cavities and their crystallization was completely suppressed.	polycaprolactone	92-118	PPR1	Homo sapiens	4-7
17969029-1	2008	Nonwoven poly(epsilon-caprolactone) (PCL) nanofibers were prepared by electrospinning technology, and a novel natural bioactive material, soluble eggshell membrane protein (SEP), which is made from natural eggshell membrane (ESM), was then immobilized on the nanofibers after the surface modification.	polycaprolactone	37-40	membrane metalloendopeptidase like 1	Homo sapiens	173-176
18604988-1	2008	A novel polymeric micellar formulation of paclitaxel (PTX) with Pluronic/poly(caprolactone) (P105/ PCL50) has been developed with the purpose of improving in vitro release and in vivo circulating time of PTX in comparison to the current Taxol injection.	polycaprolactone	73-91	nucleoporin 107	Rattus norvegicus	93-97
18537206-1	2008	Adaptive and amphiphilic poly(N,N-dimethylamino-2-ethyl methacrylate-graft-poly[epsilon-caprolactone]) co-networks (netP(DMAEMA-g-PCL)) were synthesized from a combination of controlled polymerization techniques.	polycaprolactone	75-102	PHD finger protein 1	Homo sapiens	130-133
18364565-2	2008	To mimic its structure and surface properties, soluble eggshell membrane protein (SEP) was extracted from ESM and electrospun with a biodegradable polymer, poly(epsilon-caprolactone) (PCL).	polycaprolactone	156-182	membrane metalloendopeptidase like 1	Homo sapiens	47-80
18364565-2	2008	To mimic its structure and surface properties, soluble eggshell membrane protein (SEP) was extracted from ESM and electrospun with a biodegradable polymer, poly(epsilon-caprolactone) (PCL).	polycaprolactone	156-182	membrane metalloendopeptidase like 1	Homo sapiens	82-85
18364565-2	2008	To mimic its structure and surface properties, soluble eggshell membrane protein (SEP) was extracted from ESM and electrospun with a biodegradable polymer, poly(epsilon-caprolactone) (PCL).	polycaprolactone	184-187	membrane metalloendopeptidase like 1	Homo sapiens	47-80
18364565-2	2008	To mimic its structure and surface properties, soluble eggshell membrane protein (SEP) was extracted from ESM and electrospun with a biodegradable polymer, poly(epsilon-caprolactone) (PCL).	polycaprolactone	184-187	membrane metalloendopeptidase like 1	Homo sapiens	82-85
18364565-5	2008	The SEP/PCL web, which demonstrated the feasibility of producing a scaffold with adequate hydrophilicity, suitable pore size and good mechanical properties compared to a pure PCL micro/nanofiber web, exhibits the ability to mimic a natural biomaterial.	polycaprolactone	8-11	membrane metalloendopeptidase like 1	Homo sapiens	4-7
17665113-0	2008	Encapsulation and controlled release of lysozyme from electrospun poly(epsilon-caprolactone)/poly(ethylene glycol) non-woven membranes by formation of lysozyme-oleate complexes.	polycaprolactone	66-92	lysozyme	Homo sapiens	40-48
17665113-1	2008	In this study, the concept of hydrophobic ion pairing was adopted for incorporating lysozyme into electrospun poly(epsilon-caprolactone) (PCL)/poly(ethylene glycol) (PEG) non-woven membranes.	polycaprolactone	110-136	lysozyme	Homo sapiens	84-92
17665113-1	2008	In this study, the concept of hydrophobic ion pairing was adopted for incorporating lysozyme into electrospun poly(epsilon-caprolactone) (PCL)/poly(ethylene glycol) (PEG) non-woven membranes.	polycaprolactone	138-141	lysozyme	Homo sapiens	84-92
17665113-2	2008	The solubility of lysozyme in organic solvent was enhanced through the formation of lysozyme-oleate complexes, which could be directly loaded into PCL/PEG membranes using electrospinning technique.	polycaprolactone	147-150	lysozyme	Homo sapiens	18-26
17665113-2	2008	The solubility of lysozyme in organic solvent was enhanced through the formation of lysozyme-oleate complexes, which could be directly loaded into PCL/PEG membranes using electrospinning technique.	polycaprolactone	147-150	lysozyme	Homo sapiens	84-92
17665113-4	2008	The addition of PEG into the PCL nanofibers not only improved the hydrophilicity of the membrane, but also played an important role on in vitro lysozyme release rate.	polycaprolactone	29-32	lysozyme	Homo sapiens	144-152
17127222-1	2006	A polymeric micro- and nanosphere formulation using poly (epsilon-caprolactone) (PCL) to entrap an antituberculosis drug, isoniazid (INH), was developed and characterized.	polycaprolactone	52-79	PHD finger protein 1	Homo sapiens	81-84
17429811-1	2007	Poly(epsilon-caprolactone) (PCL) macromers (M(n) = 1.7-3.8 kDa) which contain one Z-protected -NH2 group per chain were synthesized by ring-opening polymerization of epsilon-caprolactone in the presence of Sn(oct)2 using as initiator a diamine prepared by condensation of N-Boc-1,6-hexanediamine and N(alpha)-Boc-N(epsilon)-Z-L-Lysine.	polycaprolactone	0-26	POU class 2 homeobox 2	Homo sapiens	206-214
17429811-1	2007	Poly(epsilon-caprolactone) (PCL) macromers (M(n) = 1.7-3.8 kDa) which contain one Z-protected -NH2 group per chain were synthesized by ring-opening polymerization of epsilon-caprolactone in the presence of Sn(oct)2 using as initiator a diamine prepared by condensation of N-Boc-1,6-hexanediamine and N(alpha)-Boc-N(epsilon)-Z-L-Lysine.	polycaprolactone	28-31	POU class 2 homeobox 2	Homo sapiens	206-214
17546428-1	2007	In the present study, the synthesis of a semi-Interpenetrating Polymer Network (semi-IPN) incorporating linear poly-(epsilon-caprolactone) (PCL) into cross-linked poly-(2-hydroxyethylmethacrilate) (PHEMA) reinforced with hydroxyapatite (HA) has been described.	polycaprolactone	111-138	PHD finger protein 1	Homo sapiens	140-143
17250702-0	2007	Intradermal immunization with ovalbumin-loaded poly-epsilon-caprolactone microparticles conferred protection in ovalbumin-sensitized allergic mice.	polycaprolactone	47-72	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	30-39
17250702-0	2007	Intradermal immunization with ovalbumin-loaded poly-epsilon-caprolactone microparticles conferred protection in ovalbumin-sensitized allergic mice.	polycaprolactone	47-72	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	112-121
17250702-3	2007	OBJECTIVE: The aim of this work was to evaluate the properties of poly-epsilon-caprolactone (PCL) microparticles as adjuvants in immunotherapy using ovalbumin (OVA) as an allergen model.	polycaprolactone	66-91	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	149-158
17250702-3	2007	OBJECTIVE: The aim of this work was to evaluate the properties of poly-epsilon-caprolactone (PCL) microparticles as adjuvants in immunotherapy using ovalbumin (OVA) as an allergen model.	polycaprolactone	93-96	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	149-158
16969696-1	2006	PURPOSE: This study aims at developing poly(ethylene oxide)-modified poly(epsilon-caprolactone) (PEO-PCL) nanoparticulate system as an intracellular delivery vehicle for saquinavir, an anti-HIV protease inhibitor.	polycaprolactone	69-95	twinkle mtDNA helicase	Homo sapiens	97-100
18085511-8	2008	According to these results, ester bonds seem to be most sensitive to enzymatic degradation and, correspondingly, pancreatic lipase seems to be mainly responsible for the enzymatic erosion of the PCL-O films.	polycaprolactone	195-200	pancreatic lipase	Homo sapiens	113-130
17567860-4	2007	In this study, we show that the gene expression of PMN chemoattractants, CXCL1/KC and CXCL2/MIP-2, is high in GCs micro-dissected from explanted Dacron, cross-linked collagen (HDSC), and bioactive ureido-pyrimidinone functionalized oligocaprolactone (bioactive PCLdiUPy).	polycaprolactone	232-249	C-X-C motif chemokine ligand 1	Rattus norvegicus	73-78
17567860-4	2007	In this study, we show that the gene expression of PMN chemoattractants, CXCL1/KC and CXCL2/MIP-2, is high in GCs micro-dissected from explanted Dacron, cross-linked collagen (HDSC), and bioactive ureido-pyrimidinone functionalized oligocaprolactone (bioactive PCLdiUPy).	polycaprolactone	232-249	C-X-C motif chemokine ligand 2	Rattus norvegicus	86-91
17503493-5	2007	Pure polycaprolactone (PCL)-poly(ethylene glycol) (PEG)-PCL copolymer, P(100/0), was a crystalline material displaying no measurable mass loss, a 30% reduction in mean molecular weight (Mn), and only very slight changes in tensile strength.	polycaprolactone	5-21	2'-5'-oligoadenylate synthetase 3	Homo sapiens	71-78
17503493-5	2007	Pure polycaprolactone (PCL)-poly(ethylene glycol) (PEG)-PCL copolymer, P(100/0), was a crystalline material displaying no measurable mass loss, a 30% reduction in mean molecular weight (Mn), and only very slight changes in tensile strength.	polycaprolactone	23-26	2'-5'-oligoadenylate synthetase 3	Homo sapiens	71-78
17961003-0	2007	Cell guidance in tissue engineering: SDF-1 mediates site-directed homing of mesenchymal stem cells within three-dimensional polycaprolactone scaffolds.	polycaprolactone	124-140	C-X-C motif chemokine ligand 12	Rattus norvegicus	37-42
17961003-4	2007	In a subsequent three-dimensional in vitro study, MSCs were shown to migrate within a polycaprolactone scaffold in response to SDF-1, such that polarized tissue formation could be achieved.	polycaprolactone	86-102	C-X-C motif chemokine ligand 12	Rattus norvegicus	127-132
17385234-1	2007	The novel biodegradable poly(epsilon-caprolactone)/titanium dioxide hybrid materials were prepared via in situ sol-gel process of tetrabutyl titanate (TBT) as inorganic precursor in the presence of PCL.	polycaprolactone	24-50	PHD finger protein 1	Homo sapiens	198-201
17655492-7	2007	PCL induced a lower inflammatory response than PLGA, as demonstrated by lower MHC-II and GFAP expression and greater ingrowth.	polycaprolactone	0-3	glial fibrillary acidic protein	Rattus norvegicus	89-93
17497389-2	2007	The primary objective was to optimize bovine serum albumin (BSA) loaded polycaprolactone/maltodextrin (PCL/MD) microparticles in terms of its size and the hydrodynamic diameter of the released protein.	polycaprolactone	72-88	albumin	Homo sapiens	45-58
17497389-2	2007	The primary objective was to optimize bovine serum albumin (BSA) loaded polycaprolactone/maltodextrin (PCL/MD) microparticles in terms of its size and the hydrodynamic diameter of the released protein.	polycaprolactone	72-88	PHD finger protein 1	Homo sapiens	103-106
17042541-1	2006	Self-assembly of poly(ethylene oxide)-block-poly(epsilon-caprolactone) five-arm stars (PEO-b-PCL) was studied at the air/water (A/W) interface.	polycaprolactone	43-69	PHD finger protein 1	Homo sapiens	93-96
16932857-1	2006	A combination of bi-axial machining and lamination was used to fabricate macrochanneled poly (epsilon-caprolactone) (PCL)/hydroxyapatite (HA) scaffolds.	polycaprolactone	88-115	PHD finger protein 1	Homo sapiens	117-120
16969757-3	2006	A novel method given in this paper was to coat a porous layer of poly (epsilon-caprolactone) (PCL) on the outside of a poly (glycolic-co-lactic acid) (PGLA with GA:LA=90:10) fiber braided tube to give a PCL-PGLA composite.	polycaprolactone	65-92	PHD finger protein 1	Homo sapiens	94-97
16969757-3	2006	A novel method given in this paper was to coat a porous layer of poly (epsilon-caprolactone) (PCL) on the outside of a poly (glycolic-co-lactic acid) (PGLA with GA:LA=90:10) fiber braided tube to give a PCL-PGLA composite.	polycaprolactone	65-92	PHD finger protein 1	Homo sapiens	203-206
16874679-0	2006	In vitro bioactivity of poly(epsilon-caprolactone)-apatite (PCL-AP) scaffolds for bone tissue engineering: the influence of the PCL/AP ratio.	polycaprolactone	24-50	PHD finger protein 1	Homo sapiens	60-63
16874679-1	2006	Porous poly(epsilon-caprolactone) (PCL) is used as long-term bioresorbable scaffold for bone tissue engineering.	polycaprolactone	7-33	PHD finger protein 1	Homo sapiens	35-38
16413177-1	2006	The biodegradable poly(butylene succinate)/poly(epsilon-caprolactone) (PBS/PCL) microcapsules containing indomethacin were prepared by emulsion solvent evaporation method.	polycaprolactone	43-69	PHD finger protein 1	Homo sapiens	75-78
15357427-1	2004	A technique based on release of the human atrial natriuretic peptide (hANP) from plasmid hANP cDNA transfected Chinese hamster ovary (CHO) cells encapsulated in polycaprolactone (PCL)-capsules was used for a potential therapeutic approach to hypertension or congestive heart failure (CHF).	polycaprolactone	161-177	natriuretic peptide A	Homo sapiens	70-74
16186753-8	2005	Conversely, Resilon and polycaprolactone exhibited extensive surface thinning and weight losses after incubation in lipase PS and cholesterol esterase.	polycaprolactone	24-40	carboxyl ester lipase	Homo sapiens	130-150
16019904-1	2005	Felodipine-loaded poly (epsilon-caprolactone) (PCL) microspheres were prepared by two methods, the conventional emulsion solvent evapouration method and the quenching method.	polycaprolactone	18-45	PHD finger protein 1	Homo sapiens	47-50
12752682-4	2003	Ovalbumin encapsulated in the poly epsilon-caprolactone microparticles was able to induce both antibody and cell-mediated immune responses.	polycaprolactone	30-55	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	0-9
15204640-4	2004	At surfactant/polymer ratio of 1/10, the SOD-retained enzymatic activities were higher (> 95%) for PLG-RG756 and PLA-R207 but relatively lower for the PCL (approximately 85%) probably due to the PCL relatively higher hydrophobicity.	polycaprolactone	154-157	superoxide dismutase 1	Homo sapiens	41-44
15204640-4	2004	At surfactant/polymer ratio of 1/10, the SOD-retained enzymatic activities were higher (> 95%) for PLG-RG756 and PLA-R207 but relatively lower for the PCL (approximately 85%) probably due to the PCL relatively higher hydrophobicity.	polycaprolactone	198-201	superoxide dismutase 1	Homo sapiens	41-44
14999747-5	2004	No significant difference between these three fluorides was observed although a general trend was seen where KF-treated PCL appeared to degrade slower than NaF-treated PCL which was slower than NH(4)F-treated PCL.	polycaprolactone	168-171	C-X-C motif chemokine ligand 8	Homo sapiens	156-159
14999747-5	2004	No significant difference between these three fluorides was observed although a general trend was seen where KF-treated PCL appeared to degrade slower than NaF-treated PCL which was slower than NH(4)F-treated PCL.	polycaprolactone	168-171	C-X-C motif chemokine ligand 8	Homo sapiens	156-159
14612345-0	2003	Microencapsulation of superoxide dismutase into poly(epsilon-caprolactone) microparticles by reverse micelle solvent evaporation.	polycaprolactone	48-74	superoxide dismutase 1	Homo sapiens	22-42
14612345-1	2003	The aim of this work was to encapsulate superoxide dismutase (SOD) in poly(epsilon-caprolactone) (PCL) microparticles by reverse micelle solvent evaporation.	polycaprolactone	70-96	superoxide dismutase 1	Homo sapiens	40-60
14612345-1	2003	The aim of this work was to encapsulate superoxide dismutase (SOD) in poly(epsilon-caprolactone) (PCL) microparticles by reverse micelle solvent evaporation.	polycaprolactone	70-96	superoxide dismutase 1	Homo sapiens	62-65
14612345-1	2003	The aim of this work was to encapsulate superoxide dismutase (SOD) in poly(epsilon-caprolactone) (PCL) microparticles by reverse micelle solvent evaporation.	polycaprolactone	98-101	superoxide dismutase 1	Homo sapiens	40-60
14612345-1	2003	The aim of this work was to encapsulate superoxide dismutase (SOD) in poly(epsilon-caprolactone) (PCL) microparticles by reverse micelle solvent evaporation.	polycaprolactone	98-101	superoxide dismutase 1	Homo sapiens	62-65
12857090-0	2003	Two-dimensional/ATR infrared correlation spectroscopic study on water diffusion in a poly(epsilon-caprolactone) matrix.	polycaprolactone	85-111	ATR serine/threonine kinase	Homo sapiens	16-19
12857090-1	2003	In the present contribution, two-dimensional ATR-FTIR spectroscopy was used to study the diffusion of water in poly(epsilon-caprolactone) (PCL).	polycaprolactone	111-137	ATR serine/threonine kinase	Homo sapiens	45-48
12857090-1	2003	In the present contribution, two-dimensional ATR-FTIR spectroscopy was used to study the diffusion of water in poly(epsilon-caprolactone) (PCL).	polycaprolactone	139-142	ATR serine/threonine kinase	Homo sapiens	45-48
12099827-5	2002	(14)C-PCL (poly-epsilon-caprolactone) was incubated with anaerobic digester sludge and in landfill reactors.	polycaprolactone	11-36	PHD finger protein 1	Homo sapiens	6-9
15348487-2	2003	In vitro evaluation of RT PLD coatings on bioresorbable polymers (Poly-epsilon-caprolactone and Poly-L-lactide) have been carried out.	polycaprolactone	66-91	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	26-29
12433441-1	2002	To increase the local concentration of tamoxifen in estrogen receptor (ER) positive breast cancer, we have developed and characterized nanoparticle formulation using poly(epsilon -caprolactone) (PCL).	polycaprolactone	195-198	estrogen receptor 1	Homo sapiens	71-73
11749195-1	2001	Poly(epsilon-caprolactone), PCL, is a commercial biodegradable and biocompatible polyester that can be bioassimilated by outdoor microorganisms.	polycaprolactone	0-26	PHD finger protein 1	Homo sapiens	28-31
12115846-1	2002	Amphiphilic triblock copolymers, poly(epsilon-caprolactone)-poly(ethylene oxide)-poly(epsilon-caprolactone) (PCL-PEO-PCL), were synthesized by ring opening polymerization of epsilon-caprolactone initiated with the hydroxyl functional groups of poly(ethylene glycol) at both ends of the chain.	polycaprolactone	33-59	PHD finger protein 1	Homo sapiens	109-112
12115846-1	2002	Amphiphilic triblock copolymers, poly(epsilon-caprolactone)-poly(ethylene oxide)-poly(epsilon-caprolactone) (PCL-PEO-PCL), were synthesized by ring opening polymerization of epsilon-caprolactone initiated with the hydroxyl functional groups of poly(ethylene glycol) at both ends of the chain.	polycaprolactone	33-59	PHD finger protein 1	Homo sapiens	117-120
12115846-1	2002	Amphiphilic triblock copolymers, poly(epsilon-caprolactone)-poly(ethylene oxide)-poly(epsilon-caprolactone) (PCL-PEO-PCL), were synthesized by ring opening polymerization of epsilon-caprolactone initiated with the hydroxyl functional groups of poly(ethylene glycol) at both ends of the chain.	polycaprolactone	81-107	PHD finger protein 1	Homo sapiens	109-112
12115846-1	2002	Amphiphilic triblock copolymers, poly(epsilon-caprolactone)-poly(ethylene oxide)-poly(epsilon-caprolactone) (PCL-PEO-PCL), were synthesized by ring opening polymerization of epsilon-caprolactone initiated with the hydroxyl functional groups of poly(ethylene glycol) at both ends of the chain.	polycaprolactone	81-107	PHD finger protein 1	Homo sapiens	117-120
11829448-3	2002	Poly(epsilon-caprolactone) discs were first coated with fibronectin and then tTG.	polycaprolactone	0-26	fibronectin 1	Homo sapiens	56-67
11829448-3	2002	Poly(epsilon-caprolactone) discs were first coated with fibronectin and then tTG.	polycaprolactone	0-26	transglutaminase 2	Homo sapiens	77-80
11777394-1	2001	Silyl ether-coupled poly(epsilon-caprolactone)s (PCLs) with stepwise degradation profiles were synthesized via the cross-dehydrocoupling polymerizations between 1,4-bis(dimethylsilyl)benzene (BDSB) and telechelic, diol-terminated PCL macromonomers.	polycaprolactone	20-46	PHD finger protein 1	Homo sapiens	49-52
11093190-2	2001	We investigated whether tTgase enhances the biological recognition of poly (DL lactide co-glycolide) (PLG), poly (epsilon-caprolactone) (PCL), and poly (L lactide) (PLA), biomaterials widely used in medical implants.	polycaprolactone	108-135	transglutaminase 2	Homo sapiens	24-30
10499839-2	1999	The aim of this work was to optimize protein entrapment in pure poly(epsilon-caprolactone) (PCL) microparticles (MP) using the (water-in-oil)-in water solvent evaporation technique and bovine serum albumin (BSA) as drug model.	polycaprolactone	92-95	albumin	Homo sapiens	192-205
11211818-1	2000	Four observation indexes were selected to evaluate the biocompatibility and toxicology of biodegradable materials poly(epsilon-caprolactone)(PCL), which is synthesized in our laboratory using Ti(OBu)4 as an initiator.	polycaprolactone	114-140	PHD finger protein 1	Homo sapiens	141-144
11709839-3	2000	The degradation of poly(epsilon-caprolactone) took place using Candida antarctica lipase as catalyst in toluene at 60 degrees C to give oligomers with molecular weight of less than 500.	polycaprolactone	19-45	PAN0_003d1715	Moesziomyces antarcticus	82-88
9307220-2	1997	In the present work, we analysed the interaction phenomenon between lysozyme (LZM), a positively charged enzyme that is highly concentrated in mucosas, and two different drug carriers: nanocapsules made of an oily core coated by the polymer poly-epsilon-caprolactone (PECL) and nanoparticles made solely of PECL.	polycaprolactone	241-266	lysozyme	Homo sapiens	68-76
9860170-0	1998	Adsorption of albumin, collagen, and fibronectin on the surface of poly(hydroxybutyrate-hydroxyvalerate) (PHB/HV) and of poly (epsilon-caprolactone) (PCL) films modified by an alkaline hydrolysis and of poly(ethylene terephtalate) (PET) track-etched membranes.	polycaprolactone	121-148	fibronectin 1	Homo sapiens	37-48
9307220-2	1997	In the present work, we analysed the interaction phenomenon between lysozyme (LZM), a positively charged enzyme that is highly concentrated in mucosas, and two different drug carriers: nanocapsules made of an oily core coated by the polymer poly-epsilon-caprolactone (PECL) and nanoparticles made solely of PECL.	polycaprolactone	307-311	lysozyme	Homo sapiens	68-76
9549615-0	1998	Release of bioactive human growth hormone from a biodegradable material: poly(epsilon-caprolactone).	polycaprolactone	73-99	growth hormone 1	Homo sapiens	27-41
9549615-1	1998	We have characterized the biodegradable material poly(epsilon-caprolactone) (PCL) as a delivery system for recombinant human growth hormone (hGH).	polycaprolactone	49-75	growth hormone 1	Homo sapiens	125-139
9549615-1	1998	We have characterized the biodegradable material poly(epsilon-caprolactone) (PCL) as a delivery system for recombinant human growth hormone (hGH).	polycaprolactone	77-80	growth hormone 1	Homo sapiens	125-139
9307220-2	1997	In the present work, we analysed the interaction phenomenon between lysozyme (LZM), a positively charged enzyme that is highly concentrated in mucosas, and two different drug carriers: nanocapsules made of an oily core coated by the polymer poly-epsilon-caprolactone (PECL) and nanoparticles made solely of PECL.	polycaprolactone	307-311	lysozyme	Homo sapiens	78-81
9307220-2	1997	In the present work, we analysed the interaction phenomenon between lysozyme (LZM), a positively charged enzyme that is highly concentrated in mucosas, and two different drug carriers: nanocapsules made of an oily core coated by the polymer poly-epsilon-caprolactone (PECL) and nanoparticles made solely of PECL.	polycaprolactone	241-266	lysozyme	Homo sapiens	78-81
9307220-2	1997	In the present work, we analysed the interaction phenomenon between lysozyme (LZM), a positively charged enzyme that is highly concentrated in mucosas, and two different drug carriers: nanocapsules made of an oily core coated by the polymer poly-epsilon-caprolactone (PECL) and nanoparticles made solely of PECL.	polycaprolactone	268-272	lysozyme	Homo sapiens	68-76
9307220-2	1997	In the present work, we analysed the interaction phenomenon between lysozyme (LZM), a positively charged enzyme that is highly concentrated in mucosas, and two different drug carriers: nanocapsules made of an oily core coated by the polymer poly-epsilon-caprolactone (PECL) and nanoparticles made solely of PECL.	polycaprolactone	268-272	lysozyme	Homo sapiens	78-81
33971092-4	2021	This hybrid scaffold, composed of BMP-2-loaded cryoelectrospun poly(epsilon-caprolactone) (PCL) (CE) surrounded by a macroporous gelatin/heparin cryogel (GH), is designed to overcome the drawbacks of the relatively weak mechanical properties of cryogels and poor biocompatibility and hydrophobicity of electrospun PCL.	polycaprolactone	63-89	bone morphogenetic protein 2	Homo sapiens	34-39
11710174-0	2000	Lipase-catalyzed transformation of poly(epsilon-caprolactone) into cyclic dicaprolactone.	polycaprolactone	35-61	PAN0_003d1715	Moesziomyces antarcticus	0-6
33800631-2	2021	We previously demonstrated that incorporation of VEGF into electrospun tubular scaffolds from poly(3-hydroxybutyrate-co-3-hydroxyvalerate)/poly(epsilon-caprolactone) enhances formation of an endothelial cell monolayer.	polycaprolactone	139-164	vascular endothelial growth factor A	Rattus norvegicus	49-53
29027720-1	2018	Samples of polyglycolic acid PGA/polycaprolactone PCL copolymer absorbable suture materials, which is called Poliglecaprone PGC copolymer suture, were thermally treated by two different processes.	polycaprolactone	33-49	progastricsin	Homo sapiens	124-127
33812593-2	2021	In such a system, the components are miscible and interact through hydrogen bonding between the carbonyl group of PCL and the amine group of BSA, as verified by ATR-FTIR.	polycaprolactone	114-117	ataxia telangiectasia and Rad3 related	Mus musculus	161-164
29287231-2	2018	Poly(epsilon-caprolactone)/PCL is widely used in medical devices, tissue engineering, and drug delivery systems.	polycaprolactone	0-26	polycystic kidney disease 2-like 1	Mus musculus	27-30
25363620-4	2015	In the present study, we immobilized heparin onto electrospun polycaprolactone scaffolds as a means of incorporating basic fibroblast growth factor (bFGF) onto the scaffold.	polycaprolactone	62-78	fibroblast growth factor 2	Homo sapiens	117-147
25363620-4	2015	In the present study, we immobilized heparin onto electrospun polycaprolactone scaffolds as a means of incorporating basic fibroblast growth factor (bFGF) onto the scaffold.	polycaprolactone	62-78	fibroblast growth factor 2	Homo sapiens	149-153
11710174-2	2000	The enzymatic transformation of PCL having an Mn of 110,000 using Candida antarctica lipase (lipase CA) in water-containing toluene at 40 degrees C afforded the corresponding cyclic dicaprolactone (DCL, 1,8-dioxacyclotetradecane-2,9-dione) in a yield of up to 97%.	polycaprolactone	32-35	PAN0_003d1715	Moesziomyces antarcticus	85-91
11710174-2	2000	The enzymatic transformation of PCL having an Mn of 110,000 using Candida antarctica lipase (lipase CA) in water-containing toluene at 40 degrees C afforded the corresponding cyclic dicaprolactone (DCL, 1,8-dioxacyclotetradecane-2,9-dione) in a yield of up to 97%.	polycaprolactone	32-35	PAN0_003d1715	Moesziomyces antarcticus	93-99
34755744-4	2021	By loading DiR into the hydrophobic domain of folic acid-icodextrin-polycaprolactone (FA-ICO-PCL, FIP) and cisplatin-icodextrin-polycaprolactone (Pt-ICO-PCL, PtIP) co-assembly, the resultant DiR@(PtIP + FIP) (DPtFIP) NPs had a diameter of around 70 nm and showed excellent tumor targeting ability and negligible side effects.	polycaprolactone	68-84	arginine vasopressin receptor 2	Homo sapiens	11-14
34958971-11	2022	The mice implanted with the bio-mimicking M2-PCL nanofibers effectively inhibited toll like receptors signaling induced NF-kB and IRF-5 and their target genes such as Edn-1, IL-6, iNOS, TNF-alpha, etc.	polycaprolactone	45-48	interferon regulatory factor 5	Mus musculus	130-135
34958971-11	2022	The mice implanted with the bio-mimicking M2-PCL nanofibers effectively inhibited toll like receptors signaling induced NF-kB and IRF-5 and their target genes such as Edn-1, IL-6, iNOS, TNF-alpha, etc.	polycaprolactone	45-48	endothelin 1	Mus musculus	167-172
34958971-11	2022	The mice implanted with the bio-mimicking M2-PCL nanofibers effectively inhibited toll like receptors signaling induced NF-kB and IRF-5 and their target genes such as Edn-1, IL-6, iNOS, TNF-alpha, etc.	polycaprolactone	45-48	interleukin 6	Mus musculus	174-178
34958971-11	2022	The mice implanted with the bio-mimicking M2-PCL nanofibers effectively inhibited toll like receptors signaling induced NF-kB and IRF-5 and their target genes such as Edn-1, IL-6, iNOS, TNF-alpha, etc.	polycaprolactone	45-48	nitric oxide synthase 2, inducible	Mus musculus	180-184
34958971-11	2022	The mice implanted with the bio-mimicking M2-PCL nanofibers effectively inhibited toll like receptors signaling induced NF-kB and IRF-5 and their target genes such as Edn-1, IL-6, iNOS, TNF-alpha, etc.	polycaprolactone	45-48	tumor necrosis factor	Mus musculus	186-195
34938724-3	2021	We have previously shown that gelatin/polycaprolactone (GT/PCL, mass ratio 50:50) electrospun nanofibrous membranes have high potential in preventing postoperative cardiac adhesion, but the effect of GT:PCL composition on anti-adhesion efficacy was not investigated.	polycaprolactone	38-54	PHD finger protein 1	Homo sapiens	59-62
34755744-4	2021	By loading DiR into the hydrophobic domain of folic acid-icodextrin-polycaprolactone (FA-ICO-PCL, FIP) and cisplatin-icodextrin-polycaprolactone (Pt-ICO-PCL, PtIP) co-assembly, the resultant DiR@(PtIP + FIP) (DPtFIP) NPs had a diameter of around 70 nm and showed excellent tumor targeting ability and negligible side effects.	polycaprolactone	128-144	arginine vasopressin receptor 2	Homo sapiens	11-14
34755744-4	2021	By loading DiR into the hydrophobic domain of folic acid-icodextrin-polycaprolactone (FA-ICO-PCL, FIP) and cisplatin-icodextrin-polycaprolactone (Pt-ICO-PCL, PtIP) co-assembly, the resultant DiR@(PtIP + FIP) (DPtFIP) NPs had a diameter of around 70 nm and showed excellent tumor targeting ability and negligible side effects.	polycaprolactone	128-144	arginine vasopressin receptor 2	Homo sapiens	191-194
34755744-4	2021	By loading DiR into the hydrophobic domain of folic acid-icodextrin-polycaprolactone (FA-ICO-PCL, FIP) and cisplatin-icodextrin-polycaprolactone (Pt-ICO-PCL, PtIP) co-assembly, the resultant DiR@(PtIP + FIP) (DPtFIP) NPs had a diameter of around 70 nm and showed excellent tumor targeting ability and negligible side effects.	polycaprolactone	128-144	PAX interacting protein 1	Homo sapiens	196-200
34755744-4	2021	By loading DiR into the hydrophobic domain of folic acid-icodextrin-polycaprolactone (FA-ICO-PCL, FIP) and cisplatin-icodextrin-polycaprolactone (Pt-ICO-PCL, PtIP) co-assembly, the resultant DiR@(PtIP + FIP) (DPtFIP) NPs had a diameter of around 70 nm and showed excellent tumor targeting ability and negligible side effects.	polycaprolactone	128-144	upstream transcription factor 2, c-fos interacting	Homo sapiens	203-206
34993184-2	2021	We have previously reported the successful regeneration of good-quality cartilage in a nude mouse model using the electrospun gelatin/polycaprolactone (GT/PCL) nanofiber membranes.	polycaprolactone	134-150	polycystic kidney disease 2-like 1	Mus musculus	155-158
34755744-4	2021	By loading DiR into the hydrophobic domain of folic acid-icodextrin-polycaprolactone (FA-ICO-PCL, FIP) and cisplatin-icodextrin-polycaprolactone (Pt-ICO-PCL, PtIP) co-assembly, the resultant DiR@(PtIP + FIP) (DPtFIP) NPs had a diameter of around 70 nm and showed excellent tumor targeting ability and negligible side effects.	polycaprolactone	68-84	upstream transcription factor 2, c-fos interacting	Homo sapiens	98-101
34755744-4	2021	By loading DiR into the hydrophobic domain of folic acid-icodextrin-polycaprolactone (FA-ICO-PCL, FIP) and cisplatin-icodextrin-polycaprolactone (Pt-ICO-PCL, PtIP) co-assembly, the resultant DiR@(PtIP + FIP) (DPtFIP) NPs had a diameter of around 70 nm and showed excellent tumor targeting ability and negligible side effects.	polycaprolactone	68-84	arginine vasopressin receptor 2	Homo sapiens	191-194
34755744-4	2021	By loading DiR into the hydrophobic domain of folic acid-icodextrin-polycaprolactone (FA-ICO-PCL, FIP) and cisplatin-icodextrin-polycaprolactone (Pt-ICO-PCL, PtIP) co-assembly, the resultant DiR@(PtIP + FIP) (DPtFIP) NPs had a diameter of around 70 nm and showed excellent tumor targeting ability and negligible side effects.	polycaprolactone	68-84	PAX interacting protein 1	Homo sapiens	196-200
34755744-4	2021	By loading DiR into the hydrophobic domain of folic acid-icodextrin-polycaprolactone (FA-ICO-PCL, FIP) and cisplatin-icodextrin-polycaprolactone (Pt-ICO-PCL, PtIP) co-assembly, the resultant DiR@(PtIP + FIP) (DPtFIP) NPs had a diameter of around 70 nm and showed excellent tumor targeting ability and negligible side effects.	polycaprolactone	68-84	upstream transcription factor 2, c-fos interacting	Homo sapiens	203-206
34917597-9	2021	Furthermore, PCL/NO inhibited the differentiation of VPCs into osteopontin-positive cells, thereby preventing vascular calcification.	polycaprolactone	13-16	secreted phosphoprotein 1	Rattus norvegicus	63-74
34852300-0	2022	VEGF-Capturing Aligned Electrospun Polycaprolactone/Gelatin Nanofibers Promote Patellar Ligament Regeneration.	polycaprolactone	35-51	vascular endothelial growth factor A	Homo sapiens	0-4
34852300-3	2022	Herein, we developed vascular endothelial growth factor (VEGF)-binding aligned electrospun poly(caprolactone)/gelatin (PCL/Gel) scaffolds by incorporating prominin-1-binding peptide (BP) sequence and exploited them for patellar ligament regeneration.	polycaprolactone	91-109	vascular endothelial growth factor A	Homo sapiens	21-55
34852300-3	2022	Herein, we developed vascular endothelial growth factor (VEGF)-binding aligned electrospun poly(caprolactone)/gelatin (PCL/Gel) scaffolds by incorporating prominin-1-binding peptide (BP) sequence and exploited them for patellar ligament regeneration.	polycaprolactone	91-109	vascular endothelial growth factor A	Homo sapiens	57-61
34858546-0	2021	Hypoxia-Induced miR-210 Overexpression Promotes the Differentiation of Human-Induced Pluripotent Stem Cells to Hepatocyte-Like Cells on Random Nanofiber Poly-L-Lactic Acid/Poly (epsilon-Caprolactone) Scaffolds.	polycaprolactone	172-198	microRNA 210	Homo sapiens	16-23
34900965-6	2021	Compared with L-phenylalanine based gelators/poly-epsilon-caprolactone (L/PCL) and PCL, D-phenylalanine based gelators/poly-epsilon-caprolactone (D/PCL) scaffolds enhanced cell adhesion, and proliferation and upregulated the expression of fibronectin-1, and vinculin.	polycaprolactone	119-144	fibronectin 1	Homo sapiens	239-252
34900965-6	2021	Compared with L-phenylalanine based gelators/poly-epsilon-caprolactone (L/PCL) and PCL, D-phenylalanine based gelators/poly-epsilon-caprolactone (D/PCL) scaffolds enhanced cell adhesion, and proliferation and upregulated the expression of fibronectin-1, and vinculin.	polycaprolactone	119-144	vinculin	Homo sapiens	258-266
34858634-4	2021	Herein, porous nanosilicate-functionalized polycaprolactone (PCL/LAP) was fabricated by 3D printing technology, and its bioactivities in bone regeneration were investigated in vitro and in vivo.	polycaprolactone	43-59	LAP	Homo sapiens	65-68
34592398-2	2021	Here, a bioactive MSCs-sEV-loaded electrospun silk fibroin/poly(epsilon-caprolactone) (SF/PCL) scaffold was synthesized via a mussel-inspired immobilization strategy assisted by polydopamine (pDA).	polycaprolactone	59-85	kallikrein 1-related peptidase C9	Rattus norvegicus	23-26
34492244-0	2021	Vitamin D3/vitamin K2/magnesium-loaded polylactic acid/tricalcium phosphate/polycaprolactone composite nanofibers demonstrated osteoinductive effect by increasing Runx2 via Wnt/B-catenin pathway.	polycaprolactone	76-92	RUNX family transcription factor 2	Homo sapiens	163-168
34492244-0	2021	Vitamin D3/vitamin K2/magnesium-loaded polylactic acid/tricalcium phosphate/polycaprolactone composite nanofibers demonstrated osteoinductive effect by increasing Runx2 via Wnt/B-catenin pathway.	polycaprolactone	76-92	catenin beta 1	Homo sapiens	177-186
34771286-0	2021	Fabrication of 3D Printed Poly(lactic acid)/Polycaprolactone Scaffolds Using TGF-beta1 for Promoting Bone Regeneration.	polycaprolactone	44-60	transforming growth factor beta 1	Homo sapiens	77-86
34670200-2	2021	We aimed to design and fabricate 3D-polycaprolactone (PCL)-based nanocomposite scaffold containing a high concentration homogeneously distributed carbonated-nanohydroxyapatite (C-nHA)-particles in combination with immobilized-collagen to mimic real bone properties.	polycaprolactone	36-52	PHD finger protein 1	Homo sapiens	54-57
34680751-6	2021	By optimizing the relative concentration, we were able to achieve 3-fold higher proliferation and 1.6-fold higher total collagen at day 14, and a 1.7-fold higher alkaline phosphatase production at day 7 with respect to polycaprolactone/polyvinylpyrrolidone (PCL/PVP) scaffold.	polycaprolactone	219-235	AT695_RS04080	Staphylococcus aureus	162-182
34771484-3	2021	Hence, the purpose of this work is the evaluation of polycaprolactone electrospun (PCL-ES) scaffolds for culturing LCSCs in sensitive and resistant EGFR-mutated (EGFRm) lung adenocarcinoma cell models.	polycaprolactone	53-69	epidermal growth factor receptor	Homo sapiens	148-152
34489041-0	2021	Lactobacillus amylovorus derived lipase-mediated silver derivatization over poly(epsilon-caprolactone) towards antimicrobial coatings.	polycaprolactone	76-102	lipase, endothelial	Mus musculus	33-39
34901558-1	2022	This study tested whether osseous integration into poly (epsilon-caprolactone) (PCL) bioplastic scaffolds with fully-interconnecting 155 +- 8 mum pores is enhanced by an adhesive, non-inflammatory 99% degree of deacetylation (DDA) chitosan coating (99-PCL), or further incorporation of pro-inflammatory 83% DDA chitosan microparticles (83-99-PCL) to accelerate angiogenesis.	polycaprolactone	51-78	PHD finger protein 1	Homo sapiens	80-83
34461017-3	2021	The goal of the current study was to fabricate graphene-containing polycaprolactone/gelatin/polypyrrole (PCL/gelatin/PPy) and polycaprolactone/polyglycerol-sebacate/polypyrrole (PCL/PGS/PPy) with intrinsic electrical properties through an electrospinning process.	polycaprolactone	67-83	PHD finger protein 1	Homo sapiens	105-108
34461017-3	2021	The goal of the current study was to fabricate graphene-containing polycaprolactone/gelatin/polypyrrole (PCL/gelatin/PPy) and polycaprolactone/polyglycerol-sebacate/polypyrrole (PCL/PGS/PPy) with intrinsic electrical properties through an electrospinning process.	polycaprolactone	126-142	PHD finger protein 1	Homo sapiens	178-181
34688329-3	2021	In a previous study, we prepared and characterized electrospinning zinc oxide/silver/polyvinylpyrrolidone/polycaprolactone (ZnO/Ag/PVP/PCL) nanofibers using ZnO and Ag nanoparticles, and evaluated their antibacterial effect in vitro.	polycaprolactone	106-122	PHD finger protein 1	Homo sapiens	135-138
34451127-4	2021	A polycaprolactone PCL/keratin electrospun scaffold showed better cell adhesion and proliferation than the keratin-free PCL scaffold, and keratinocytes and fibroblasts showed better survival, adhesion, and proliferation in the PCL/keratin electrospun nanofiber scaffold and microfiber scaffold, respectively.	polycaprolactone	2-18	PHD finger protein 1	Homo sapiens	19-22
34474851-1	2021	The present experimental study aims to extend know-how on resorbable polycaprolactone/hydroxyapatite (PCL/HA, 70/30 wt%) scaffolds, produced by Laser Powder Bed Fusion (LPBF) technology, to geometrically complex lattice structures and micro porous struts.	polycaprolactone	69-85	PHD finger protein 1	Homo sapiens	102-105
34474864-3	2021	Here, we engineered a BMAT analog made of a GelMA (gelatin methacryloyl) hydrogel/medical-grade polycaprolactone (mPCL) scaffold composite to structurally and biologically mimic key aspects of the bone marrow microenvironment, and exploited an innovative bioreactor to study the effects of mechanical loading.	polycaprolactone	96-112	polycystic kidney disease 2-like 1	Mus musculus	114-118
34361466-5	2021	We have produced a polycaprolactone (PCL) nanofiber cloth after electrospinning it onto a drum for 3 and 10 min, referred to hereafter as PCL-3 and PCL-10, respectively.	polycaprolactone	19-35	PHD finger protein 19	Homo sapiens	138-143
34372160-0	2021	Effect of Crystallinity on the Properties of Polycaprolactone Nanoparticles Containing the Dual FLAP/mPEGS-1 Inhibitor BRP-187.	polycaprolactone	45-61	arachidonate 5-lipoxygenase activating protein	Homo sapiens	96-100
34314063-8	2022	New bone growth, vascularization, and CD163+ macrophage populations surrounding the polymer implants were also quantified; and blood vessel formation around high dose PCL-MMA was found to be significantly decreased compared with PCL alone.	polycaprolactone	229-232	CD163 molecule	Rattus norvegicus	38-43
34161403-4	2021	First, the p53 expression plasmid (p53 DNA) was ultrasonically sprayed on a polycaprolactone (PCL) microneedle patch (D@MNP).	polycaprolactone	76-92	tumor protein p53	Homo sapiens	11-14
34350160-4	2021	An MC/CS cast film was coated with polycaprolactone (PCL)/polyvinylpyrrolidone (PVP) electrospun nanofibers loaded with BER, yielding the BER@PCL/PVP-MC/CS bilayer membrane.	polycaprolactone	35-51	citrate synthase	Rattus norvegicus	146-155
34350160-4	2021	An MC/CS cast film was coated with polycaprolactone (PCL)/polyvinylpyrrolidone (PVP) electrospun nanofibers loaded with BER, yielding the BER@PCL/PVP-MC/CS bilayer membrane.	polycaprolactone	53-56	citrate synthase	Rattus norvegicus	146-155
35396960-0	2022	Bone morphogenetic protein (BMP)-modified graphene oxide-reinforced polycaprolactone-gelatin nanofiber scaffolds for application in bone tissue engineering.	polycaprolactone	68-84	bone morphogenetic protein 1	Homo sapiens	0-26
34064278-1	2021	The studied samples were prepared from polyethylene (PE) polymer which was coated with modified polycaprolactone (PCL) film in order to obtain bilayer films.	polycaprolactone	96-112	PHD finger protein 1	Homo sapiens	114-117
35545079-0	2022	Environmentally friendly fabrication of electrospun nanofibers made of polycaprolactone, chitosan and kappa-carrageenan (PCL/CS/kappa-C).	polycaprolactone	71-87	PHD finger protein 1	Homo sapiens	121-127
35545079-2	2022	In this work, electrospun nanofibers made from poly(epsilon caprolactone) (PCL), chitosan (CS) and kappa-carrageenan (kappa-C) were successfully fabricated using several mixtures of benign solvents containing formic acid (FA) and acetic acid (AA).	polycaprolactone	47-73	PHD finger protein 1	Homo sapiens	75-78
34097140-4	2021	Our previous study showed that epsilon-poly-L-lysine (EPL)-coated nanoscale polycaprolactone/hydroxyapatite (EPL/PCL/HA) composite scaffold has enhanced antibacterial and osteogenic properties in vitro.	polycaprolactone	76-92	PHD finger protein 1	Homo sapiens	113-116
34093011-5	2021	Methods: Different layers of VEGF-A loaded polycaprolactone (PCL) nanofibrous membranes were first synthesized by using layer-by-layer (LBL) self-assembly of electrospinning methods.	polycaprolactone	43-59	vascular endothelial growth factor A	Homo sapiens	29-35
34093011-5	2021	Methods: Different layers of VEGF-A loaded polycaprolactone (PCL) nanofibrous membranes were first synthesized by using layer-by-layer (LBL) self-assembly of electrospinning methods.	polycaprolactone	61-64	vascular endothelial growth factor A	Homo sapiens	29-35
34066640-0	2021	Incorporation of Elastin to Improve Polycaprolactone-Based Scaffolds for Skeletal Muscle via Electrospinning.	polycaprolactone	36-52	elastin	Homo sapiens	17-24
34066640-2	2021	The main objective of this work was to improve the characteristics of polycaprolactone (PCL) scaffolds by incorporating elastin to achieve better cell proliferation and biocompatibility.	polycaprolactone	70-86	elastin	Homo sapiens	120-127
34066640-2	2021	The main objective of this work was to improve the characteristics of polycaprolactone (PCL) scaffolds by incorporating elastin to achieve better cell proliferation and biocompatibility.	polycaprolactone	88-91	elastin	Homo sapiens	120-127
35337497-1	2022	In this work, the solution blow spinning (SBS) technique was used to rapidly fabricate the thymol (THY)/2-hydroxypropyl-beta-cyclodextrin (HPbetaCD) inclusion complexes loaded chitosan (CS)/polycaprolactone (PCL) nanofibrous films for fruit preservation and packaging.	polycaprolactone	190-206	citrate synthase	Homo sapiens	186-188
35337497-1	2022	In this work, the solution blow spinning (SBS) technique was used to rapidly fabricate the thymol (THY)/2-hydroxypropyl-beta-cyclodextrin (HPbetaCD) inclusion complexes loaded chitosan (CS)/polycaprolactone (PCL) nanofibrous films for fruit preservation and packaging.	polycaprolactone	208-211	citrate synthase	Homo sapiens	186-188
35337497-2	2022	XRD results indicated that the THY/HPbetaCD inclusion complexes were successfully incorporated into the CS/PCL nanofibers.	polycaprolactone	107-110	citrate synthase	Homo sapiens	104-106
35337497-4	2022	FTIR and thermal analysis showed that the thermal stability was also improved due to the formation of hydrogen bonds between THY/HPbetaCD inclusion complexes and CS/PCL nanofibers.	polycaprolactone	165-168	citrate synthase	Homo sapiens	162-164
35396960-0	2022	Bone morphogenetic protein (BMP)-modified graphene oxide-reinforced polycaprolactone-gelatin nanofiber scaffolds for application in bone tissue engineering.	polycaprolactone	68-84	bone morphogenetic protein 1	Homo sapiens	28-31
35396960-1	2022	In this study, blend nanofibrous scaffolds were electrospun from polycaprolactone/gelatin (PCL/Gel) blend solutions reinforced by bone morphogenetic protein (BMP)-modified graphene oxide (GO).	polycaprolactone	65-81	PHD finger protein 1	Homo sapiens	91-94
35396960-1	2022	In this study, blend nanofibrous scaffolds were electrospun from polycaprolactone/gelatin (PCL/Gel) blend solutions reinforced by bone morphogenetic protein (BMP)-modified graphene oxide (GO).	polycaprolactone	65-81	bone morphogenetic protein 1	Homo sapiens	130-156
35396960-1	2022	In this study, blend nanofibrous scaffolds were electrospun from polycaprolactone/gelatin (PCL/Gel) blend solutions reinforced by bone morphogenetic protein (BMP)-modified graphene oxide (GO).	polycaprolactone	65-81	bone morphogenetic protein 1	Homo sapiens	158-161
35622002-0	2022	Spatially and Temporally Controllable BMP-2 and TGF-beta3 Double Release From Polycaprolactone Fiber Scaffolds via Chitosan-Based Polyelectrolyte Coatings.	polycaprolactone	78-94	bone morphogenetic protein 2	Homo sapiens	38-43
35118913-1	2022	Herein, a facile macro- and microporous polycaprolactone/duck"s feet collagen scaffold (PCL/DC) was fabricated and characterized to confirm its applicability in bone tissue engineering.	polycaprolactone	40-56	PHD finger protein 1	Homo sapiens	88-91
35622002-0	2022	Spatially and Temporally Controllable BMP-2 and TGF-beta3 Double Release From Polycaprolactone Fiber Scaffolds via Chitosan-Based Polyelectrolyte Coatings.	polycaprolactone	78-94	transforming growth factor beta 3	Homo sapiens	48-57
35622002-2	2022	For this purpose, polycaprolactone fiber mats were coated with tailored chitosan-based nanogels to bind and release the growth factors bone morphogenetic protein 2 (BMP-2) and transforming growth factor-beta3 (TGF-beta3), respectively.	polycaprolactone	18-34	bone morphogenetic protein 2	Homo sapiens	135-163
35622002-2	2022	For this purpose, polycaprolactone fiber mats were coated with tailored chitosan-based nanogels to bind and release the growth factors bone morphogenetic protein 2 (BMP-2) and transforming growth factor-beta3 (TGF-beta3), respectively.	polycaprolactone	18-34	bone morphogenetic protein 2	Homo sapiens	165-170
35622002-2	2022	For this purpose, polycaprolactone fiber mats were coated with tailored chitosan-based nanogels to bind and release the growth factors bone morphogenetic protein 2 (BMP-2) and transforming growth factor-beta3 (TGF-beta3), respectively.	polycaprolactone	18-34	transforming growth factor beta 3	Homo sapiens	176-208
35622002-2	2022	For this purpose, polycaprolactone fiber mats were coated with tailored chitosan-based nanogels to bind and release the growth factors bone morphogenetic protein 2 (BMP-2) and transforming growth factor-beta3 (TGF-beta3), respectively.	polycaprolactone	18-34	transforming growth factor beta 3	Homo sapiens	210-219
35622002-5	2022	Layer-by-layer coatings based on BMP-2-containing chitosan tripolyphosphate nanogel particles and negatively charged alginate showed a good sustainment of BMP-2 release from chemically modified polycaprolactone fiber mats.	polycaprolactone	194-210	bone morphogenetic protein 2	Homo sapiens	33-38
35622002-5	2022	Layer-by-layer coatings based on BMP-2-containing chitosan tripolyphosphate nanogel particles and negatively charged alginate showed a good sustainment of BMP-2 release from chemically modified polycaprolactone fiber mats.	polycaprolactone	194-210	bone morphogenetic protein 2	Homo sapiens	155-160
35331832-1	2022	A novel drug eluting retrievable vena cava filter (RVCF) with a heparin-modified poly(epsilon-caprolactone) (hPCL) coating containing rapamycin was prepared by electrospraying.	polycaprolactone	81-107	PHD finger protein 1	Homo sapiens	109-113
35218809-4	2022	Then the MSN-SF/CS microspheres were sprayed on the silk fibroin (SF)/polycaprolactone (PCL)-polyvinyl alcohol (PVA) unidirectional water-conducting composite nanofiber membrane.	polycaprolactone	70-86	citrate synthase	Homo sapiens	9-18
35218809-4	2022	Then the MSN-SF/CS microspheres were sprayed on the silk fibroin (SF)/polycaprolactone (PCL)-polyvinyl alcohol (PVA) unidirectional water-conducting composite nanofiber membrane.	polycaprolactone	88-91	citrate synthase	Homo sapiens	9-18
35123243-1	2022	A novel and disposable biosensor based on superoxide dismutase (SOD) immobilized on gold metallized polycaprolactone electrospun polymeric fibers (PCl/Au) has been developed for the determination of superoxide (O2 -) in cell culture media.	polycaprolactone	100-116	superoxide dismutase 1	Homo sapiens	42-62
35452580-4	2022	In the present study, chemically synthesized polythiophene nanoparticles (PTh NPs) are incorporated into polycaprolactone (PCL) nanofibers, and subsequent changes in physicochemical, mechanical, and electrical properties are observed in a concentration-dependent manner.	polycaprolactone	105-121	parathyroid hormone	Mus musculus	74-77
35452580-4	2022	In the present study, chemically synthesized polythiophene nanoparticles (PTh NPs) are incorporated into polycaprolactone (PCL) nanofibers, and subsequent changes in physicochemical, mechanical, and electrical properties are observed in a concentration-dependent manner.	polycaprolactone	123-126	parathyroid hormone	Mus musculus	74-77
35075781-0	2022	Three-dimensional-printed polycaprolactone/polypyrrole conducting scaffolds for differentiation of human olfactory ecto-mesenchymal stem cells into Schwann cell-like phenotypes and promotion of neurite outgrowth.	polycaprolactone	26-42	tripartite motif containing 33	Homo sapiens	115-119
35123243-0	2022	Disposable superoxide dismutase biosensors based on gold covered polycaprolactone fibers for the detection of superoxide in cell culture media.	polycaprolactone	65-81	superoxide dismutase 1	Homo sapiens	11-31
35446751-0	2022	Physico-mechanical and Biological Evaluation of Heparin/VEGF-loaded Electrospun Polycaprolactone/ Decellularized Rat Aorta Extracellular Matrix for Small-Diameter Vascular Grafts.	polycaprolactone	80-96	vascular endothelial growth factor A	Rattus norvegicus	56-60
35385718-3	2022	Polycaprolactone (PCL) polymer was used here to prepare nanoparticles as carriers for insulin molecules.	polycaprolactone	0-16	insulin	Homo sapiens	86-93
35458246-2	2022	The aim of this work was to produce a new type of hybrid polycaprolactone (PCL)/chitosan (CS) electrospun mat through the controlled deposition of CS flakes interspaced between the PCL fibers.	polycaprolactone	57-73	citrate synthase	Homo sapiens	90-92
35458246-2	2022	The aim of this work was to produce a new type of hybrid polycaprolactone (PCL)/chitosan (CS) electrospun mat through the controlled deposition of CS flakes interspaced between the PCL fibers.	polycaprolactone	57-73	citrate synthase	Homo sapiens	147-149
35458246-2	2022	The aim of this work was to produce a new type of hybrid polycaprolactone (PCL)/chitosan (CS) electrospun mat through the controlled deposition of CS flakes interspaced between the PCL fibers.	polycaprolactone	75-78	citrate synthase	Homo sapiens	90-92
35458246-2	2022	The aim of this work was to produce a new type of hybrid polycaprolactone (PCL)/chitosan (CS) electrospun mat through the controlled deposition of CS flakes interspaced between the PCL fibers.	polycaprolactone	75-78	citrate synthase	Homo sapiens	147-149
35385718-3	2022	Polycaprolactone (PCL) polymer was used here to prepare nanoparticles as carriers for insulin molecules.	polycaprolactone	18-21	insulin	Homo sapiens	86-93
35219147-5	2022	We could engage ITGAV on the cell surface and improve reparative capacity by culturing CPCs on electrospun polycaprolactone (PCL) patches coated with fibronectin (PCL + FN).	polycaprolactone	107-123	integrin subunit alpha V	Homo sapiens	16-21
35219147-5	2022	We could engage ITGAV on the cell surface and improve reparative capacity by culturing CPCs on electrospun polycaprolactone (PCL) patches coated with fibronectin (PCL + FN).	polycaprolactone	107-123	fibronectin 1	Homo sapiens	150-161
35219147-5	2022	We could engage ITGAV on the cell surface and improve reparative capacity by culturing CPCs on electrospun polycaprolactone (PCL) patches coated with fibronectin (PCL + FN).	polycaprolactone	125-128	integrin subunit alpha V	Homo sapiens	16-21
35219147-5	2022	We could engage ITGAV on the cell surface and improve reparative capacity by culturing CPCs on electrospun polycaprolactone (PCL) patches coated with fibronectin (PCL + FN).	polycaprolactone	125-128	fibronectin 1	Homo sapiens	150-161
35077264-2	2022	In this study, we synthesized nanosheets of Molybdenum disulfide (MoS2), and integrated them into polycaprolactone (PCL) and electrospun on the surface of decellularized human amniotic membrane (DHAM) with the purpose of improving the scaffolds mechanical properties and electrical conductivity.	polycaprolactone	116-119	mago homolog, exon junction complex core component	Mus musculus	66-70
35350312-0	2022	Toughening Poly(l-lactide) Blends: Effectiveness of Sequence-Controlled Six-Arm Star-Branched Block Copolymers of Poly(l-lactide) and Poly(epsilon-caprolactone).	polycaprolactone	134-159	steroidogenic acute regulatory protein	Homo sapiens	80-84
35335450-3	2022	Herein, poly (epsilon-caprolactone) (PCL) and poly (lactic-co-glycolic acid) (PLGA) polymers were used to make scaffolds and were functionalized with peptides (RGD (Arginine-glycine-aspartate), VEGF (Vascular endothelial growth factor), laminin) or gelatin to augment engraftment.	polycaprolactone	8-35	polycystic kidney disease 2-like 1	Mus musculus	37-40
35335450-3	2022	Herein, poly (epsilon-caprolactone) (PCL) and poly (lactic-co-glycolic acid) (PLGA) polymers were used to make scaffolds and were functionalized with peptides (RGD (Arginine-glycine-aspartate), VEGF (Vascular endothelial growth factor), laminin) or gelatin to augment engraftment.	polycaprolactone	8-35	vascular endothelial growth factor A	Mus musculus	194-198
35335450-3	2022	Herein, poly (epsilon-caprolactone) (PCL) and poly (lactic-co-glycolic acid) (PLGA) polymers were used to make scaffolds and were functionalized with peptides (RGD (Arginine-glycine-aspartate), VEGF (Vascular endothelial growth factor), laminin) or gelatin to augment engraftment.	polycaprolactone	8-35	vascular endothelial growth factor A	Mus musculus	200-234
35235295-6	2022	Moreover, the discontinued surface topography of the shish-kebab structure altered the surface chemistry from hydrophobic for the original poly(epsilon-caprolactone) (PCL) nanofibers to hydrophilic for the PCL nanofibers with the shish-kebab structure, which might have inhibited the activation of fibrinogen and thus improved the anticoagulant ability.	polycaprolactone	139-165	fibrinogen beta chain	Homo sapiens	298-308
35415291-4	2022	Here, we developed a functional vascular graft by surface immobilization of stem cell antigen-1 (Sca-1) antibody on an electrospun poly(epsilon-caprolactone) graft (PCL-Sca-1 Ab).	polycaprolactone	131-157	lymphocyte antigen 6 complex, locus A	Mus musculus	97-102
35179903-5	2022	Incubation with 1,25(OH)2D3/VID400-coencapsulated poly(epsilon-caprolactone) nanofiber membranes greatly induced the hCAP18/LL-37 gene expression in monocytes, neutrophils, and keratinocytes in vitro.	polycaprolactone	50-76	cathelicidin antimicrobial peptide	Homo sapiens	117-123
35179903-5	2022	Incubation with 1,25(OH)2D3/VID400-coencapsulated poly(epsilon-caprolactone) nanofiber membranes greatly induced the hCAP18/LL-37 gene expression in monocytes, neutrophils, and keratinocytes in vitro.	polycaprolactone	50-76	cathelicidin antimicrobial peptide	Homo sapiens	124-129
35001550-2	2022	Perylenebisimide (PBI) chromophore tagged fluorescent ABC-triblock polycaprolactone (PCL) nanoscaffold was engineered having carboxylic acid blocks for the chemical conjugation of cisplatin at the core and hydrophilic PEG blocks at the periphery.	polycaprolactone	67-83	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	54-57
35001550-2	2022	Perylenebisimide (PBI) chromophore tagged fluorescent ABC-triblock polycaprolactone (PCL) nanoscaffold was engineered having carboxylic acid blocks for the chemical conjugation of cisplatin at the core and hydrophilic PEG blocks at the periphery.	polycaprolactone	85-88	ATP binding cassette subfamily B member 6 (Langereis blood group)	Homo sapiens	54-57
34999039-3	2022	In the present study, Methoxypoly(ethylene glycol) - Poly(caprolactone) was hybridized with Dimethyldioctadecylammonium bromide (DDAB) cationic lipid (mPEG-PCL-DDAB) nanoparticles (NPs) and used as a carrier for simultaneous delivery of lycopene and insulin-like growth factor 1 receptor-specific lycopene encapsulated-mPEG-PCL-DDAB nanoparticle/siRNA to MCF-7 breast cancer cells.	polycaprolactone	53-70	insulin like growth factor 1 receptor	Homo sapiens	250-287
35208131-4	2022	Herein, a three-dimensional layered reticulated polycaprolactone (PCL) scaffold coated with poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) (PCEC) was developed to proliferate human embryonic kidney cells and to be used to amplify the Ad5 vector.	polycaprolactone	48-64	Alzheimer disease, familial, type 5	Homo sapiens	263-266
35090961-6	2022	Among these, poly (epsilon-caprolactone) (PCL) polymer has been recognized and approved by the FDA for numerous biomedical applications.	polycaprolactone	13-40	PHD finger protein 1	Homo sapiens	42-45
35214032-3	2022	Here, we propose to overcome this limitation by incorporating antiviral essential oils (EOs) within polycaprolactone (PCL) electrospun fibrous mats to be used as intermediate layers in individual protection masks.	polycaprolactone	100-116	PHD finger protein 1	Homo sapiens	118-121
35198635-4	2022	Methods: Poly (epsilon-caprolactone) (PCL)/chitosan- (CS-) based highly porous scaffold (PCL/CS) was prepared and evaluated by scanning electron microscopy (SEM) and Fourier transform infrared spectroscopy (FTIR) analyses.	polycaprolactone	9-36	citrate synthase	Homo sapiens	93-95
34973132-2	2022	Indeed, we have developed biodegradable nanoparticles (NPs) of poly(ethylene glycol)-poly(epsilon-caprolactone), exposing on the surface both folate motifs (Fol) for recognition in cells overexpressing Folate receptor-alpha (FRalpha) and the anti-angiogenic hexapeptide aFLT1.	polycaprolactone	85-110	laminin, alpha 5	Danio rerio	225-232
35049727-2	2022	Poly epsilon-caprolactone (PCL) electrospun nanofiber material (ENF) was assembled with polyethylene glycol diacrylate (PEGDA), sodium alginate (SA) and type I collagen (CG1) to develop three groups of dermal equivalent scaffolds.	polycaprolactone	0-25	mastermind like domain containing 1	Homo sapiens	170-173
35049727-2	2022	Poly epsilon-caprolactone (PCL) electrospun nanofiber material (ENF) was assembled with polyethylene glycol diacrylate (PEGDA), sodium alginate (SA) and type I collagen (CG1) to develop three groups of dermal equivalent scaffolds.	polycaprolactone	27-30	mastermind like domain containing 1	Homo sapiens	170-173
35517875-7	2022	The 2% MgO/PCL nanofibrous scaffold showed significant increase in ALP activity (P < 0.05) and osteogenic-related gene expressions (Col1a1 and OPN) (P < 0.05) in compared to pure PCL and (0, 0.5 and 1%) MgO/PCL scaffolds.	polycaprolactone	11-14	alkaline phosphatase, placental	Homo sapiens	67-70
35517875-7	2022	The 2% MgO/PCL nanofibrous scaffold showed significant increase in ALP activity (P < 0.05) and osteogenic-related gene expressions (Col1a1 and OPN) (P < 0.05) in compared to pure PCL and (0, 0.5 and 1%) MgO/PCL scaffolds.	polycaprolactone	11-14	collagen type I alpha 1 chain	Homo sapiens	132-138
35517875-7	2022	The 2% MgO/PCL nanofibrous scaffold showed significant increase in ALP activity (P < 0.05) and osteogenic-related gene expressions (Col1a1 and OPN) (P < 0.05) in compared to pure PCL and (0, 0.5 and 1%) MgO/PCL scaffolds.	polycaprolactone	11-14	secreted phosphoprotein 1	Homo sapiens	143-146
32608183-1	2021	Polycaprolactone (PCL) fiber mats with different surface modifications were functionalized with a chitosan nanogel coating to attach the growth factor human bone morphogenetic protein 2 (BMP-2).	polycaprolactone	0-16	bone morphogenetic protein 2	Homo sapiens	157-185
33673981-1	2021	In this study, the electrospun poly(epsilon-caprolactone) (PCL)/Chitosan (CS)/curcumin (CUR) nanofiber was fabricated successfully with curcumin loaded chitosan nano-encapsulated particles (CURCSNPs).	polycaprolactone	31-57	PHD finger protein 1	Homo sapiens	59-62
33673981-1	2021	In this study, the electrospun poly(epsilon-caprolactone) (PCL)/Chitosan (CS)/curcumin (CUR) nanofiber was fabricated successfully with curcumin loaded chitosan nano-encapsulated particles (CURCSNPs).	polycaprolactone	31-57	citrate synthase	Homo sapiens	74-76
35079629-5	2022	The inner electrospun fibrous layer was made of nanoscale-macroscale polycaprolactone fibers acting to promote the hCdHs attachment and differentiation, while the outer microporous foam layer served to increase mechanical stability.	polycaprolactone	69-85	paired box 3	Homo sapiens	115-120
2915248-2	1989	The thermoplastic Minerva body jacket is a new lightweight modification of a Minerva jacket which is fabricated from Polyform (a splinting material made of a polyester polycaprolactone) and Polycushion (a closed-cell foam for padding).	polycaprolactone	168-184	niban apoptosis regulator 2	Homo sapiens	18-25
33988364-0	2021	Extraordinary Superhydrophobic Polycaprolactone-Based Composite Membrane with an Alternated Micro-Nano Hierarchical Structure as an Eco-friendly Oil/Water Separator.	polycaprolactone	31-47	ciliogenesis associated kinase 1	Homo sapiens	132-135
33527343-3	2021	Inspired by extracellular matrix protein and topographical cues, we developed a polycaprolactone-based scaffold for bone regeneration using a soluble eggshell membrane protein (SEP) coating and a nanotopography structure for enhancing the physical properties and bioactivity.	polycaprolactone	80-96	membrane metallo-endopeptidase-like 1	Mus musculus	142-175
33527343-3	2021	Inspired by extracellular matrix protein and topographical cues, we developed a polycaprolactone-based scaffold for bone regeneration using a soluble eggshell membrane protein (SEP) coating and a nanotopography structure for enhancing the physical properties and bioactivity.	polycaprolactone	80-96	membrane metallo-endopeptidase-like 1	Mus musculus	177-180
32608183-1	2021	Polycaprolactone (PCL) fiber mats with different surface modifications were functionalized with a chitosan nanogel coating to attach the growth factor human bone morphogenetic protein 2 (BMP-2).	polycaprolactone	0-16	bone morphogenetic protein 2	Homo sapiens	187-192
32608183-1	2021	Polycaprolactone (PCL) fiber mats with different surface modifications were functionalized with a chitosan nanogel coating to attach the growth factor human bone morphogenetic protein 2 (BMP-2).	polycaprolactone	18-21	bone morphogenetic protein 2	Homo sapiens	157-185
32608183-1	2021	Polycaprolactone (PCL) fiber mats with different surface modifications were functionalized with a chitosan nanogel coating to attach the growth factor human bone morphogenetic protein 2 (BMP-2).	polycaprolactone	18-21	bone morphogenetic protein 2	Homo sapiens	187-192
33924348-4	2021	The natural cavity structure of the polymeric complex, which was comprised with beta-cyclodextrin-graft-(poly(epsilon-caprolactone)-adamantly (beta-CD-PCL-AD) and beta-cyclodextrin-graft-(poly(epsilon-caprolactone)-poly(2-(dimethylamino) ethyl methacrylate) (beta-CD-PCL-PDMAEMA), can achieve the efficient drug loading and delivery to overcome pump drug resistance.	polycaprolactone	105-130	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	143-150
33864528-3	2021	Herein, biomimetic gelatin (Gt)/polycaprolactone (PCL) composite nanofibers incorporating a different amount of chondroitin sulfate (CS) were developed via electrospinning technology to investigate their effects on antithrombogenicity and endothelial cell affinity.	polycaprolactone	32-48	PHD finger protein 1	Homo sapiens	50-53
33573471-2	2021	In the present study, we examined the potential of transferring a recombinant adeno-associated virus (rAAV) vector carrying a sequence for the highly chondroregenerative transforming growth factor beta (TGF-beta) using poly(epsilon-caprolactone) (PCL) films functionalized via the grafting of poly(sodium styrene sulfonate) (pNaSS) in chondrogenically competent bone marrow aspirates as future targets for therapy in cartilage lesions.	polycaprolactone	247-250	tumor necrosis factor	Homo sapiens	170-201
33573471-2	2021	In the present study, we examined the potential of transferring a recombinant adeno-associated virus (rAAV) vector carrying a sequence for the highly chondroregenerative transforming growth factor beta (TGF-beta) using poly(epsilon-caprolactone) (PCL) films functionalized via the grafting of poly(sodium styrene sulfonate) (pNaSS) in chondrogenically competent bone marrow aspirates as future targets for therapy in cartilage lesions.	polycaprolactone	247-250	transforming growth factor alpha	Homo sapiens	203-211
33997500-3	2021	Here, a porous scaffold polycaprolactone (PCL)/decellularized small intestine submucosa (SIS) was fabricated via cryogenic free-form extrusion, followed by surface modification with aptamer and PlGF-2123-144*-fused BMP2 (pBMP2).	polycaprolactone	24-40	placental growth factor	Rattus norvegicus	194-198
33997495-2	2021	Based on soybean-lecithin as an adjuvant biosurfactant, we designed a novel cell-free-scaffold of polymer of poly(epsilon-caprolactone) and poly(lactide-co-glycolide)-co-polyetherimide with abundant entrapped and continuously released BMP2 for in vivo stem cell-capture and in situ osteogenic induction, avoiding the use of exogenous cells.	polycaprolactone	109-135	bone morphogenetic protein 2	Mus musculus	235-239
33921560-2	2021	Here, the plain and hydrophilic-modified poly(epsilon-caprolactone) (PCL) fiber mats were used for the absorption of indolyl acetate and acetylcholinesterase (AChE), respectively.	polycaprolactone	41-67	acetylcholinesterase (Cartwright blood group)	Homo sapiens	137-157
33921560-2	2021	Here, the plain and hydrophilic-modified poly(epsilon-caprolactone) (PCL) fiber mats were used for the absorption of indolyl acetate and acetylcholinesterase (AChE), respectively.	polycaprolactone	41-67	acetylcholinesterase (Cartwright blood group)	Homo sapiens	159-163
33928587-0	2021	Production and Characterization of Anti-CCR5 siRNA-Loaded Polycaprolactone Nanoparticles for Topical Pre-exposure Prophylaxis.	polycaprolactone	58-74	C-C motif chemokine receptor 5	Homo sapiens	40-44
33667016-6	2021	Scanning electron microscopy and ATR-FTIR confirmed productive biomacromolecular surface treatment of the polycaprolactone scaffold.	polycaprolactone	106-122	ATR serine/threonine kinase	Homo sapiens	33-36
33368746-0	2021	Flexible Cyclic-Poly(phthalaldehyde)/Poly(epsilon-caprolactone) Blend Fibers with Fast Daylight-Triggered Transience.	polycaprolactone	37-62	Fas activated serine/threonine kinase	Homo sapiens	82-86
33883730-5	2021	Poly(caprolactone) and poly(lactic acid) containing less than 2 weight per cent enzymes are depolymerized in days, with up to 98 per cent polymer-to-small-molecule conversion in standard soil composts and household tap water, completely eliminating current needs to separate and landfill their products in compost facilities.	polycaprolactone	0-17	nuclear RNA export factor 1	Homo sapiens	215-218
33869154-2	2021	Biodegradable medical-grade polycaprolactone (mPCL) scaffolds designed and rooted in evidence-based research offer a promising alternative to overcome the limitations of routinely used silicone implants for breast reconstruction.	polycaprolactone	28-44	polycystic kidney disease 2-like 1	Mus musculus	46-50
33576220-5	2021	Toward this objective, we synthesized an amphiphilic block copolymer (QPA-P) composed of NQO1 enzyme-triggered depolymerizable QPA-locked polycaprolactone (PCL) and poly(ethylene glycol) (PEG) as hydrophobic and hydrophilic constituents, respectively.	polycaprolactone	138-154	NAD(P)H quinone dehydrogenase 1	Homo sapiens	89-93
33576220-5	2021	Toward this objective, we synthesized an amphiphilic block copolymer (QPA-P) composed of NQO1 enzyme-triggered depolymerizable QPA-locked polycaprolactone (PCL) and poly(ethylene glycol) (PEG) as hydrophobic and hydrophilic constituents, respectively.	polycaprolactone	156-159	NAD(P)H quinone dehydrogenase 1	Homo sapiens	89-93
33246048-4	2021	The formed THEDES was evaluated for its dissolution behaviour from a simple polycaprolactone (PCL) matrix, in order to achieve an extended release, balanced with an appropriate onset of action, hence offering improved MET intravaginal application.	polycaprolactone	94-97	SAFB like transcription modulator	Homo sapiens	218-221
33467090-6	2021	The poly(epsilon-caprolactone) and poly(3-hydroxybutyrate) microcarriers reached an IC50 value with an encapsulated chrysin content of 149.19 microM and 312.18 microM, respectively, and showed sufficient blood compatibility displaying significantly low (up to 2%) hemolytic percentages at concentrations between 5 and 500 microg mL-1.	polycaprolactone	4-30	L1 cell adhesion molecule	Mus musculus	329-333
33732968-2	2021	A novel short peptide, mechano-growth factor (MGF), was introduced in this study to modify an electrospun polycaprolactone (PCL) fibrous scaffold to direct the macrophage phenotype transition and mitigate the FBR.	polycaprolactone	106-122	KIT ligand	Rattus norvegicus	23-44
33732968-2	2021	A novel short peptide, mechano-growth factor (MGF), was introduced in this study to modify an electrospun polycaprolactone (PCL) fibrous scaffold to direct the macrophage phenotype transition and mitigate the FBR.	polycaprolactone	106-122	KIT ligand	Rattus norvegicus	46-49
33732968-2	2021	A novel short peptide, mechano-growth factor (MGF), was introduced in this study to modify an electrospun polycaprolactone (PCL) fibrous scaffold to direct the macrophage phenotype transition and mitigate the FBR.	polycaprolactone	124-127	KIT ligand	Rattus norvegicus	23-44
33732968-2	2021	A novel short peptide, mechano-growth factor (MGF), was introduced in this study to modify an electrospun polycaprolactone (PCL) fibrous scaffold to direct the macrophage phenotype transition and mitigate the FBR.	polycaprolactone	124-127	KIT ligand	Rattus norvegicus	46-49
33385823-0	2021	Surface modification of a three-dimensional polycaprolactone scaffold by polydopamine, biomineralization, and BMP-2 immobilization for potential bone tissue applications.	polycaprolactone	44-60	bone morphogenetic protein 2	Homo sapiens	110-115
33385823-3	2021	Herein, we elaborated this approach to produce a 3D polycaprolactone (PCL) scaffold with long-term osteogenic activity.	polycaprolactone	52-68	PHD finger protein 1	Homo sapiens	70-73
33572786-0	2021	Incorporation of Calcium Sulfate Dihydrate into a Mesoporous Calcium Silicate/Poly-epsilon-Caprolactone Scaffold to Regulate the Release of Bone Morphogenetic Protein-2 and Accelerate Bone Regeneration.	polycaprolactone	78-103	bone morphogenetic protein 2	Homo sapiens	140-168
33307369-1	2021	Biomimetically designed medical-grade polycaprolactone (mPCL) dressings are 3D-printed with pore architecture and anisotropic mechanical characteristics that favor skin wound healing with reduced scarring.	polycaprolactone	38-54	polycystic kidney disease 2-like 1	Mus musculus	56-60
32867596-8	2021	Indeed, the number of living human mesenchymal stem cells determined after 7-day culture was larger on the polystyrene and polycaprolactone surfaces with EGF tethered through the KL5 peptide than control surfaces.	polycaprolactone	123-139	epidermal growth factor	Homo sapiens	154-157
33928587-3	2021	Here we describe the production protocol of anti-CCR5 siRNA-loaded polycaprolactone-based nanoparticles ( 100 nm).	polycaprolactone	67-83	C-C motif chemokine receptor 5	Homo sapiens	49-53
33039595-2	2020	Thus, we locally applied 3D-printed medical-grade polycaprolactone (mPCL) scaffolds loaded with Doxorubicin (DOX) and measured its effect in a humanized primary bone cancer model.	polycaprolactone	50-66	polycystic kidney disease 2-like 1	Mus musculus	68-72
32827908-3	2020	Through using in situ high-pressure ATR-FTIR spectroscopic imaging, this work visualized the dynamic process of phase separation in Polycaprolactone (PCL)/Poly (lactic acid) (PLA) blend under high-pressure CO2 for the first time.	polycaprolactone	132-148	ATR serine/threonine kinase	Homo sapiens	36-39
33086111-0	2020	The response surface methodology for optimization of tyrosinase immobilization onto electrospun polycaprolactone-chitosan fibers for use in bisphenol A removal.	polycaprolactone	96-112	tyrosinase	Homo sapiens	53-63
34035190-1	2020	An innovative basic fibroblast growth factor (bFGF)-loaded polycaprolactone (PCL) fibrous membrane with highly aligned structure is developed for guided tissue regeneration (GTR).	polycaprolactone	59-75	fibroblast growth factor 2	Mus musculus	14-46
33005252-3	2020	The present study aimed to investigate whether the application of LIPUS combined with bone morphogenetic protein-2 (BMP-2)-loaded poly-L-lactic acid/polylactic-co-glycolic acid/poly-epsilon-caprolactone (PLLA/PLGA/PCL) composite scaffolds can improve recovery in a rat model of steroid-induced osteonecrosis of the femoral head (ONFH).	polycaprolactone	177-202	bone morphogenetic protein 2	Rattus norvegicus	86-114
33005252-3	2020	The present study aimed to investigate whether the application of LIPUS combined with bone morphogenetic protein-2 (BMP-2)-loaded poly-L-lactic acid/polylactic-co-glycolic acid/poly-epsilon-caprolactone (PLLA/PLGA/PCL) composite scaffolds can improve recovery in a rat model of steroid-induced osteonecrosis of the femoral head (ONFH).	polycaprolactone	177-202	bone morphogenetic protein 2	Rattus norvegicus	116-121
34035190-1	2020	An innovative basic fibroblast growth factor (bFGF)-loaded polycaprolactone (PCL) fibrous membrane with highly aligned structure is developed for guided tissue regeneration (GTR).	polycaprolactone	59-75	fibroblast growth factor 2	Mus musculus	46-50
33007484-3	2020	In the present study, we enhanced the repair efficiency of osteochondral defects by developing a bi-layer scaffold: an interleukin-4 (IL-4)-loaded radially oriented gelatin methacrylate (GelMA) scaffold printed with digital light processing (DLP) in the upper layer and a porous polycaprolactone and hydroxyapatite (PCL-HA) scaffold printed with fused deposition modeling (FDM) in the lower layer.	polycaprolactone	279-295	interleukin 4	Mus musculus	119-132
33007484-3	2020	In the present study, we enhanced the repair efficiency of osteochondral defects by developing a bi-layer scaffold: an interleukin-4 (IL-4)-loaded radially oriented gelatin methacrylate (GelMA) scaffold printed with digital light processing (DLP) in the upper layer and a porous polycaprolactone and hydroxyapatite (PCL-HA) scaffold printed with fused deposition modeling (FDM) in the lower layer.	polycaprolactone	279-295	interleukin 4	Mus musculus	134-138
32806224-1	2020	In this study, a polyhedral oligomeric silsesquioxane-polycaprolactone (POSS-PCL)-cored octa-arm star-shaped glyco block copolymer (BCP), poly(epsilon-caprolactone)-b-poly(glucopyranose) (Star-POSS-PCL-b-PGlc) was successfully synthesized via the combination of ring opening polymerization (ROP) and MADIX (macromolecular design by interchange of xanthate) polymerization technique.	polycaprolactone	53-70	steroidogenic acute regulatory protein	Homo sapiens	188-197
32952482-2	2020	Herein, for the first time, we demonstrated the functional restoration of an injured spinal cord by the nano CeO2 particles assembled onto poly ( -caprolactone) (PCL)/resveratrol (RVL) were synthesized using the biocompatible ionic liquid.	polycaprolactone	139-160	PHD finger protein 1	Homo sapiens	162-165
32806283-0	2020	Albumin-induced exfoliation of molybdenum disulfide nanosheets incorporated polycaprolactone/zein composite nanofibers for bone tissue regeneration.	polycaprolactone	76-92	albumin	Mus musculus	0-7
32750216-4	2020	Herein, 3D foams of polycaprolactone doped with polydopamine and polymethacrylic acid (PCL pDA pMAA) were created.	polycaprolactone	20-36	PHD finger protein 1	Homo sapiens	87-90
32600706-7	2020	Despite the notable reduction in the cell viability, significant differentiation was revealed by ALP assay on PCL/GO-Dex scaffolds.	polycaprolactone	110-113	alkaline phosphatase, placental	Homo sapiens	97-100
32667794-10	2020	Moreover, the ALA/PCL based ENMs could increase the synthesis of type I collagen and decrease the expression of alpha-smooth muscle actin, conferring that the novel wound dressings could reduce the formation of scars.	polycaprolactone	18-21	actin gamma 2, smooth muscle	Rattus norvegicus	112-137
32911737-0	2020	A New Polycaprolactone-Based Biomembrane Functionalized with BMP-2 and Stem Cells Improves Maxillary Bone Regeneration.	polycaprolactone	6-22	bone morphogenetic protein 2	Homo sapiens	61-66
32911737-3	2020	Recently, bone neoformation was demonstrated after in vivo implantation of polycaprolactone (PCL) biomembranes functionalized with bone morphogenic protein 2 (BMP-2) and ibuprofen in a mouse maxillary bone lesion.	polycaprolactone	75-91	bone morphogenetic protein 2	Mus musculus	131-157
32911737-3	2020	Recently, bone neoformation was demonstrated after in vivo implantation of polycaprolactone (PCL) biomembranes functionalized with bone morphogenic protein 2 (BMP-2) and ibuprofen in a mouse maxillary bone lesion.	polycaprolactone	75-91	bone morphogenetic protein 2	Mus musculus	159-164
32743958-4	2020	To this end, a porous polycaprolactone/hydroxyapatite (PCL/HA) scaffold is prepared via the SLS technique, which is further modified with vascular endothelial growth factor (VEGF) by coprecipitation with apatite.	polycaprolactone	22-38	vascular endothelial growth factor A	Rattus norvegicus	138-172
33072535-1	2020	Purpose: In the present study, the poly (epsilon-caprolactone)/cellulose nanofiber containing ZrO2 nanoparticles (PCL/CNF/ZrO2 ) nanocomposite was synthesized for wound dressing bandage with antimicrobial activity.	polycaprolactone	35-62	PHD finger protein 1	Homo sapiens	114-117
33072535-1	2020	Purpose: In the present study, the poly (epsilon-caprolactone)/cellulose nanofiber containing ZrO2 nanoparticles (PCL/CNF/ZrO2 ) nanocomposite was synthesized for wound dressing bandage with antimicrobial activity.	polycaprolactone	35-62	NPHS1 adhesion molecule, nephrin	Homo sapiens	118-121
32656942-6	2020	Subsequently, a polycaprolactone (PCL)-reinforced porcine blood-derived fibrinogen scaffold (isolated using the same protocol as cord blood fibrinogen) was used to develop a rolled-sheet graft which employed topographical and biochemical guidance cues to promote elastogenesis and cellular orientation.	polycaprolactone	16-32	fibrinogen beta chain	Homo sapiens	72-82
32656942-6	2020	Subsequently, a polycaprolactone (PCL)-reinforced porcine blood-derived fibrinogen scaffold (isolated using the same protocol as cord blood fibrinogen) was used to develop a rolled-sheet graft which employed topographical and biochemical guidance cues to promote elastogenesis and cellular orientation.	polycaprolactone	34-37	fibrinogen beta chain	Homo sapiens	72-82
32743958-4	2020	To this end, a porous polycaprolactone/hydroxyapatite (PCL/HA) scaffold is prepared via the SLS technique, which is further modified with vascular endothelial growth factor (VEGF) by coprecipitation with apatite.	polycaprolactone	22-38	vascular endothelial growth factor A	Rattus norvegicus	174-178
32213362-4	2020	First, siRNAs that target the heat-shock-protein 70 (Hsp70) serve as crosslinkers to guide the DNA-grafted polycaprolactone (DNA-g-PCL) assemble into nanosized hydrogel particles through nucleic acid hybridization.	polycaprolactone	107-123	heat shock protein family A (Hsp70) member 4	Homo sapiens	30-51
32569814-3	2020	Besifloxacin HCl (BH) or BH-hydroxypropyl-beta-cyclodextrin (HP-beta-CD) complex containing poly(caprolactone)/polyethylene glycol (PLC/PEG) fibrous inserts were prepared with an electrospinning method.	polycaprolactone	92-110	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	64-71
28011394-3	2020	131I-DOX-NL was constructed based on bovine serum albumin (BSA)-tailor made hydrophobic maleimide-functionalized poly(epsilon-caprolactone) (PCL) (Fig.	polycaprolactone	141-144	albumin	Mus musculus	44-57
32501667-7	2020	Arg-rich poly(epsilon-caprolactone) (PCL)-b-PArg, a macromolecular NO donor, was accurately synthesized to avoid premature L-Arg leakage during in vivo transportation.	polycaprolactone	9-35	poly(ADP-ribose) glycohydrolase	Homo sapiens	44-48
32501667-7	2020	Arg-rich poly(epsilon-caprolactone) (PCL)-b-PArg, a macromolecular NO donor, was accurately synthesized to avoid premature L-Arg leakage during in vivo transportation.	polycaprolactone	37-40	poly(ADP-ribose) glycohydrolase	Homo sapiens	44-48
32213362-4	2020	First, siRNAs that target the heat-shock-protein 70 (Hsp70) serve as crosslinkers to guide the DNA-grafted polycaprolactone (DNA-g-PCL) assemble into nanosized hydrogel particles through nucleic acid hybridization.	polycaprolactone	107-123	heat shock protein family A (Hsp70) member 4	Homo sapiens	53-58
32204042-12	2020	It revealed that the pro-inflammatory cytokines (TNF-alpha and IL-1beta) were significantly upregulated on PCL nanofibers, while their expression was comparatively lower on poly-l-lysine coated PCL or PVP-I/PCL(c/s) nanofibers.	polycaprolactone	107-110	tumor necrosis factor	Mus musculus	49-58
32610580-0	2020	Assessment of the Release of Vascular Endothelial Growth Factor from 3D-Printed Poly-epsilon-Caprolactone/Hydroxyapatite/Calcium Sulfate Scaffold with Enhanced Osteogenic Capacity.	polycaprolactone	80-105	vascular endothelial growth factor A	Homo sapiens	29-63
32545664-3	2020	Here, we characterized SRL-enriched matrices, intended for coating vascular stents, that were produced by electrospinning (ES) on a drum collector from a solution of polycaprolactone (PCL) and human serum albumin (HSA), 1,1,1,3,3,3-hexafluoroisopropanol (HFIP), dimethyl sulfoxide (DMSO), and SRL.	polycaprolactone	166-182	sarcalumenin	Homo sapiens	23-26
32547010-10	2020	Cell studies further confirmed pronounced expression of HIF-1alpha at gene and protein levels in cells seeded on PCL-sodium percarbonate (SPC) and PCL scaffolds compared with the cells cultured on a tissue culture plate.	polycaprolactone	113-116	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	56-66
32387702-1	2020	We previously developed a nose-to-brain delivery system using poly(ethylene glycol)-polycaprolactone block polymeric micelles modified by a cell-penetrating peptide, Tat (PEG-PCL-Tat).	polycaprolactone	84-100	tyrosine aminotransferase	Rattus norvegicus	166-169
32387702-1	2020	We previously developed a nose-to-brain delivery system using poly(ethylene glycol)-polycaprolactone block polymeric micelles modified by a cell-penetrating peptide, Tat (PEG-PCL-Tat).	polycaprolactone	84-100	tyrosine aminotransferase	Rattus norvegicus	179-182
32369347-3	2020	Specifically, zwitterion- and trehalose-substituted polycaprolactone, polyvalerolactone, polycarbonate, and polylactide were prepared and characterized with regards to their hydrolytic degradation and ability to stabilize insulin to mechanical agitation during heat.	polycaprolactone	52-68	insulin	Homo sapiens	222-229
32279777-3	2020	Poly (epsilon-caprolactone) (PCL) is a biodegradable polymer, semi crystalline, with superior mechanical properties and has attracted an increasing interest due to its usefulness in various biomedical applications.	polycaprolactone	0-27	PHD finger protein 1	Homo sapiens	29-32
32466329-6	2020	In this work, reclaimed rubber/poly(epsilon-caprolactone) (RR/PCL) blends are proposed to enhance the recycling and upcycling possibilities of waste rubbers.	polycaprolactone	31-57	PHD finger protein 1	Homo sapiens	62-65
32240810-2	2020	In order to develop such a system to support bone tissue regeneration, in the present study, we developed a three-dimensional poly(L-lactic-co-glycolic acid) (PLGA)/Polycaprolactone (PCL) nanohybrid scaffold embedded with PLGA macroparticles (MPs) conjugated with TGF-beta3 for the growth and chondrogenic differentiation of human mesenchymal stem cells (hMSCs).	polycaprolactone	183-186	transforming growth factor beta 3	Homo sapiens	264-273
32370165-10	2020	The presented methodology was validated by the analysis of fibronectin on the surface of plasma-coated poly(epsilon-caprolactone) (PCL) nanofibers.	polycaprolactone	103-129	fibronectin 1	Homo sapiens	59-70
32204042-12	2020	It revealed that the pro-inflammatory cytokines (TNF-alpha and IL-1beta) were significantly upregulated on PCL nanofibers, while their expression was comparatively lower on poly-l-lysine coated PCL or PVP-I/PCL(c/s) nanofibers.	polycaprolactone	107-110	interleukin 1 alpha	Mus musculus	63-71
32235724-7	2020	Furthermore, in terms of extracellular signal-regulated kinase (ERK)1/2 phosphorylation, an insight into the role of the magnetic stimulation was reported, also demonstrating a strong effect due the combination of the magnetic field with PCL/Fe3O4 nanocomposites (PCL/Fe3O4 Mag).	polycaprolactone	238-241	mitogen-activated protein kinase 3	Homo sapiens	25-71
32295900-4	2020	Further analysis in a murine model demonstrated an early innate IL17 response to implanted synthetic material (polycaprolactone) particles that was mediated by innate lymphoid cells and gammadelta+ T cells.	polycaprolactone	111-127	interleukin 17A	Mus musculus	64-68
32125862-4	2020	For this, a supramolecular polymer, beta-CD-g-PDMAEMA@Azo-PCL, was designed and developed through the host-guest inclusion complexation interactions between a host polymer, beta-cyclodextrin-graft-poly(2-(dimethylamino)ethyl methacrylate) (beta-CD-g-PDMAEMA), and a guest polymer, azobenzene modified poly(epsilon-caprolactone) (Azo-PCL), and was characterized by various analysis techniques.	polycaprolactone	301-327	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	36-43
32245159-2	2020	METHODS: Here, we evaluated the benefits of providing a sequence for the cartilage-specific sex-determining region Y-type high-mobility group box 9 (SOX9) transcription factor to human marrow aspirates via recombinant adeno-associated virus (rAAV) vectors delivered by poly(epsilon-caprolactone) (PCL) films functionalized via grafting with poly(sodium styrene sulfonate) (pNaSS) to enhance the marrow chondrogenic potential over time.	polycaprolactone	269-295	SRY-box transcription factor 9	Homo sapiens	149-153
32245159-2	2020	METHODS: Here, we evaluated the benefits of providing a sequence for the cartilage-specific sex-determining region Y-type high-mobility group box 9 (SOX9) transcription factor to human marrow aspirates via recombinant adeno-associated virus (rAAV) vectors delivered by poly(epsilon-caprolactone) (PCL) films functionalized via grafting with poly(sodium styrene sulfonate) (pNaSS) to enhance the marrow chondrogenic potential over time.	polycaprolactone	297-300	SRY-box transcription factor 9	Homo sapiens	149-153
32235724-7	2020	Furthermore, in terms of extracellular signal-regulated kinase (ERK)1/2 phosphorylation, an insight into the role of the magnetic stimulation was reported, also demonstrating a strong effect due the combination of the magnetic field with PCL/Fe3O4 nanocomposites (PCL/Fe3O4 Mag).	polycaprolactone	264-267	mitogen-activated protein kinase 3	Homo sapiens	25-71
33405721-0	2019	Poly(epsilon-caprolactone) Scaffolds Doped with c-Jun N-terminal Kinase Inhibitors Modulate Phagocyte Activation.	polycaprolactone	0-26	mitogen-activated protein kinase 8	Homo sapiens	48-71
32188900-2	2020	In this study, poly caprolactone/beta tricalcium phosphate (PCL/beta-TCP) scaffolds were fabricated by multi-head deposition system.	polycaprolactone	15-32	serine peptidase inhibitor Kazal type 1	Homo sapiens	69-72
31007068-4	2019	Cytotoxicity was tested against the immortalized mouse brain endothelioma cells over 96 h. Moreover, cells monolayer integrity and transportation ability were examined for 24 h. Pentamidine-loaded polycaprolactone (PCL) nanoparticles had a mean size of 267.58, PDI of 0.25 and zeta potential of -28.1 mV and pentamidine-loaded liposomes had a mean size of 119.61 nm, PDI of 0.25 and zeta potential 11.78.	polycaprolactone	197-213	peptidyl arginine deiminase 1	Homo sapiens	261-264
31007068-4	2019	Cytotoxicity was tested against the immortalized mouse brain endothelioma cells over 96 h. Moreover, cells monolayer integrity and transportation ability were examined for 24 h. Pentamidine-loaded polycaprolactone (PCL) nanoparticles had a mean size of 267.58, PDI of 0.25 and zeta potential of -28.1 mV and pentamidine-loaded liposomes had a mean size of 119.61 nm, PDI of 0.25 and zeta potential 11.78.	polycaprolactone	197-213	peptidyl arginine deiminase 1	Homo sapiens	367-370
31923967-3	2020	In this work, a cellulose-graft-poly(epsilon-caprolactone) (cell-g-PCL) was synthetized and characterized by FTIR, TGA and DSC in order to validate the synthesis process.	polycaprolactone	31-58	T-box transcription factor 1	Homo sapiens	115-118
31923967-3	2020	In this work, a cellulose-graft-poly(epsilon-caprolactone) (cell-g-PCL) was synthetized and characterized by FTIR, TGA and DSC in order to validate the synthesis process.	polycaprolactone	31-58	desmocollin 3	Homo sapiens	123-126
32103947-0	2020	Regulation of ERK1/2 and SMAD2/3 Pathways by Using Multi-Layered Electrospun PCL-Amnion Nanofibrous Membranes for the Prevention of Post-Surgical Tendon Adhesion.	polycaprolactone	77-80	mothers against decapentaplegic homolog 2	Oryctolagus cuniculus	25-32
31761205-1	2020	Polymer blend made from poly(epsilon - caprolactone)/chitosan (PCL/CHT) offers interesting opportunities for biological applications.	polycaprolactone	24-52	solute carrier family 5 member 7	Homo sapiens	67-70
31740904-0	2019	Substance P-loaded electrospun small intestinal submucosa/poly(epsilon-caprolactone)-ran-poly(l-lactide) sheet to facilitate wound healing through MSC recruitment.	polycaprolactone	58-84	musculin	Homo sapiens	147-150
33405721-2	2019	Herein, we developed electrospun poly(epsilon-caprolactone) (PCL) scaffolds doped with the novel potent c-Jun N-terminal kinase (JNK) inhibitors 11H-indeno[1,2-b]quinoxalin-11-one oxime (IQ-1) and 11H-indeno[1,2-b]quinoxalin-11-one O-(O-ethylcarboxymethyl) oxime(IQ-1E) as a promising approach for modulating phagocyte activation.	polycaprolactone	33-59	mitogen-activated protein kinase 8	Homo sapiens	104-127
33405721-2	2019	Herein, we developed electrospun poly(epsilon-caprolactone) (PCL) scaffolds doped with the novel potent c-Jun N-terminal kinase (JNK) inhibitors 11H-indeno[1,2-b]quinoxalin-11-one oxime (IQ-1) and 11H-indeno[1,2-b]quinoxalin-11-one O-(O-ethylcarboxymethyl) oxime(IQ-1E) as a promising approach for modulating phagocyte activation.	polycaprolactone	33-59	mitogen-activated protein kinase 8	Homo sapiens	129-132
31076208-3	2019	In this study, we have developed a triple-polymer scaffold made of collagen-elastin-polycaprolactone (CEP) composite, aiming to enhance the mechanical properties of the scaffold while retaining its biological properties in promoting cell attachment, proliferation and tissue regeneration.	polycaprolactone	84-100	elastin	Mus musculus	76-83
31382833-4	2019	METHODS: A tumor suppressor gene GRIM-19 was delivered by an amphiphilic copolymer consisted of Poly(epsilon-caprolactone) and ethanolamine-functionalized poly (glycidyl methacrylate) (PCG).	polycaprolactone	96-122	NADH:ubiquinone oxidoreductase subunit A13	Mus musculus	33-40
31400571-4	2019	Further, bone morphogenic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) mimicking peptides have been successfully tethered onto poly(epsilon-caprolactone) (PCL):gelatin:(gelatin-methacryloyl) (GelMA)(1:0.5:0.5) NMs through photocrosslinking of the methacrylic group in GelMA and octenyl alanine (OCTAL) in the modified peptides.	polycaprolactone	146-172	bone morphogenetic protein 2	Homo sapiens	9-35
31472212-2	2019	In this study, CA and polycaprolactone (PCL) was applied to fabricate the electrospun nanofibrous for wound dressing application.	polycaprolactone	22-38	citrate synthase-like	Apis mellifera	40-43
31500024-1	2019	Graphene-contained calcium silicate (CS)/polycaprolactone (PCL) scaffold (GCP) provides an alternative solution that can bring several bone formation properties, such as osteoinductive.	polycaprolactone	41-57	golgin B1	Homo sapiens	74-77
31500024-1	2019	Graphene-contained calcium silicate (CS)/polycaprolactone (PCL) scaffold (GCP) provides an alternative solution that can bring several bone formation properties, such as osteoinductive.	polycaprolactone	59-62	golgin B1	Homo sapiens	74-77
31500029-2	2019	Here we fabricated poly (lactic-co-glycolic acid) (PLGA)/poly(caprolactone) (PCL)-doped octacalcium phosphate (OCP) nanofiber membranes via electrospinning and investigated the osteogenic behavior of marrow mesenchymal stem cells (MSCs) on the membranes.	polycaprolactone	57-75	PHD finger protein 1	Homo sapiens	77-80
31400571-4	2019	Further, bone morphogenic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) mimicking peptides have been successfully tethered onto poly(epsilon-caprolactone) (PCL):gelatin:(gelatin-methacryloyl) (GelMA)(1:0.5:0.5) NMs through photocrosslinking of the methacrylic group in GelMA and octenyl alanine (OCTAL) in the modified peptides.	polycaprolactone	146-172	bone morphogenetic protein 2	Homo sapiens	37-42
31400571-4	2019	Further, bone morphogenic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) mimicking peptides have been successfully tethered onto poly(epsilon-caprolactone) (PCL):gelatin:(gelatin-methacryloyl) (GelMA)(1:0.5:0.5) NMs through photocrosslinking of the methacrylic group in GelMA and octenyl alanine (OCTAL) in the modified peptides.	polycaprolactone	146-172	vascular endothelial growth factor A	Homo sapiens	48-82
31400571-4	2019	Further, bone morphogenic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) mimicking peptides have been successfully tethered onto poly(epsilon-caprolactone) (PCL):gelatin:(gelatin-methacryloyl) (GelMA)(1:0.5:0.5) NMs through photocrosslinking of the methacrylic group in GelMA and octenyl alanine (OCTAL) in the modified peptides.	polycaprolactone	146-172	vascular endothelial growth factor A	Homo sapiens	84-88
31400571-4	2019	Further, bone morphogenic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) mimicking peptides have been successfully tethered onto poly(epsilon-caprolactone) (PCL):gelatin:(gelatin-methacryloyl) (GelMA)(1:0.5:0.5) NMs through photocrosslinking of the methacrylic group in GelMA and octenyl alanine (OCTAL) in the modified peptides.	polycaprolactone	174-177	bone morphogenetic protein 2	Homo sapiens	9-35
31400571-4	2019	Further, bone morphogenic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) mimicking peptides have been successfully tethered onto poly(epsilon-caprolactone) (PCL):gelatin:(gelatin-methacryloyl) (GelMA)(1:0.5:0.5) NMs through photocrosslinking of the methacrylic group in GelMA and octenyl alanine (OCTAL) in the modified peptides.	polycaprolactone	174-177	bone morphogenetic protein 2	Homo sapiens	37-42
31400571-4	2019	Further, bone morphogenic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) mimicking peptides have been successfully tethered onto poly(epsilon-caprolactone) (PCL):gelatin:(gelatin-methacryloyl) (GelMA)(1:0.5:0.5) NMs through photocrosslinking of the methacrylic group in GelMA and octenyl alanine (OCTAL) in the modified peptides.	polycaprolactone	174-177	vascular endothelial growth factor A	Homo sapiens	48-82
31400571-4	2019	Further, bone morphogenic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) mimicking peptides have been successfully tethered onto poly(epsilon-caprolactone) (PCL):gelatin:(gelatin-methacryloyl) (GelMA)(1:0.5:0.5) NMs through photocrosslinking of the methacrylic group in GelMA and octenyl alanine (OCTAL) in the modified peptides.	polycaprolactone	174-177	vascular endothelial growth factor A	Homo sapiens	84-88
31081968-0	2019	Incorporated-bFGF polycaprolactone/polyvinylidene fluoride nanocomposite scaffold promotes human induced pluripotent stem cells osteogenic differentiation.	polycaprolactone	18-34	fibroblast growth factor 2	Homo sapiens	13-17
31437637-3	2019	Here we constructed a composite membrane consisting of an electrospun bioabsorbable poly(epsilon-caprolactone) (PCL) nanofiber mesh to significantly improve the ultimate tensile strength, toughness, and suture retention strength by 4-10-fold in comparison with decellularized AM sheet.	polycaprolactone	84-110	Fs(3)Dam	Drosophila melanogaster	276-278
31437637-3	2019	Here we constructed a composite membrane consisting of an electrospun bioabsorbable poly(epsilon-caprolactone) (PCL) nanofiber mesh to significantly improve the ultimate tensile strength, toughness, and suture retention strength by 4-10-fold in comparison with decellularized AM sheet.	polycaprolactone	112-115	Fs(3)Dam	Drosophila melanogaster	276-278
31437637-9	2019	Here we constructed a composite membrane using a layer of electrospun poly(epsilon-caprolactone) (PCL) nanofiber mesh to reinforce the dAM sheet through covalent interfacial bonding, while retaining the unique bioactivity of dAM.	polycaprolactone	70-96	Fs(3)Dam	Drosophila melanogaster	135-138
31437637-9	2019	Here we constructed a composite membrane using a layer of electrospun poly(epsilon-caprolactone) (PCL) nanofiber mesh to reinforce the dAM sheet through covalent interfacial bonding, while retaining the unique bioactivity of dAM.	polycaprolactone	70-96	Fs(3)Dam	Drosophila melanogaster	225-228
31437637-9	2019	Here we constructed a composite membrane using a layer of electrospun poly(epsilon-caprolactone) (PCL) nanofiber mesh to reinforce the dAM sheet through covalent interfacial bonding, while retaining the unique bioactivity of dAM.	polycaprolactone	98-101	Fs(3)Dam	Drosophila melanogaster	135-138
31437637-9	2019	Here we constructed a composite membrane using a layer of electrospun poly(epsilon-caprolactone) (PCL) nanofiber mesh to reinforce the dAM sheet through covalent interfacial bonding, while retaining the unique bioactivity of dAM.	polycaprolactone	98-101	Fs(3)Dam	Drosophila melanogaster	225-228
31330782-0	2019	Sustained Release of Basic Fibroblast Growth Factor (bFGF) Encapsulated Polycaprolactone (PCL) Microspheres Promote Angiogenesis In Vivo.	polycaprolactone	72-88	fibroblast growth factor 2	Rattus norvegicus	21-51
31344444-3	2019	Polycaprolactone (PCL) has low toxicity with good mechanical strength and controlled release properties, but lack cell recognition signals.	polycaprolactone	0-16	PHD finger protein 1	Homo sapiens	18-21
31393107-0	2019	Programmed Release of Multimodal, Cross-Linked Vascular Endothelial Growth Factor and Heparin Layers on Electrospun Polycaprolactone Vascular Grafts.	polycaprolactone	116-132	vascular endothelial growth factor A	Homo sapiens	47-81
31393107-2	2019	In this study, multiple layers of various bioactive molecules, such as vascular endothelial growth factor (VEGF) and heparin, on an electrospun polycaprolactone scaffold have been developed through repeated electrostatic adsorption self-assembly (up to 20 layers), followed by genipin cross-linking.	polycaprolactone	144-160	vascular endothelial growth factor A	Homo sapiens	71-105
31393107-2	2019	In this study, multiple layers of various bioactive molecules, such as vascular endothelial growth factor (VEGF) and heparin, on an electrospun polycaprolactone scaffold have been developed through repeated electrostatic adsorption self-assembly (up to 20 layers), followed by genipin cross-linking.	polycaprolactone	144-160	vascular endothelial growth factor A	Homo sapiens	107-111
31146979-8	2019	Western blot analysis showed the porous structure facilitate the secretion of bone morphogenic protein-2 (BMP-2) and osteopontin at both day 7 and 14 which galvanizes the osteogenic capability of PCL and PCL + GO scaffolds.	polycaprolactone	196-199	bone morphogenetic protein 2	Homo sapiens	78-104
31146979-8	2019	Western blot analysis showed the porous structure facilitate the secretion of bone morphogenic protein-2 (BMP-2) and osteopontin at both day 7 and 14 which galvanizes the osteogenic capability of PCL and PCL + GO scaffolds.	polycaprolactone	196-199	bone morphogenetic protein 2	Homo sapiens	106-111
31146979-8	2019	Western blot analysis showed the porous structure facilitate the secretion of bone morphogenic protein-2 (BMP-2) and osteopontin at both day 7 and 14 which galvanizes the osteogenic capability of PCL and PCL + GO scaffolds.	polycaprolactone	204-207	bone morphogenetic protein 2	Homo sapiens	78-104
31146979-8	2019	Western blot analysis showed the porous structure facilitate the secretion of bone morphogenic protein-2 (BMP-2) and osteopontin at both day 7 and 14 which galvanizes the osteogenic capability of PCL and PCL + GO scaffolds.	polycaprolactone	204-207	bone morphogenetic protein 2	Homo sapiens	106-111
31089062-8	2019	CD4 immunoreactivity was obviously weaker in rats subjected to repair with electrospun absorbable biopolymer nanofiber conduits than in those subjected to repair with poly(epsilon-caprolactone) or silicone.	polycaprolactone	167-193	Cd4 molecule	Rattus norvegicus	0-3
31330782-0	2019	Sustained Release of Basic Fibroblast Growth Factor (bFGF) Encapsulated Polycaprolactone (PCL) Microspheres Promote Angiogenesis In Vivo.	polycaprolactone	72-88	fibroblast growth factor 2	Rattus norvegicus	53-57
31330782-0	2019	Sustained Release of Basic Fibroblast Growth Factor (bFGF) Encapsulated Polycaprolactone (PCL) Microspheres Promote Angiogenesis In Vivo.	polycaprolactone	90-93	fibroblast growth factor 2	Rattus norvegicus	21-51
31330782-0	2019	Sustained Release of Basic Fibroblast Growth Factor (bFGF) Encapsulated Polycaprolactone (PCL) Microspheres Promote Angiogenesis In Vivo.	polycaprolactone	90-93	fibroblast growth factor 2	Rattus norvegicus	53-57
31330782-4	2019	The goal of this study was to develop bFGF-loaded polycaprolactone (PCL) microspheres for sustained release of bFGF and to evaluate its angiogenic potential.	polycaprolactone	50-66	fibroblast growth factor 2	Rattus norvegicus	38-42
31330782-4	2019	The goal of this study was to develop bFGF-loaded polycaprolactone (PCL) microspheres for sustained release of bFGF and to evaluate its angiogenic potential.	polycaprolactone	50-66	fibroblast growth factor 2	Rattus norvegicus	111-115
31330782-4	2019	The goal of this study was to develop bFGF-loaded polycaprolactone (PCL) microspheres for sustained release of bFGF and to evaluate its angiogenic potential.	polycaprolactone	68-71	fibroblast growth factor 2	Rattus norvegicus	38-42
31330782-4	2019	The goal of this study was to develop bFGF-loaded polycaprolactone (PCL) microspheres for sustained release of bFGF and to evaluate its angiogenic potential.	polycaprolactone	68-71	fibroblast growth factor 2	Rattus norvegicus	111-115
31413943-0	2019	Bone Morphogenetic Protein 2-Conjugated Silica Particles Enhanced Early Osteogenic Differentiation of Adipose Stem Cells on the Polycaprolactone Scaffold.	polycaprolactone	128-144	bone morphogenetic protein 2	Homo sapiens	0-28
31336891-0	2019	Boosting Drug Discovery for Parkinson"s: Enhancement of the Delivery of a Monoamine Oxidase-B Inhibitor by Brain-Targeted PEGylated Polycaprolactone-Based Nanoparticles.	polycaprolactone	132-148	monoamine oxidase B	Homo sapiens	74-93
30315717-8	2019	Immunoflourescence staining using von Willibrand factor (vWF) antibody shows improved endothelialization in SP and Hep/SP grafts compared with the PCL grafts.	polycaprolactone	147-150	von Willebrand factor	Rattus norvegicus	57-60
31117353-6	2019	The growth of HAp crystals was facilitated by simple incubation of the electrospun lignin/polycaprolactone (PCL) matrix in a simulated body fluid.	polycaprolactone	90-106	reticulon 3	Homo sapiens	14-17
31243558-7	2019	The mineralization and ALP activity was higher for polycaprolactone membranes modified with Zn doped bioglass than compared to pure PCL membranes or control material.	polycaprolactone	51-67	ATHS	Homo sapiens	23-26
30797003-4	2019	In this study, tubular electrospun scaffolds loaded with TGFbeta2 were fabricated using various ratios of gelatin/polycaprolactone (PCL), resulting in scaffolds with porous nano-woven architecture suitable for tissue ingrowth.	polycaprolactone	114-130	transforming growth factor beta 2	Homo sapiens	57-65
30548655-0	2019	Bone morphogenetic protein-7 incorporated polycaprolactone scaffold has a great potential to improve survival and proliferation rate of the human embryonic kidney cells.	polycaprolactone	42-58	bone morphogenetic protein 7	Homo sapiens	0-28
30956516-7	2019	A 75:25 ratio of PCL:CA was found to be optimal in promoting cellular attachment and insulin immobilization.	polycaprolactone	17-20	insulin	Homo sapiens	85-92
30775753-4	2019	Here, we report a method to stably label self-assembled nanoparticles by the incorporation of rhodamine B-conjugated poly(epsilon-caprolactone) (PCL-RhoB).	polycaprolactone	117-143	ras homolog family member B	Homo sapiens	149-153
33405654-3	2019	Porous poly(epsilon-caprolactone) (PCL)/bioactive glass (BG) composite scaffolds with strong anchor of CS were fabricated via mussel-inspired polydopamine (PDA) coating as a bridging layer.	polycaprolactone	7-33	citrate synthase	Homo sapiens	103-105
33405654-3	2019	Porous poly(epsilon-caprolactone) (PCL)/bioactive glass (BG) composite scaffolds with strong anchor of CS were fabricated via mussel-inspired polydopamine (PDA) coating as a bridging layer.	polycaprolactone	35-38	citrate synthase	Homo sapiens	103-105
30985969-4	2019	To this end, a polylactide-co-glycolide/poly-epsilon-caprolactone mesh was designed to localize the delivery of insulin-like growth factor 1 (IGF-1), a well-established chondrocyte attractant.	polycaprolactone	40-65	insulin like growth factor 1	Homo sapiens	112-140
31001528-2	2019	In particular three different approaches were investigated to achieve the functionalization of poly(epsilon caprolactone) (PCL) electrospun fibers with fibronectin.	polycaprolactone	95-121	fibronectin 1	Homo sapiens	152-163
31001528-2	2019	In particular three different approaches were investigated to achieve the functionalization of poly(epsilon caprolactone) (PCL) electrospun fibers with fibronectin.	polycaprolactone	123-126	fibronectin 1	Homo sapiens	152-163
30985969-4	2019	To this end, a polylactide-co-glycolide/poly-epsilon-caprolactone mesh was designed to localize the delivery of insulin-like growth factor 1 (IGF-1), a well-established chondrocyte attractant.	polycaprolactone	40-65	insulin like growth factor 1	Homo sapiens	142-147
30940304-5	2019	In this study, leflunomide-loaded poly(epsilon-caprolactone) implants (leflunomide PCL implants) were evaluated as local drug delivery systems capable of attenuating inflammation and angiogenesis, which represent events of synovitis.	polycaprolactone	34-60	polycystic kidney disease 2-like 1	Mus musculus	83-86
30678950-3	2019	In this work, we encapsulated vascular endothelial growth factor (VEGF) into polycaprolactone (PCL) nanoparticles.	polycaprolactone	77-93	vascular endothelial growth factor A	Rattus norvegicus	30-64
30678950-3	2019	In this work, we encapsulated vascular endothelial growth factor (VEGF) into polycaprolactone (PCL) nanoparticles.	polycaprolactone	77-93	vascular endothelial growth factor A	Rattus norvegicus	66-70
30678950-3	2019	In this work, we encapsulated vascular endothelial growth factor (VEGF) into polycaprolactone (PCL) nanoparticles.	polycaprolactone	95-98	vascular endothelial growth factor A	Rattus norvegicus	30-64
30678950-3	2019	In this work, we encapsulated vascular endothelial growth factor (VEGF) into polycaprolactone (PCL) nanoparticles.	polycaprolactone	95-98	vascular endothelial growth factor A	Rattus norvegicus	66-70
30678950-5	2019	The encapsulation efficiency of the PCL nanoparticles for VEGF was up to 82%, and the in vitro accumulated release rate was slow without an evident initial burst release.	polycaprolactone	36-39	vascular endothelial growth factor A	Rattus norvegicus	58-62
30841972-6	2019	Firstly, this study demonstrated that AST-PCL (polycaprolactone) degradation media protects endothelial cells from apoptosis by down-regulating the expression of cleaved Caspase 3 and decreasing the ratio of Bax/Bcl-2, it also attenuates the stress fiber formation in vitro.	polycaprolactone	47-63	BCL2 associated X, apoptosis regulator	Rattus norvegicus	208-211
30841972-6	2019	Firstly, this study demonstrated that AST-PCL (polycaprolactone) degradation media protects endothelial cells from apoptosis by down-regulating the expression of cleaved Caspase 3 and decreasing the ratio of Bax/Bcl-2, it also attenuates the stress fiber formation in vitro.	polycaprolactone	47-63	BCL2, apoptosis regulator	Rattus norvegicus	212-217
30599245-3	2019	In this study, we fabricated two different growth factor (GF) [single basic fibroblast growth factor (bFGF), single hepatocyte growth factor (HGF), or dual bFGF/HGF]-immobilized polycaprolactone (PCL)/Pluronic F127 microspheres.	polycaprolactone	178-194	fibroblast growth factor 2	Homo sapiens	156-160
33405624-2	2019	Herein, we present a plasmid DNA (pDNA; bFGF gene encoding) complex-loaded alginate (ALG)/hyaluronic acid (HA) mixture hydrogel dispersed with polycaprolactone (PCL) microspheres that can enhance simultaneous regeneration of VF muscle and lamina propria, as well as have a bulking effect on atrophied VF.	polycaprolactone	143-159	fibroblast growth factor 2	Homo sapiens	40-44
33405624-2	2019	Herein, we present a plasmid DNA (pDNA; bFGF gene encoding) complex-loaded alginate (ALG)/hyaluronic acid (HA) mixture hydrogel dispersed with polycaprolactone (PCL) microspheres that can enhance simultaneous regeneration of VF muscle and lamina propria, as well as have a bulking effect on atrophied VF.	polycaprolactone	161-164	fibroblast growth factor 2	Homo sapiens	40-44
30976294-4	2019	Methods: As an important enzyme for glucose metabolism, alpha-glucosidase was immobilized on polycaprolactone-chitosan-modified paper to prepare the microdevice with unique microfluid structure generated by 3D printing technology, which can be easily applied to screen active compounds in herbal extracts.	polycaprolactone	93-109	sucrase-isomaltase	Homo sapiens	56-73
30783426-4	2019	Culturing of ALL Jurkat cell line in collagen type I coated polycaprolactone scaffold for 168 h increased cell proliferation, attachment, as well as the drug resistance to cytarabine (Ara-C) and daunorubicin (DNR) without changing the original CD2+CD3+CD4+dimCD8-CD34-CD45+dim phenotype, compared to uncoated PCL scaffold and tissue culture plate systems.	polycaprolactone	60-76	CD34 molecule	Homo sapiens	263-267
30638510-0	2019	Optimization and modelling of enzymatic polymerization of epsilon-caprolactone to polycaprolactone using Candida Antartica Lipase B with response surface methodology and artificial neural network.	polycaprolactone	82-98	calbindin 1	Homo sapiens	105-131
30638510-3	2019	In this research, the enzymatic ring-opening polymerization (e-ROP) of e-caprolactone (e-CL) using Candida Antartica Lipase B (CALB) as catalyst to produce the Polycaprolactone.	polycaprolactone	71-85	calbindin 1	Homo sapiens	99-125
30638510-3	2019	In this research, the enzymatic ring-opening polymerization (e-ROP) of e-caprolactone (e-CL) using Candida Antartica Lipase B (CALB) as catalyst to produce the Polycaprolactone.	polycaprolactone	71-85	calbindin 1	Homo sapiens	127-131
30638510-3	2019	In this research, the enzymatic ring-opening polymerization (e-ROP) of e-caprolactone (e-CL) using Candida Antartica Lipase B (CALB) as catalyst to produce the Polycaprolactone.	polycaprolactone	160-176	calbindin 1	Homo sapiens	99-125
30638510-3	2019	In this research, the enzymatic ring-opening polymerization (e-ROP) of e-caprolactone (e-CL) using Candida Antartica Lipase B (CALB) as catalyst to produce the Polycaprolactone.	polycaprolactone	160-176	calbindin 1	Homo sapiens	127-131
30783426-4	2019	Culturing of ALL Jurkat cell line in collagen type I coated polycaprolactone scaffold for 168 h increased cell proliferation, attachment, as well as the drug resistance to cytarabine (Ara-C) and daunorubicin (DNR) without changing the original CD2+CD3+CD4+dimCD8-CD34-CD45+dim phenotype, compared to uncoated PCL scaffold and tissue culture plate systems.	polycaprolactone	60-76	protein tyrosine phosphatase receptor type C	Homo sapiens	268-272
30453227-5	2019	We confirmed that the coated-PDA layer was evenly deposited on the bare polycaprolactone (PCL) scaffold and could enable abundant VEGF immobilization with enhanced hydrophilicity.	polycaprolactone	72-88	vascular endothelial growth factor A	Homo sapiens	130-134
30453227-5	2019	We confirmed that the coated-PDA layer was evenly deposited on the bare polycaprolactone (PCL) scaffold and could enable abundant VEGF immobilization with enhanced hydrophilicity.	polycaprolactone	90-93	vascular endothelial growth factor A	Homo sapiens	130-134
30606573-6	2019	Compared to keratin, the assembly of vimentin intermediate filaments were promoted by incorporating bovine serum albumin (BSA) functionalized graphene oxide (BSA-GO) into polycaprolactone (PCL) nanofibers.	polycaprolactone	171-187	vimentin	Homo sapiens	37-45
30606573-6	2019	Compared to keratin, the assembly of vimentin intermediate filaments were promoted by incorporating bovine serum albumin (BSA) functionalized graphene oxide (BSA-GO) into polycaprolactone (PCL) nanofibers.	polycaprolactone	189-192	vimentin	Homo sapiens	37-45
30538466-9	2018	Moreover, increases in ALP activity (10-fold at day 14) and calcium deposition (1.3-fold at day 21) by hFOBs were detected after PEG and GelMA incorporation after UV photocross-linking compared to pure PCL.	polycaprolactone	202-205	alkaline phosphatase, placental	Homo sapiens	23-26
30507537-1	2019	In this paper, we separately fabricated the poly ( epsilon -caprolactone) (PCL) scaffolds containing epidermal growth factor (EGF) by using our-self fabricated electrospinning machine for tissue regeneration application.	polycaprolactone	44-73	epidermal growth factor	Mus musculus	101-124
30507537-1	2019	In this paper, we separately fabricated the poly ( epsilon -caprolactone) (PCL) scaffolds containing epidermal growth factor (EGF) by using our-self fabricated electrospinning machine for tissue regeneration application.	polycaprolactone	44-73	epidermal growth factor	Mus musculus	126-129
30423735-2	2019	In this study we tested a poly-(epsilon) caprolactone (PCL)-laponite-strontium ranelate (SRA) composite scaffold (PLS3) for its abilities to support growth and osteogenic differentiation of human marrow derived stromal stem cells (hMSC).	polycaprolactone	26-53	plastin 3	Homo sapiens	114-118
30423735-2	2019	In this study we tested a poly-(epsilon) caprolactone (PCL)-laponite-strontium ranelate (SRA) composite scaffold (PLS3) for its abilities to support growth and osteogenic differentiation of human marrow derived stromal stem cells (hMSC).	polycaprolactone	26-53	musculin	Homo sapiens	231-235
30423735-2	2019	In this study we tested a poly-(epsilon) caprolactone (PCL)-laponite-strontium ranelate (SRA) composite scaffold (PLS3) for its abilities to support growth and osteogenic differentiation of human marrow derived stromal stem cells (hMSC).	polycaprolactone	55-58	plastin 3	Homo sapiens	114-118
30423735-2	2019	In this study we tested a poly-(epsilon) caprolactone (PCL)-laponite-strontium ranelate (SRA) composite scaffold (PLS3) for its abilities to support growth and osteogenic differentiation of human marrow derived stromal stem cells (hMSC).	polycaprolactone	55-58	musculin	Homo sapiens	231-235
33312462-7	2019	Results: The obtained results showed that adhesion, viability and ALP activity of MSCs on PCL/MgO/GO scaffold considerably enhanced compared with pure PCL.	polycaprolactone	90-93	ATHS	Homo sapiens	66-69
30526272-5	2019	CONCLUSION: The functionalized polycaprolactone/gelatin/silk fibroin/VEGF (250 ng) core/shell nanofibers were fabricated for the controlled release of VEGF in a persistent manner for the differentiation of MSCs into smooth muscle cells for vascular tissue engineering.	polycaprolactone	31-47	vascular endothelial growth factor A	Homo sapiens	151-155
30029031-2	2018	EXPERIMENTS: Polycaprolactone (PCL) and polycaprolactone/polyvinyl acetate (PCL/PVAc) core-shell fibers were synthesised and decorated with poly(lactic-co-glycolic acid) [PLGA] particles loaded with bone morphogenetic protein 2 (BMP2) by simultaneous electrospinning and electrospraying.	polycaprolactone	40-56	bone morphogenetic protein 2	Homo sapiens	199-227
30029031-2	2018	EXPERIMENTS: Polycaprolactone (PCL) and polycaprolactone/polyvinyl acetate (PCL/PVAc) core-shell fibers were synthesised and decorated with poly(lactic-co-glycolic acid) [PLGA] particles loaded with bone morphogenetic protein 2 (BMP2) by simultaneous electrospinning and electrospraying.	polycaprolactone	40-56	bone morphogenetic protein 2	Homo sapiens	229-233
29600349-3	2018	In this paper we present a biocompatible microfabricated poly-epsilon-caprolactone (PCL) scaffold for primary neuron growth and maturation that has been optimized for the in vitro controlled release of brain-derived neurotrophic factor (BDNF).	polycaprolactone	57-82	brain derived neurotrophic factor	Homo sapiens	202-235
29600349-3	2018	In this paper we present a biocompatible microfabricated poly-epsilon-caprolactone (PCL) scaffold for primary neuron growth and maturation that has been optimized for the in vitro controlled release of brain-derived neurotrophic factor (BDNF).	polycaprolactone	57-82	brain derived neurotrophic factor	Homo sapiens	237-241
29600349-3	2018	In this paper we present a biocompatible microfabricated poly-epsilon-caprolactone (PCL) scaffold for primary neuron growth and maturation that has been optimized for the in vitro controlled release of brain-derived neurotrophic factor (BDNF).	polycaprolactone	84-87	brain derived neurotrophic factor	Homo sapiens	202-235
29600349-3	2018	In this paper we present a biocompatible microfabricated poly-epsilon-caprolactone (PCL) scaffold for primary neuron growth and maturation that has been optimized for the in vitro controlled release of brain-derived neurotrophic factor (BDNF).	polycaprolactone	84-87	brain derived neurotrophic factor	Homo sapiens	237-241
30445673-1	2018	In this study, a novel three-dimensional (3D) bone morphogenic protein-2 (BMP-2)-delivering tannylated polycaprolactone (PCL) (BMP-2/tannic acid (TA)/PCL) scaffold with anti-oxidant, anti-inflammatory, and osteogenic activities was fabricated via simple surface coating with TA, followed by the immobilization of BMP-2 on the TA-coated PCL scaffold.	polycaprolactone	150-153	bone morphogenetic protein 2	Mus musculus	46-72
30445673-1	2018	In this study, a novel three-dimensional (3D) bone morphogenic protein-2 (BMP-2)-delivering tannylated polycaprolactone (PCL) (BMP-2/tannic acid (TA)/PCL) scaffold with anti-oxidant, anti-inflammatory, and osteogenic activities was fabricated via simple surface coating with TA, followed by the immobilization of BMP-2 on the TA-coated PCL scaffold.	polycaprolactone	103-119	bone morphogenetic protein 2	Mus musculus	46-72
30445673-1	2018	In this study, a novel three-dimensional (3D) bone morphogenic protein-2 (BMP-2)-delivering tannylated polycaprolactone (PCL) (BMP-2/tannic acid (TA)/PCL) scaffold with anti-oxidant, anti-inflammatory, and osteogenic activities was fabricated via simple surface coating with TA, followed by the immobilization of BMP-2 on the TA-coated PCL scaffold.	polycaprolactone	150-153	bone morphogenetic protein 2	Mus musculus	74-79
30445673-1	2018	In this study, a novel three-dimensional (3D) bone morphogenic protein-2 (BMP-2)-delivering tannylated polycaprolactone (PCL) (BMP-2/tannic acid (TA)/PCL) scaffold with anti-oxidant, anti-inflammatory, and osteogenic activities was fabricated via simple surface coating with TA, followed by the immobilization of BMP-2 on the TA-coated PCL scaffold.	polycaprolactone	103-119	bone morphogenetic protein 2	Mus musculus	74-79
30445673-1	2018	In this study, a novel three-dimensional (3D) bone morphogenic protein-2 (BMP-2)-delivering tannylated polycaprolactone (PCL) (BMP-2/tannic acid (TA)/PCL) scaffold with anti-oxidant, anti-inflammatory, and osteogenic activities was fabricated via simple surface coating with TA, followed by the immobilization of BMP-2 on the TA-coated PCL scaffold.	polycaprolactone	103-119	bone morphogenetic protein 2	Mus musculus	127-132
30445673-1	2018	In this study, a novel three-dimensional (3D) bone morphogenic protein-2 (BMP-2)-delivering tannylated polycaprolactone (PCL) (BMP-2/tannic acid (TA)/PCL) scaffold with anti-oxidant, anti-inflammatory, and osteogenic activities was fabricated via simple surface coating with TA, followed by the immobilization of BMP-2 on the TA-coated PCL scaffold.	polycaprolactone	150-153	bone morphogenetic protein 2	Mus musculus	46-72
30445673-1	2018	In this study, a novel three-dimensional (3D) bone morphogenic protein-2 (BMP-2)-delivering tannylated polycaprolactone (PCL) (BMP-2/tannic acid (TA)/PCL) scaffold with anti-oxidant, anti-inflammatory, and osteogenic activities was fabricated via simple surface coating with TA, followed by the immobilization of BMP-2 on the TA-coated PCL scaffold.	polycaprolactone	103-119	bone morphogenetic protein 2	Mus musculus	127-132
30445673-1	2018	In this study, a novel three-dimensional (3D) bone morphogenic protein-2 (BMP-2)-delivering tannylated polycaprolactone (PCL) (BMP-2/tannic acid (TA)/PCL) scaffold with anti-oxidant, anti-inflammatory, and osteogenic activities was fabricated via simple surface coating with TA, followed by the immobilization of BMP-2 on the TA-coated PCL scaffold.	polycaprolactone	121-124	bone morphogenetic protein 2	Mus musculus	46-72
30445673-1	2018	In this study, a novel three-dimensional (3D) bone morphogenic protein-2 (BMP-2)-delivering tannylated polycaprolactone (PCL) (BMP-2/tannic acid (TA)/PCL) scaffold with anti-oxidant, anti-inflammatory, and osteogenic activities was fabricated via simple surface coating with TA, followed by the immobilization of BMP-2 on the TA-coated PCL scaffold.	polycaprolactone	150-153	bone morphogenetic protein 2	Mus musculus	74-79
30445673-1	2018	In this study, a novel three-dimensional (3D) bone morphogenic protein-2 (BMP-2)-delivering tannylated polycaprolactone (PCL) (BMP-2/tannic acid (TA)/PCL) scaffold with anti-oxidant, anti-inflammatory, and osteogenic activities was fabricated via simple surface coating with TA, followed by the immobilization of BMP-2 on the TA-coated PCL scaffold.	polycaprolactone	121-124	bone morphogenetic protein 2	Mus musculus	74-79
30445673-1	2018	In this study, a novel three-dimensional (3D) bone morphogenic protein-2 (BMP-2)-delivering tannylated polycaprolactone (PCL) (BMP-2/tannic acid (TA)/PCL) scaffold with anti-oxidant, anti-inflammatory, and osteogenic activities was fabricated via simple surface coating with TA, followed by the immobilization of BMP-2 on the TA-coated PCL scaffold.	polycaprolactone	121-124	bone morphogenetic protein 2	Mus musculus	127-132
30445673-2	2018	The BMP-2/TA/PCL scaffold showed controlled and sustained BMP-2 release.	polycaprolactone	13-16	bone morphogenetic protein 2	Mus musculus	4-9
30445673-1	2018	In this study, a novel three-dimensional (3D) bone morphogenic protein-2 (BMP-2)-delivering tannylated polycaprolactone (PCL) (BMP-2/tannic acid (TA)/PCL) scaffold with anti-oxidant, anti-inflammatory, and osteogenic activities was fabricated via simple surface coating with TA, followed by the immobilization of BMP-2 on the TA-coated PCL scaffold.	polycaprolactone	121-124	bone morphogenetic protein 2	Mus musculus	127-132
30445673-2	2018	The BMP-2/TA/PCL scaffold showed controlled and sustained BMP-2 release.	polycaprolactone	13-16	bone morphogenetic protein 2	Mus musculus	58-63
29513041-0	2018	VEGF-mediated angiogenesis and vascularization of a fumarate-crosslinked polycaprolactone (PCLF) scaffold.	polycaprolactone	73-89	vascular endothelial growth factor A	Rattus norvegicus	0-4
30296827-8	2018	CNF supported the formation of a well-organized actin cytoskeleton and cellular production of vinculin protein on the surfaces of TCP and PCL scaffolds.	polycaprolactone	138-141	vinculin	Homo sapiens	94-102
30277233-2	2018	To direct neuronal differentiation of stem cells, we have previously developed an electrospun polycaprolactone nanofiber scaffold that was functionalized with siRNA targeting Re-1 silencing transcription factor (REST), by mussel-inspired bioadhesive coating.	polycaprolactone	94-110	RE1 silencing transcription factor	Homo sapiens	175-210
30409449-3	2018	METHODS: The aim of this study was to investigate a novel osteoinductive scaffold by loading bone morphogenetic protein 2 (BMP-2) to mesoporous calcium silicate (MesoCS) and fabricating it as 3-dimensional scaffolds using fused deposition modeling combined with polycaprolactone.	polycaprolactone	262-278	bone morphogenetic protein 2	Homo sapiens	93-121
30325093-3	2018	In this work, the potential of three-dimensional (3D) nanofibrous graphene and poly(caprolactone) (PCL + G) composite scaffold for cardiac tissue engineering has been explored for the first time.	polycaprolactone	79-97	polycystic kidney disease 2-like 1	Mus musculus	99-102
30409449-3	2018	METHODS: The aim of this study was to investigate a novel osteoinductive scaffold by loading bone morphogenetic protein 2 (BMP-2) to mesoporous calcium silicate (MesoCS) and fabricating it as 3-dimensional scaffolds using fused deposition modeling combined with polycaprolactone.	polycaprolactone	262-278	bone morphogenetic protein 2	Homo sapiens	123-128
29773387-2	2018	For this, hydrolyzed (hHL) and sulfated hydrolyzed (ShHL) Halomonas levan were chemically synthesized and used together with polycaprolactone (PCL) and polyethyleneoxide (PEO) for the spinning process.	polycaprolactone	125-141	hes family bHLH transcription factor 1	Homo sapiens	22-25
32254712-2	2018	In this paper, we propose a general strategy to obtain biodegradable cationic NPs of poly(epsilon-caprolactone) (PCL) based on an amine terminated PCL (NH2-PCL4.2k) or its mixture with monomethoxypoly(ethylene glycol)-PCL (mPEG1k-PCL4k).	polycaprolactone	85-111	fms related receptor tyrosine kinase 4	Homo sapiens	113-116
32254712-2	2018	In this paper, we propose a general strategy to obtain biodegradable cationic NPs of poly(epsilon-caprolactone) (PCL) based on an amine terminated PCL (NH2-PCL4.2k) or its mixture with monomethoxypoly(ethylene glycol)-PCL (mPEG1k-PCL4k).	polycaprolactone	85-111	fms related receptor tyrosine kinase 4	Homo sapiens	147-150
32254712-2	2018	In this paper, we propose a general strategy to obtain biodegradable cationic NPs of poly(epsilon-caprolactone) (PCL) based on an amine terminated PCL (NH2-PCL4.2k) or its mixture with monomethoxypoly(ethylene glycol)-PCL (mPEG1k-PCL4k).	polycaprolactone	85-111	fms related receptor tyrosine kinase 4	Homo sapiens	147-150
30074814-7	2018	METHODS: BMP-2 binding peptides were synthetized, purified, and immobilized on polycaprolactone (PCL) films.	polycaprolactone	79-95	bone morphogenetic protein 2	Homo sapiens	9-14
30074814-7	2018	METHODS: BMP-2 binding peptides were synthetized, purified, and immobilized on polycaprolactone (PCL) films.	polycaprolactone	97-100	bone morphogenetic protein 2	Homo sapiens	9-14
30277375-4	2018	The oligoethylenimine-conjugated beta-cyclodextrin (beta-CD-PEI600) and benzimidazole-modified four-arm-polycaprolactone-initiated hyperbranched polyglycerol (PCL-HPG-BM) were synthesized as the host and guest molecules, respectively, and then the co-delivery carrier of PCL-HPG-PEI600 was formed from the pH-mediated inclusion interaction between beta-CD and BM.	polycaprolactone	104-120	PHD finger protein 1	Homo sapiens	159-162
30277375-4	2018	The oligoethylenimine-conjugated beta-cyclodextrin (beta-CD-PEI600) and benzimidazole-modified four-arm-polycaprolactone-initiated hyperbranched polyglycerol (PCL-HPG-BM) were synthesized as the host and guest molecules, respectively, and then the co-delivery carrier of PCL-HPG-PEI600 was formed from the pH-mediated inclusion interaction between beta-CD and BM.	polycaprolactone	104-120	PHD finger protein 1	Homo sapiens	271-274
29909312-4	2018	The traditional Chinese medicine icariin (ICA) was subsequently introduced into poly (epsilon-caprolactone) (PCL) /gelatin nanofibers to fabricate an artificial periosteum for the first time.	polycaprolactone	80-107	polycystic kidney disease 2-like 1	Mus musculus	109-112
30021337-3	2018	The present study aimed to evaluate the efficiency of implantable 17-dimethylaminoethylamino-17-demethoxy geldanamycin (17-DMAG)-loaded Poly(caprolactone)-poly(ethylene glycol) (PCL/PEG) nanofibers to increase the anti-cancer effects via inhibition of HSP90 expression and telomerase activity.	polycaprolactone	136-154	heat shock protein 90 alpha family class A member 1	Homo sapiens	252-257
29863327-3	2018	Herein, we describe bone morphogenetic protein-2 (BMP-2)-immobilized porous polycaprolactone particles with unique leaf-stacked structures (LSS particles) prepared using clinically feasible materials and procedures.	polycaprolactone	76-92	bone morphogenetic protein 2	Homo sapiens	20-48
30046239-4	2018	Materials and methods: In this study, core-shell poly(lactide-co-glycolide) (PLGA)/polycaprolactone (PCL)-BMP-2 (PP-B) fibrous scaffolds were prepared through coaxial electrospinning.	polycaprolactone	83-99	bone morphogenetic protein 2	Rattus norvegicus	106-111
30046239-4	2018	Materials and methods: In this study, core-shell poly(lactide-co-glycolide) (PLGA)/polycaprolactone (PCL)-BMP-2 (PP-B) fibrous scaffolds were prepared through coaxial electrospinning.	polycaprolactone	101-104	bone morphogenetic protein 2	Rattus norvegicus	106-111
30960678-11	2018	The Reverse Transcription-Polymerase Chain Reaction (RT-PCR) results involving the three most important genes concerning neural differentiation, namely beta3-tubulin, NF-H, and GAP-43, confirm that the scaffolds with a pore size of 125 +- 15 mum have the highest gene expression of all the other pore sizes and also outperform the electrospun Polycaprolactone (PCL) scaffold.	polycaprolactone	343-359	neurofilament heavy chain	Homo sapiens	167-171
30960678-11	2018	The Reverse Transcription-Polymerase Chain Reaction (RT-PCR) results involving the three most important genes concerning neural differentiation, namely beta3-tubulin, NF-H, and GAP-43, confirm that the scaffolds with a pore size of 125 +- 15 mum have the highest gene expression of all the other pore sizes and also outperform the electrospun Polycaprolactone (PCL) scaffold.	polycaprolactone	343-359	growth associated protein 43	Homo sapiens	177-183
30960678-11	2018	The Reverse Transcription-Polymerase Chain Reaction (RT-PCR) results involving the three most important genes concerning neural differentiation, namely beta3-tubulin, NF-H, and GAP-43, confirm that the scaffolds with a pore size of 125 +- 15 mum have the highest gene expression of all the other pore sizes and also outperform the electrospun Polycaprolactone (PCL) scaffold.	polycaprolactone	361-364	neurofilament heavy chain	Homo sapiens	167-171
30960678-11	2018	The Reverse Transcription-Polymerase Chain Reaction (RT-PCR) results involving the three most important genes concerning neural differentiation, namely beta3-tubulin, NF-H, and GAP-43, confirm that the scaffolds with a pore size of 125 +- 15 mum have the highest gene expression of all the other pore sizes and also outperform the electrospun Polycaprolactone (PCL) scaffold.	polycaprolactone	361-364	growth associated protein 43	Homo sapiens	177-183
29863327-3	2018	Herein, we describe bone morphogenetic protein-2 (BMP-2)-immobilized porous polycaprolactone particles with unique leaf-stacked structures (LSS particles) prepared using clinically feasible materials and procedures.	polycaprolactone	76-92	bone morphogenetic protein 2	Homo sapiens	50-55
29683273-3	2018	For wound healing, transforming growth factor-beta1 is incorporated into polycaprolactone/collagen (PCL/Coll) nanofibers via electrospinning and the myofibroblastic differentiation of human dermal fibroblasts is locally stimulated.	polycaprolactone	73-89	transforming growth factor beta 1	Homo sapiens	19-51
29808993-3	2018	Herein, an injectable poly(caprolactone)-poly(ethylene glycol)-poly(caprolactone) thermosensitive hydrogel coencapsulating GM-CSF and ovalbumin nanoparticles was developed to enhance antigen uptake efficiency.	polycaprolactone	22-40	colony stimulating factor 2	Homo sapiens	123-129
29808993-3	2018	Herein, an injectable poly(caprolactone)-poly(ethylene glycol)-poly(caprolactone) thermosensitive hydrogel coencapsulating GM-CSF and ovalbumin nanoparticles was developed to enhance antigen uptake efficiency.	polycaprolactone	22-39	colony stimulating factor 2	Homo sapiens	123-129
29683273-3	2018	For wound healing, transforming growth factor-beta1 is incorporated into polycaprolactone/collagen (PCL/Coll) nanofibers via electrospinning and the myofibroblastic differentiation of human dermal fibroblasts is locally stimulated.	polycaprolactone	73-89	PHD finger protein 1	Homo sapiens	100-103
28685587-3	2018	The objective of this study was an ex vivo expansion of CB HSCs in a new three-dimensional polycaprolactone nano-scaffold coated with fibronectin (FN).	polycaprolactone	91-107	fibronectin 1	Homo sapiens	147-149
30480167-5	2018	To enhance its bioavailability and to provide higher release, we have used poly (epsilon-caprolactone) (PCL), poly ethylene glycol (PEG) and poly lactide co glycolide (PLGA) as the polymeric system to enable continuous release of curcumin from the hydroxyapatite matrix for 22 days.	polycaprolactone	75-102	PHD finger protein 1	Homo sapiens	104-107
29926276-0	2018	Endothelialization of Polycaprolactone Vascular Graft under the Action of Locally Applied Vascular Endothelial Growth Factor.	polycaprolactone	22-38	vascular endothelial growth factor A	Rattus norvegicus	90-124
29926276-1	2018	We have previously developed a polycaprolactone (PCL) vascular graft with incorporated vascular endothelial growth factor (VEGF).	polycaprolactone	31-47	vascular endothelial growth factor A	Rattus norvegicus	87-121
29926276-1	2018	We have previously developed a polycaprolactone (PCL) vascular graft with incorporated vascular endothelial growth factor (VEGF).	polycaprolactone	31-47	vascular endothelial growth factor A	Rattus norvegicus	123-127
29926276-1	2018	We have previously developed a polycaprolactone (PCL) vascular graft with incorporated vascular endothelial growth factor (VEGF).	polycaprolactone	49-52	vascular endothelial growth factor A	Rattus norvegicus	87-121
29926276-1	2018	We have previously developed a polycaprolactone (PCL) vascular graft with incorporated vascular endothelial growth factor (VEGF).	polycaprolactone	49-52	vascular endothelial growth factor A	Rattus norvegicus	123-127
29972648-5	2018	Treatment of U937 and HaCaT cells with 1,25(OH)2D3-loaded poly(epsilon-caprolactone) nanofibers significantly induced hCAP18/LL37 expression in monocytes and keratinocytes, skin wounds of humanized transgenic mice and artificial wounds of human skin explants.	polycaprolactone	58-84	cathelicidin antimicrobial peptide	Homo sapiens	118-124
29972648-5	2018	Treatment of U937 and HaCaT cells with 1,25(OH)2D3-loaded poly(epsilon-caprolactone) nanofibers significantly induced hCAP18/LL37 expression in monocytes and keratinocytes, skin wounds of humanized transgenic mice and artificial wounds of human skin explants.	polycaprolactone	58-84	cathelicidin antimicrobial peptide	Homo sapiens	125-129
29314595-4	2018	Neat HNT, HNT-NH2 , and HNT-COOH were subsequently introduced into polycaprolactone/Pluronic P123 (PCL/P123) electrospun substrate.	polycaprolactone	67-83	PHD finger protein 1	Homo sapiens	99-107
29739918-3	2018	MATERIALS AND METHODS: We prepared bovine serum albumin (BSA) blend microfibers from the auxiliary proteins polyethylene oxide (PEO), polycaprolactone (PCL), polyvinyl alcohol (PVA) and gelatin.	polycaprolactone	134-150	albumin	Homo sapiens	42-55
29896385-7	2018	The films prepared by solution-deposition of BNP-based compounds in the presence of polycaprolactone also showed good ratiometric sensing for fluoride ions.	polycaprolactone	84-100	natriuretic peptide B	Homo sapiens	45-48
29642582-2	2018	The aim of this study was to develop a new anti-inflammatory scaffold by functionalizing an electrospun nanofibrous poly-epsilon-caprolactone membrane with IBU (IBU-PCL) and to evaluate its impact on periodontal inflammation, wound healing and regeneration in vitro and in vivo.	polycaprolactone	116-141	polycystic kidney disease 2-like 1	Mus musculus	165-168
29581433-6	2018	To demonstrate the synthesis of biocompatible microparticles, we generated 8-16 microm polycaprolactone particles with a CV &lt;5% at a rate of 277 g h-1.	polycaprolactone	87-103	H1.5 linker histone, cluster member	Homo sapiens	150-153
29407748-0	2018	Characterization of a bioactive Jagged1-coated polycaprolactone-based membrane for guided tissue regeneration.	polycaprolactone	47-63	jagged canonical Notch ligand 1	Homo sapiens	32-39
29407748-1	2018	OBJECTIVE: The aim of the present study was to develop a Jagged1-coated polycaprolactone (PCL) membrane and to evaluate the response of human periodontal ligament cells (hPDL) on this membrane in vitro.	polycaprolactone	72-88	jagged canonical Notch ligand 1	Homo sapiens	57-64
29407748-1	2018	OBJECTIVE: The aim of the present study was to develop a Jagged1-coated polycaprolactone (PCL) membrane and to evaluate the response of human periodontal ligament cells (hPDL) on this membrane in vitro.	polycaprolactone	90-93	jagged canonical Notch ligand 1	Homo sapiens	57-64
28456004-3	2018	Previous research from our laboratory has revealed that ICAM-1 can be used as a marker to investigate cell adhesion, an effect which was closely associated with cell behavior on the surface of polycaprolactone (PCL) films.	polycaprolactone	193-209	intercellular adhesion molecule 1	Homo sapiens	56-62
28456004-3	2018	Previous research from our laboratory has revealed that ICAM-1 can be used as a marker to investigate cell adhesion, an effect which was closely associated with cell behavior on the surface of polycaprolactone (PCL) films.	polycaprolactone	211-214	intercellular adhesion molecule 1	Homo sapiens	56-62
29568048-8	2018	We have showed dramatic improvement in flexibility of poly(epsilon-caprolactone) based nanofiber matrix prepared by electrospinning method whereas solvent casting method without any plasticizer produced very brittle, inflexible film of PCL.	polycaprolactone	54-80	PHD finger protein 1	Homo sapiens	236-239
29510552-1	2018	The present work studies the functional behavior of novel poly(epsilon-caprolactone) (PCL) membranes functionalized with reduced graphene oxide (rGO) nanoplatelets under simulated in vitro culture conditions (phosphate buffer solution (PBS) at 37  C) during 1 year, in order to elucidate their applicability as scaffolds for in vitro neural regeneration.	polycaprolactone	58-84	PHD finger protein 1	Homo sapiens	86-89
29806274-1	2018	Objective: To explore the effect of vascular endothelial growth factor 165 (VEGF 165)-loaded porous poly (epsilon-caprolactone) (PCL) scaffolds on the osteogenic differentiation of adipose-derived stem cells (ADSCs).	polycaprolactone	100-127	vascular endothelial growth factor A	Rattus norvegicus	76-80
29517988-0	2018	Electrospun F18 Bioactive Glass/PCL-Poly (epsilon-caprolactone)-Membrane for Guided Tissue Regeneration.	polycaprolactone	36-63	mastermind like domain containing 1	Homo sapiens	12-15
29682553-3	2018	In vivo implantation of polycaprolactone (PCL) biomembrane functionalized with BMP-2/Ibuprofen in mouse maxillary defects was followed by bone neoformation kinetics evaluation using microcomputed tomography.	polycaprolactone	24-40	bone morphogenetic protein 2	Mus musculus	79-84
29868646-0	2018	Extracellular matrix protein production in human adipose-derived mesenchymal stem cells on three-dimensional polycaprolactone (PCL) scaffolds responds to GDF5 or FGF2.	polycaprolactone	109-125	growth differentiation factor 5	Homo sapiens	154-158
29868646-0	2018	Extracellular matrix protein production in human adipose-derived mesenchymal stem cells on three-dimensional polycaprolactone (PCL) scaffolds responds to GDF5 or FGF2.	polycaprolactone	109-125	fibroblast growth factor 2	Homo sapiens	162-166
29868646-0	2018	Extracellular matrix protein production in human adipose-derived mesenchymal stem cells on three-dimensional polycaprolactone (PCL) scaffolds responds to GDF5 or FGF2.	polycaprolactone	127-130	growth differentiation factor 5	Homo sapiens	154-158
29868646-0	2018	Extracellular matrix protein production in human adipose-derived mesenchymal stem cells on three-dimensional polycaprolactone (PCL) scaffolds responds to GDF5 or FGF2.	polycaprolactone	127-130	fibroblast growth factor 2	Homo sapiens	162-166
29682553-3	2018	In vivo implantation of polycaprolactone (PCL) biomembrane functionalized with BMP-2/Ibuprofen in mouse maxillary defects was followed by bone neoformation kinetics evaluation using microcomputed tomography.	polycaprolactone	42-45	bone morphogenetic protein 2	Mus musculus	79-84
29806415-0	2018	[Dopamine modified and cartilage derived morphogenetic protein 1 laden polycaprolactone-hydroxyapatite composite scaffolds fabricated by three-dimensional printing improve chondrogenic differentiation of human bone marrow mesenchymal stem cells].	polycaprolactone	71-87	growth differentiation factor 5	Homo sapiens	23-64
29128835-1	2018	In this work, a novel drug delivery system consisting of poly(epsilon-caprolactone) (PCL) electrospun fibers containing an ad-hoc-synthesized star polymer made up of a poly(amido-amine) (PAMAM) core and PCL branches (PAMAM-PCL) was developed.	polycaprolactone	57-83	PHD finger protein 1	Homo sapiens	85-88
31008184-3	2018	Electrospinning is used to create a mesh of poly(epsilon-caprolactone) fibers, which is used to present activating ligands to CD3 and CD28, which activate T cells for expansion.	polycaprolactone	44-70	CD28 molecule	Homo sapiens	134-138
29216515-6	2018	The comprehensive results of proliferation, osteogenic gene expression, ALP staining, and ALP activity demonstrated that PCL coating slightly impaired the bone repair potential of CPB.	polycaprolactone	121-124	ATHS	Homo sapiens	72-75
29216515-6	2018	The comprehensive results of proliferation, osteogenic gene expression, ALP staining, and ALP activity demonstrated that PCL coating slightly impaired the bone repair potential of CPB.	polycaprolactone	121-124	ATHS	Homo sapiens	90-93
29160080-0	2018	Adjuvant Activity of Poly-epsilon-caprolactone/Chitosan Nanoparticles Characterized by Mast Cell Activation and IFN-gamma and IL-17 Production.	polycaprolactone	21-46	interferon gamma	Homo sapiens	112-121
29160080-0	2018	Adjuvant Activity of Poly-epsilon-caprolactone/Chitosan Nanoparticles Characterized by Mast Cell Activation and IFN-gamma and IL-17 Production.	polycaprolactone	21-46	interleukin 17A	Homo sapiens	126-131
29227904-5	2018	Detailed investigation revealed that certain TPU/PCL hybrid SDVSs closely resembled the mechanical behaviors of blood vessels due to the presence of a wavy region and the combination of flexible TPU and rigid PCL, which mimicked the properties of elastin and collagen in blood vessels.	polycaprolactone	49-52	elastin	Homo sapiens	247-254
29463375-5	2018	In this study, poly(lactic-co-glycolic acid) and polycaprolactone were used to prepare nanofibrous membranes suitable for the efficient capture of particulate matter formed in haze-fog episodes, especially particles smaller than 0.5 mum.	polycaprolactone	49-65	zinc finger protein, FOG family member 1	Homo sapiens	181-184
28880464-2	2018	In this study, dual growth factor (platelet-derived growth factor-BB [PDGF-BB] and bone morphogenetic protein-2 [BMP-2])-immobilized polycaprolactone (PCL)/Pluronic F127 asymmetrically porous membrane was fabricated to estimate its feasibility as a potential strategy for effective regeneration of BTI injury.	polycaprolactone	133-149	myotrophin	Rattus norvegicus	20-33
32264572-2	2017	In this study, albendazole was encapsulated into bovine serum albumin (BSA)-polycaprolactone (PCL) conjugates and the formed nanoparticles with a size about 100 nm were used to treat pancreatic carcinoma cells.	polycaprolactone	76-92	albumin	Homo sapiens	56-69
28880464-2	2018	In this study, dual growth factor (platelet-derived growth factor-BB [PDGF-BB] and bone morphogenetic protein-2 [BMP-2])-immobilized polycaprolactone (PCL)/Pluronic F127 asymmetrically porous membrane was fabricated to estimate its feasibility as a potential strategy for effective regeneration of BTI injury.	polycaprolactone	133-149	myotrophin	Rattus norvegicus	52-65
28880464-2	2018	In this study, dual growth factor (platelet-derived growth factor-BB [PDGF-BB] and bone morphogenetic protein-2 [BMP-2])-immobilized polycaprolactone (PCL)/Pluronic F127 asymmetrically porous membrane was fabricated to estimate its feasibility as a potential strategy for effective regeneration of BTI injury.	polycaprolactone	133-149	bone morphogenetic protein 2	Rattus norvegicus	83-111
28880464-2	2018	In this study, dual growth factor (platelet-derived growth factor-BB [PDGF-BB] and bone morphogenetic protein-2 [BMP-2])-immobilized polycaprolactone (PCL)/Pluronic F127 asymmetrically porous membrane was fabricated to estimate its feasibility as a potential strategy for effective regeneration of BTI injury.	polycaprolactone	133-149	bone morphogenetic protein 2	Rattus norvegicus	113-118
28880464-2	2018	In this study, dual growth factor (platelet-derived growth factor-BB [PDGF-BB] and bone morphogenetic protein-2 [BMP-2])-immobilized polycaprolactone (PCL)/Pluronic F127 asymmetrically porous membrane was fabricated to estimate its feasibility as a potential strategy for effective regeneration of BTI injury.	polycaprolactone	151-154	myotrophin	Rattus norvegicus	20-33
28880464-2	2018	In this study, dual growth factor (platelet-derived growth factor-BB [PDGF-BB] and bone morphogenetic protein-2 [BMP-2])-immobilized polycaprolactone (PCL)/Pluronic F127 asymmetrically porous membrane was fabricated to estimate its feasibility as a potential strategy for effective regeneration of BTI injury.	polycaprolactone	151-154	myotrophin	Rattus norvegicus	52-65
28880464-2	2018	In this study, dual growth factor (platelet-derived growth factor-BB [PDGF-BB] and bone morphogenetic protein-2 [BMP-2])-immobilized polycaprolactone (PCL)/Pluronic F127 asymmetrically porous membrane was fabricated to estimate its feasibility as a potential strategy for effective regeneration of BTI injury.	polycaprolactone	151-154	bone morphogenetic protein 2	Rattus norvegicus	83-111
30966035-3	2017	In this work, the surface of PCL nanofibers is modified by Ar/CO2/C2H4 plasma depositing active COOH groups in the amount of 0.57 at % that were later used for the immobilization of platelet-rich plasma (PRP).	polycaprolactone	29-32	complement component 4 binding protein alpha	Homo sapiens	204-207
30966035-7	2017	Hence, our new method for the modification of PCL nanofibers with PRP opens new possibilities for its application in tissue engineering.	polycaprolactone	46-49	complement component 4 binding protein alpha	Homo sapiens	66-69
28887992-2	2017	In the present study, we develop a bilayer poly(epsilon-caprolactone, PCL) fibrous vascular graft consisting of a thin internal layer made of longitudinally aligned fibers and a relatively thick highly porous external layer.	polycaprolactone	43-68	PHD finger protein 1	Homo sapiens	70-73
28718680-3	2017	In the present study, a polymeric nanofibrous scaffold was developed based on the polycaprolactone/Collagen (PCL/Coll) containing Emu oil as a bioactive material to induce the proliferation of ASCs, while simultaneously preserving the stemness property of those cells.	polycaprolactone	82-98	PHD finger protein 1	Homo sapiens	109-112
28703122-3	2017	CNF-based nanocomposite scaffolds showed the highest electrical conductivity with significant improvements in mechanical properties (more than 50% tensile strength increase than PCL with 10% (w/w) CNF).	polycaprolactone	178-181	NPHS1 adhesion molecule, nephrin	Homo sapiens	0-3
28608777-10	2017	MCT4 staining in the perinodal stroma was significantly higher in specimens with ECE greater than 1 mm (macro-ECE, P = .01).	polycaprolactone	81-84	solute carrier family 16 member 3	Homo sapiens	0-4
28608777-10	2017	MCT4 staining in the perinodal stroma was significantly higher in specimens with ECE greater than 1 mm (macro-ECE, P = .01).	polycaprolactone	110-113	solute carrier family 16 member 3	Homo sapiens	0-4
28868964-1	2017	AIM: This work aims to investigate the adjuvant effect of poly-epsilon-caprolactone/chitosan nanoparticles (NPs) for hepatitis B surface antigen (HBsAg) and the plasmid DNA encoding HBsAg (pRC/CMV-HBs).	polycaprolactone	58-83	PPARG related coactivator 1	Homo sapiens	189-192
30965790-2	2017	In the present paper, electrospinning is used to fabricate novel SiO2 particles (type MCM-41) containing poly(epsilon-caprolactone) (PCL) fibers.	polycaprolactone	105-131	methylmalonyl-CoA mutase	Homo sapiens	86-89
30965790-2	2017	In the present paper, electrospinning is used to fabricate novel SiO2 particles (type MCM-41) containing poly(epsilon-caprolactone) (PCL) fibers.	polycaprolactone	133-136	methylmalonyl-CoA mutase	Homo sapiens	86-89
28589686-2	2017	In this study, recombinant human granulocyte colony-stimulating factor (G-CSF)-loaded chitosan nanoparticles were incorporated in Poly(epsilon-caprolactone) (PCL) nanofibers, followed by surface coating with collagen type I.	polycaprolactone	130-156	colony stimulating factor 3	Homo sapiens	33-70
28589686-2	2017	In this study, recombinant human granulocyte colony-stimulating factor (G-CSF)-loaded chitosan nanoparticles were incorporated in Poly(epsilon-caprolactone) (PCL) nanofibers, followed by surface coating with collagen type I.	polycaprolactone	130-156	colony stimulating factor 3	Homo sapiens	72-77
28512793-3	2017	Here, we investigate the in vitro response of human mesenchymal stem cells (hMSC) on electrospun fibers made of polycaprolactone (PCL) in the presence of 5-azacytidine (5-AZA) to evaluate how fibrous network may influence the therapeutic effect of drug during in vitro myogenesis.	polycaprolactone	112-128	musculin	Homo sapiens	76-80
28874815-7	2017	In this study, a novel TGF-beta1-loaded poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) (PCEC) hydrogel was fabricated using simple procedures.	polycaprolactone	40-66	transforming growth factor, beta 1	Rattus norvegicus	23-32
28874815-7	2017	In this study, a novel TGF-beta1-loaded poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) (PCEC) hydrogel was fabricated using simple procedures.	polycaprolactone	89-115	transforming growth factor, beta 1	Rattus norvegicus	23-32
28875694-3	2017	Herein, we present a TGF-beta1-inhibitor-doped poly(epsilon-caprolactone) (PCL)/gelatin (PG) coelectrospun nanofibrous scaffold (PGT) for HS prevention during wound healing.	polycaprolactone	47-73	transforming growth factor beta 1	Homo sapiens	21-30
28875694-3	2017	Herein, we present a TGF-beta1-inhibitor-doped poly(epsilon-caprolactone) (PCL)/gelatin (PG) coelectrospun nanofibrous scaffold (PGT) for HS prevention during wound healing.	polycaprolactone	75-78	transforming growth factor beta 1	Homo sapiens	21-30
29383097-4	2017	Here we developed intelligent nanoparticles (NPs) comprising gelatinase with polyethylene glycol (PEG) and poly-epsilon-caprolactone) (PCL) to specifically deliver DAC (DAC-TNPs) to tumors.	polycaprolactone	107-132	arylacetamide deacetylase	Homo sapiens	164-167
29383097-4	2017	Here we developed intelligent nanoparticles (NPs) comprising gelatinase with polyethylene glycol (PEG) and poly-epsilon-caprolactone) (PCL) to specifically deliver DAC (DAC-TNPs) to tumors.	polycaprolactone	107-132	arylacetamide deacetylase	Homo sapiens	169-172
29383097-4	2017	Here we developed intelligent nanoparticles (NPs) comprising gelatinase with polyethylene glycol (PEG) and poly-epsilon-caprolactone) (PCL) to specifically deliver DAC (DAC-TNPs) to tumors.	polycaprolactone	107-132	C1GALT1 specific chaperone 1	Homo sapiens	173-177
26616273-4	2017	Increasing PCL concentration had a considerable influence on PDI while increasing PVA concentration had a lesser effect.	polycaprolactone	11-14	peptidyl arginine deiminase 1	Homo sapiens	61-64
28777354-2	2017	Such a nano-hybrid was incorporated into a poly (epsilon-caprolactone) (PCL) matrix at 10 wt % and films were obtained.	polycaprolactone	43-70	PHD finger protein 1	Homo sapiens	72-75
28228626-1	2017	A novel chitosan/polycaprolactone (CS/PCL) nanofibrous membrane by electrospinning was developed for guided tissue regeneration (GTR) to improve mechanical properties and to promote osteogenic differentiation.	polycaprolactone	17-33	PHD finger protein 1	Homo sapiens	38-41
28345449-1	2017	In this study, biomimic porous polycaprolactone/poly (lactide-co-glycolide) loading biphasic tricalcium phosphate (PCL/PLGA-BCP) scaffolds were fabricated successfully by solvent evaporation method.	polycaprolactone	31-47	PHD finger protein 1	Homo sapiens	115-127
28278041-0	2017	Fabrication and characterization of chitosan/OGP coated porous poly(epsilon-caprolactone) scaffold for bone tissue engineering.	polycaprolactone	63-89	oviductal glycoprotein 1	Homo sapiens	45-48
28278041-2	2017	The aim of this work was the preparation of three dimensional porous poly(epsilon-caprolactone) (PCL) scaffold with high porosity, well interpore connectivity, and then its surface was modified by using chitosan (CS)/OGP coating for application in bone regeneration.	polycaprolactone	69-95	oviductal glycoprotein 1	Homo sapiens	217-220
28278041-2	2017	The aim of this work was the preparation of three dimensional porous poly(epsilon-caprolactone) (PCL) scaffold with high porosity, well interpore connectivity, and then its surface was modified by using chitosan (CS)/OGP coating for application in bone regeneration.	polycaprolactone	97-100	oviductal glycoprotein 1	Homo sapiens	217-220
28278041-3	2017	In present study, the properties of porous PCL and CS/OGP coated PCL scaffold, including the microstructure, water absorption, porosity, hydrophilicity, mechanical properties, and biocompatibility in vitro were investigated.	polycaprolactone	65-68	oviductal glycoprotein 1	Homo sapiens	54-57
28278041-5	2017	The CS/OGP-PCL scaffold exhibited better hydrophilicity and mechanical properties than that of uncoated PCL scaffold.	polycaprolactone	11-14	oviductal glycoprotein 1	Homo sapiens	7-10
28278041-6	2017	Moreover, the results of cell culture test showed that CS/OGP coating could stimulate the proliferation and growth of osteoblast cells on CS/OGP-PCL scaffold.	polycaprolactone	145-148	oviductal glycoprotein 1	Homo sapiens	55-61
28278041-6	2017	Moreover, the results of cell culture test showed that CS/OGP coating could stimulate the proliferation and growth of osteoblast cells on CS/OGP-PCL scaffold.	polycaprolactone	145-148	oviductal glycoprotein 1	Homo sapiens	58-61
28374682-3	2017	Melt electrospinning writing allows the design and fabrication of medical grade polycaprolactone (mPCL) fibrous networks for the reinforcement of soft hydrogel matrices for cartilage tissue engineering.	polycaprolactone	80-96	polycystic kidney disease 2-like 1	Mus musculus	98-102
28301223-0	2017	Antitumor Effect of Nanoparticle 131I-Labeled Arginine-Glycine-Aspartate-Bovine Serum Albumin-Polycaprolactone in Lung Cancer.	polycaprolactone	94-110	albumin	Mus musculus	80-93
28240815-3	2017	In this study, the authors describe the development and characterization of a GBR membrane made of medical grade polycaprolactone (mPCL) electrospun fibers with antibacterial and immunomodulatory properties.	polycaprolactone	113-129	polycystic kidney disease 2-like 1	Mus musculus	131-135
28238969-3	2017	This article reports a novel polyamide 6/poly(epsilon-caprolactone) (PA6/PCL) blends solution which was fabricated to create composite fibrous tissue scaffolds by varying the concentration ratios of PA6 and PCL.	polycaprolactone	41-67	PHD finger protein 1	Homo sapiens	69-76
28238969-3	2017	This article reports a novel polyamide 6/poly(epsilon-caprolactone) (PA6/PCL) blends solution which was fabricated to create composite fibrous tissue scaffolds by varying the concentration ratios of PA6 and PCL.	polycaprolactone	41-67	PHD finger protein 1	Homo sapiens	73-76
28285076-4	2017	As-prepared PCL/CS-NO dressing released NO sustainably under the physiological conditions, which was controlled by the catalysis of beta-galactosidase.	polycaprolactone	12-15	galactosidase, beta 1	Mus musculus	132-150
28301223-1	2017	OBJECTIVE: The aim of the present study is to investigate the biologic effects of internal irradiation and the therapeutic effectiveness of 131I-labeled arginine-glycine-aspartate (RGD)-bovine serum albumin (BSA)-polycaprolactone (PCL) (131I-RGD-BSA-PCL) in murine lung cancer models.	polycaprolactone	213-229	albumin	Mus musculus	193-206
28301223-1	2017	OBJECTIVE: The aim of the present study is to investigate the biologic effects of internal irradiation and the therapeutic effectiveness of 131I-labeled arginine-glycine-aspartate (RGD)-bovine serum albumin (BSA)-polycaprolactone (PCL) (131I-RGD-BSA-PCL) in murine lung cancer models.	polycaprolactone	231-234	albumin	Mus musculus	193-206
28124460-3	2017	In this study, we differentiated neonate keratinocytes for epithelialization on the polycaprolactone-Platelet gel (PCL-PG) scaffold.	polycaprolactone	84-100	PHD finger protein 1	Homo sapiens	115-118
28161547-5	2017	Aiming this, two different systems are proposed: (a) chitosan-coated poly(epsilon-caprolactone)-nanocapsules incorporated into hydroxyethylcellulose gel (HEC-NCimiq-chit), and (b) poly(epsilon-caprolactone)-nanocapsules incorporated into chitosan hydrogel (CHIT-NCimiq).	polycaprolactone	69-95	chitinase 1	Homo sapiens	53-57
28263565-4	2017	Poly(oligo(ethylene glycol) methyl ether acrylate)-poly(epsilon-caprolactone) (POEGMEA-PCL) was prepared by a combination of ring-opening polymerization and reversible addition-fragmentation chain transfer (RAFT) polymerization, while the polymer-protein conjugate was obtained by reacting poly(epsilon-caprolactone) with bovine serum albumin (BSA-PCL).	polycaprolactone	51-77	albumin	Mus musculus	329-342
28254327-5	2017	PCL was mixed with 1-15wt% of MgO and HAp.	polycaprolactone	0-3	scaffold attachment factor B	Mus musculus	38-41
26993294-0	2017	Inhibitor of PI3K/Akt Signaling Pathway Small Molecule Promotes Motor Neuron Differentiation of Human Endometrial Stem Cells Cultured on Electrospun Biocomposite Polycaprolactone/Collagen Scaffolds.	polycaprolactone	162-178	AKT serine/threonine kinase 1	Homo sapiens	18-21
28132919-5	2017	Here we demonstrate that the modification of films of polycaprolactone (PCL) with transforming growth factor beta1 (TGF-beta1)-binding peptides allows GFs to be captured and presented to the target cells.	polycaprolactone	72-75	transforming growth factor beta 1	Homo sapiens	82-114
28303795-2	2017	Here, we develop a novel scaffold approach based on bioactive fibers of poly(epsilon-caprolactone) where nanotopographical guidance and neuregulin 1 (NRG1) cues are combined.	polycaprolactone	72-97	neuregulin 1	Rattus norvegicus	136-148
28303795-2	2017	Here, we develop a novel scaffold approach based on bioactive fibers of poly(epsilon-caprolactone) where nanotopographical guidance and neuregulin 1 (NRG1) cues are combined.	polycaprolactone	72-97	neuregulin 1	Rattus norvegicus	150-154
28132919-5	2017	Here we demonstrate that the modification of films of polycaprolactone (PCL) with transforming growth factor beta1 (TGF-beta1)-binding peptides allows GFs to be captured and presented to the target cells.	polycaprolactone	72-75	transforming growth factor beta 1	Homo sapiens	116-125
28132919-0	2017	TGF-beta1 activation in human hamstring cells through growth factor binding peptides on polycaprolactone surfaces.	polycaprolactone	88-104	transforming growth factor beta 1	Homo sapiens	0-9
28694960-6	2017	In this study, we propose a biodegradable, tri-layered (poly(glycolic acid) mesh/poly(l-lactic acid)-colorant tidemark layer/collagen Type I and ceramic microparticle-coated poly(l-lactic acid)-poly(epsilon-caprolactone) monolith) osteochondral plug indicated for the repair of cartilage defects.	polycaprolactone	194-220	tRNA-Ile (anticodon AAT) 9-1	Homo sapiens	43-46
28132919-5	2017	Here we demonstrate that the modification of films of polycaprolactone (PCL) with transforming growth factor beta1 (TGF-beta1)-binding peptides allows GFs to be captured and presented to the target cells.	polycaprolactone	54-70	transforming growth factor beta 1	Homo sapiens	82-114
28132919-5	2017	Here we demonstrate that the modification of films of polycaprolactone (PCL) with transforming growth factor beta1 (TGF-beta1)-binding peptides allows GFs to be captured and presented to the target cells.	polycaprolactone	54-70	transforming growth factor beta 1	Homo sapiens	116-125
28276249-0	2017	Functional Modification of Electrospun Poly(epsilon-caprolactone) Vascular Grafts with the Fusion Protein VEGF-HGFI Enhanced Vascular Regeneration.	polycaprolactone	39-65	vascular endothelial growth factor A	Homo sapiens	106-110
28276249-2	2017	In this study, small-caliber (2.0 mm) electrospun poly(epsilon-caprolactone) (PCL) vascular grafts were modified with a fusion protein VEGF-HGFI which consists of the class I hydrophobin (HGFI) and vascular endothelial growth factor (VEGF), via hydrophobic interactions.	polycaprolactone	50-76	vascular endothelial growth factor A	Homo sapiens	135-139
29744416-2	2017	The present study outlines the fabrication of daunorubicin hydrochloride-loaded poly (epsilon-caprolactone) (PCL) fibrous membranes by melt electrospinning for potential application in localized tumor therapy.	polycaprolactone	80-107	PHD finger protein 1	Homo sapiens	109-112
28276249-9	2017	Immunofluorescence staining revealed that endothelialization, vascularization, and smooth muscle cell (SMC) regeneration were markedly improved in the VEGF-HGFI-modified PCL grafts.	polycaprolactone	170-173	vascular endothelial growth factor A	Homo sapiens	151-155
28236696-1	2017	We report in this paper the effects of Ethyl Ester L-Lysine Triisocyanate (LTI) on the physical-mechanical properties of Poly(lactide)/Poly(epsilon-caprolactone) (PLA/PCL) polyesters blends.	polycaprolactone	135-161	polycystin 2 like 1, transient receptor potential cation channel	Homo sapiens	167-170
28032906-2	2017	This study assessed the mineralized tissue forming potential of 3-D printed medical grade polycaprolactone (mPCL) constructs containing osteoblasts (OB) encapsulated in a hyaluronic acid (HA)-hydrogel incorporating bone morphogenetic protein-7 (BMP-7).	polycaprolactone	90-106	polycystic kidney disease 2-like 1	Mus musculus	108-112
32263691-7	2017	Finally, bicyclononyne groups were grafted onto the star-pPR based fibers allowing the conjugation of a fluorescent dye by click chemistry in water without any copper catalyst proving the potential of the method for the biofunctionalization of PCL-based fibers.	polycaprolactone	244-247	PPR1	Homo sapiens	57-60
32264633-4	2017	An amphiphilic block copolymer of poly(2-hydroxyethyl methacrylate)-block-poly(epsilon-caprolactone)-graft-poly(ethylene glycol)-graft-poly(ethyleneimine) conjugated with REDV peptide (PHEMA-b-PCL-g-PEG-g-PEI-REDV) is synthesized, and nanoparticles of it are prepared by polymer self-assembly.	polycaprolactone	74-100	progestagen associated endometrial protein	Homo sapiens	199-202
28003144-2	2017	Herein, we demonstrate a novel supramolecular poly(epsilon-caprolactone) (PCL) containing self-complementary sextuple hydrogen-bonded uracil-diamidopyridine (U-DPy) moieties, which undergoes spontaneous self-assembly to form supramolecular polymer networks.	polycaprolactone	46-72	dumpy	Mus musculus	160-163
28003144-2	2017	Herein, we demonstrate a novel supramolecular poly(epsilon-caprolactone) (PCL) containing self-complementary sextuple hydrogen-bonded uracil-diamidopyridine (U-DPy) moieties, which undergoes spontaneous self-assembly to form supramolecular polymer networks.	polycaprolactone	74-77	dumpy	Mus musculus	160-163
28003144-3	2017	Inclusion of various U-DPy contents enhanced the mechanical strength and viscosities of the resulting materials by up to two orders of magnitude compared to control PCL.	polycaprolactone	165-168	dumpy	Mus musculus	23-26
28057509-3	2017	To avoid the CsA side effects, we report in this study the preparation of CsA loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles, their embedding on polycaprolactone (PCL)-based scaffolds and their possible use as templates for the innervation of bioengineered teeth.	polycaprolactone	156-172	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	74-77
28057509-3	2017	To avoid the CsA side effects, we report in this study the preparation of CsA loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles, their embedding on polycaprolactone (PCL)-based scaffolds and their possible use as templates for the innervation of bioengineered teeth.	polycaprolactone	174-177	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	74-77
28199184-1	2017	In bone tissue engineering, the organo-ceramic composite, electrospun polycaprolactone/hydroxyapatite (PCL/HA) scaffold has the potential to support cell proliferation, migration, differentiation, and homeostasis.	polycaprolactone	70-86	PHD finger protein 1	Homo sapiens	103-106
29250460-4	2017	Genetically engineered EGF containing a matrix metalloproteinase (MMP) cleavage site was covalently conjugated to a nonwoven poly(epsilon-caprolactone) (PCL) fiber mat fabricated by multilayered melt coextrusion.	polycaprolactone	125-151	epidermal growth factor	Homo sapiens	23-26
26883261-0	2017	Structural and Surface Compatibility Study of Modified Electrospun Poly(epsilon-caprolactone) (PCL) Composites for Skin Tissue Engineering.	polycaprolactone	67-93	polycystic kidney disease 2-like 1	Mus musculus	95-98
28068081-2	2017	In the present study, a chemically defined peptide-decorated polycaprolactone (PCL) nanofibrous microenvironment was prepared through electrospinning technology and subsequent conjugation with vitronectin peptide to promote the culture and osteogenic potential of hPSCs in vitro.	polycaprolactone	61-77	vitronectin	Homo sapiens	193-204
28068081-2	2017	In the present study, a chemically defined peptide-decorated polycaprolactone (PCL) nanofibrous microenvironment was prepared through electrospinning technology and subsequent conjugation with vitronectin peptide to promote the culture and osteogenic potential of hPSCs in vitro.	polycaprolactone	79-82	vitronectin	Homo sapiens	193-204
29250460-4	2017	Genetically engineered EGF containing a matrix metalloproteinase (MMP) cleavage site was covalently conjugated to a nonwoven poly(epsilon-caprolactone) (PCL) fiber mat fabricated by multilayered melt coextrusion.	polycaprolactone	125-151	matrix metallopeptidase 9	Homo sapiens	66-69
27832279-11	2016	For PCL, 87.10 +- 3.17% of cells were CK7-positive compared to PET where 67.10 +- 12.08% of cells were CK7-positive cells.	polycaprolactone	4-7	keratin 7	Homo sapiens	38-41
29241186-4	2017	This study is a continuation of earlier findings involving poly(epsilon-caprolactone) (PCL)-poly (ethylene glycol) (PEG) nanoparticles (PEG-PCL NPs), which were coated with trastuzumab to target GC with HER2 receptor over-expression using anti-miRNA-21 (AMO-21) and 5-Fu.	polycaprolactone	87-90	erb-b2 receptor tyrosine kinase 2	Homo sapiens	203-207
29241186-4	2017	This study is a continuation of earlier findings involving poly(epsilon-caprolactone) (PCL)-poly (ethylene glycol) (PEG) nanoparticles (PEG-PCL NPs), which were coated with trastuzumab to target GC with HER2 receptor over-expression using anti-miRNA-21 (AMO-21) and 5-Fu.	polycaprolactone	87-90	microRNA 21	Homo sapiens	244-252
28592972-1	2017	Polycaprolactone/polyurethane (PCL/PU) fibrous scaffold was loaded with conjugated linoleic acid (CLA) by electrospinning method to improve the hemocompatibility of the polymeric surface.	polycaprolactone	0-16	selectin P ligand	Homo sapiens	98-101
27980405-7	2016	Interleukin (IL)-1beta, IL-6, and transforming growth factor-beta expression decreased significantly in the PCL group compared with the control.	polycaprolactone	108-111	interleukin 1 beta	Homo sapiens	0-22
27980405-7	2016	Interleukin (IL)-1beta, IL-6, and transforming growth factor-beta expression decreased significantly in the PCL group compared with the control.	polycaprolactone	108-111	interleukin 6	Homo sapiens	24-28
27714703-0	2016	Sustained delivery of recombinant human bone morphogenetic protein-2 from perlecan domain I - functionalized electrospun poly (epsilon-caprolactone) scaffolds for bone regeneration.	polycaprolactone	121-148	bone morphogenetic protein 2	Homo sapiens	40-68
29491778-7	2017	This PCL-(PI)2 macrophotoinitiator was used as a precursor in photoinduced free radical promoted cationic polymerization to synthesize an AB2-type miktoarm star copolymer consisting of poly(epsilon-caprolactone) (PCL, as A block) and poly(cyclohexene oxide) (PCHO, as B block), namely PCL(PCHO)2.	polycaprolactone	185-211	PHD finger protein 1	Homo sapiens	285-295
27345288-1	2016	Here, we investigate the relationship between the expression of intercellular adhesion molecule-1 (ICAM-1) and the adhesion of human umbilical vein endothelial cells (HUVECs) on a poly-epsilon-caprolactone (PCL) film with micropores of different pore sizes.	polycaprolactone	180-205	intercellular adhesion molecule 1	Homo sapiens	64-97
27345288-1	2016	Here, we investigate the relationship between the expression of intercellular adhesion molecule-1 (ICAM-1) and the adhesion of human umbilical vein endothelial cells (HUVECs) on a poly-epsilon-caprolactone (PCL) film with micropores of different pore sizes.	polycaprolactone	180-205	intercellular adhesion molecule 1	Homo sapiens	99-105
27345288-1	2016	Here, we investigate the relationship between the expression of intercellular adhesion molecule-1 (ICAM-1) and the adhesion of human umbilical vein endothelial cells (HUVECs) on a poly-epsilon-caprolactone (PCL) film with micropores of different pore sizes.	polycaprolactone	207-210	intercellular adhesion molecule 1	Homo sapiens	64-97
27345288-1	2016	Here, we investigate the relationship between the expression of intercellular adhesion molecule-1 (ICAM-1) and the adhesion of human umbilical vein endothelial cells (HUVECs) on a poly-epsilon-caprolactone (PCL) film with micropores of different pore sizes.	polycaprolactone	207-210	intercellular adhesion molecule 1	Homo sapiens	99-105
27504858-3	2016	Through electrospinning of polycaprolactone (PCL) containing JK1, a novel pH-controllable H2S donor, nanofibers with H2S releasing function, PCL-JK1, are fabricated.	polycaprolactone	27-43	reticulophagy regulator 1	Homo sapiens	61-64
27504858-3	2016	Through electrospinning of polycaprolactone (PCL) containing JK1, a novel pH-controllable H2S donor, nanofibers with H2S releasing function, PCL-JK1, are fabricated.	polycaprolactone	27-43	reticulophagy regulator 1	Homo sapiens	145-148
27504858-3	2016	Through electrospinning of polycaprolactone (PCL) containing JK1, a novel pH-controllable H2S donor, nanofibers with H2S releasing function, PCL-JK1, are fabricated.	polycaprolactone	45-48	reticulophagy regulator 1	Homo sapiens	61-64
27504858-3	2016	Through electrospinning of polycaprolactone (PCL) containing JK1, a novel pH-controllable H2S donor, nanofibers with H2S releasing function, PCL-JK1, are fabricated.	polycaprolactone	45-48	reticulophagy regulator 1	Homo sapiens	145-148
27487149-3	2016	To directly investigate the anti-tumor property, full length human recombinant ID4 encapsulated in biodegradable Polycaprolactone/Maltodextrin (PCL-MD) nano-carrier was delivered to LNCaP cells in which the native ID4 was stably silenced (LNCaP(-)ID4).	polycaprolactone	113-129	inhibitor of DNA binding 4, HLH protein	Homo sapiens	79-82
29491778-7	2017	This PCL-(PI)2 macrophotoinitiator was used as a precursor in photoinduced free radical promoted cationic polymerization to synthesize an AB2-type miktoarm star copolymer consisting of poly(epsilon-caprolactone) (PCL, as A block) and poly(cyclohexene oxide) (PCHO, as B block), namely PCL(PCHO)2.	polycaprolactone	5-8	PHD finger protein 1	Homo sapiens	285-295
32263471-4	2016	Electrospinning of PCL solutions (6% w/w) in hexafluoro-2-propanol (HFIP) containing up to 40 mg mL-1 P11-8 resulted in the formation of fibres in both nano- (10-100 nm) and submicron range (100-700 nm), in contrast to PCL only webs, which displayed a predominantly submicron fibre distribution.	polycaprolactone	19-22	L1 cell adhesion molecule	Mus musculus	97-101
27385628-2	2016	In this work, surface-modified polycaprolactone-polylactic acid scaffolds using self-assembled heterojunction carbon nanotubes (sh-CNTs) combined with insulin-like growth factor-1 are synthesized and a series of structural and biological characterizations are carried out, with particular attention to cell senescence mechanism.	polycaprolactone	31-47	insulin like growth factor 1	Homo sapiens	151-179
26906227-1	2016	In the study presented here, in order to improve the surface functionality and topography of poly (epsilon-caprolactone) (PCL)/chitosan/PCL hybrid tissue scaffolds fabricated layer by layer with electrospinning technique, an atmospheric pressure nozzle type plasma surface modification was utilized.	polycaprolactone	93-120	polycystic kidney disease 2-like 1	Mus musculus	122-125
27524968-0	2016	Vascular Endothelial Growth Factor Improves Physico-Mechanical Properties and Enhances Endothelialization of Poly(3-hydroxybutyrate-co-3-hydroxyvalerate)/Poly(epsilon-caprolactone) Small-Diameter Vascular Grafts In vivo.	polycaprolactone	154-179	vascular endothelial growth factor A	Rattus norvegicus	0-34
27113576-0	2016	Hybrid Polycaprolactone/Alginate Scaffolds Functionalized with VEGF to Promote de Novo Vessel Formation for the Transplantation of Islets of Langerhans.	polycaprolactone	7-23	vascular endothelial growth factor A	Gallus gallus	63-67
27483240-4	2016	A purpose of this study is to analyze polycaprolactone/silk fibroin/hyaluronic acid/minocycline hydrochloride (PCL/SF/HA/MH) nanoparticles initiate human mesenchymal stem cells (MSCs) proliferation and differentiation into osteogenesis.	polycaprolactone	38-54	PHD finger protein 1	Homo sapiens	111-114
27154500-0	2016	Synthesis of intracellular reduction-sensitive amphiphilic polyethyleneimine and poly(epsilon-caprolactone) graft copolymer for on-demand release of doxorubicin and p53 plasmid DNA.	polycaprolactone	81-107	tumor protein p53	Homo sapiens	165-168
27113576-4	2016	The construct consists of a 3D ring-shaped polycaprolactone (PCL) scaffold with heparinized surface to electrostatically bind vascular endothelial growth factor (VEGF), surrounding a hydrogel core for islets encapsulation.	polycaprolactone	61-64	vascular endothelial growth factor A	Gallus gallus	126-160
27113576-4	2016	The construct consists of a 3D ring-shaped polycaprolactone (PCL) scaffold with heparinized surface to electrostatically bind vascular endothelial growth factor (VEGF), surrounding a hydrogel core for islets encapsulation.	polycaprolactone	61-64	vascular endothelial growth factor A	Gallus gallus	162-166
30979316-0	2016	Production and Characterization of a Novel, Electrospun, Tri-Layer Polycaprolactone Membrane for the Segregated Co-Culture of Bone and Soft Tissue.	polycaprolactone	67-83	tRNA-Ile (anticodon AAT) 9-1	Homo sapiens	57-60
30979316-2	2016	This study generated a tri-layer, electrospun, poly-epsilon-caprolactone membrane, with two microfiber layers separated by a layer of nanofibers, for the spatially segregated culture of mesenchymal progenitor cells (MPCs) and fibroblasts.	polycaprolactone	47-72	tRNA-Ile (anticodon AAT) 9-1	Homo sapiens	23-26
27186292-0	2016	Electrospun nanofibrous sheets of collagen/elastin/polycaprolactone improve cardiac repair after myocardial infarction.	polycaprolactone	51-67	elastin	Mus musculus	43-50
27286857-2	2016	The purpose of this study was to investigate the effect of cold and non-thermal plasma surface modification of poly (epsilon-caprolactone) (PCL) scaffolds on fibroblast cell behavior.	polycaprolactone	111-138	PHD finger protein 1	Homo sapiens	140-143
26782272-1	2016	This study reports the structural transition of electrospun poly(epsilon-caprolactone) (PCL)/poly[(propylmethacryl-heptaisobutyl-polyhedral oligomeric silsesquioxane)-co-(methyl meth-acrylate)] (POSS-MMA) blends, from PCL-rich fibers, to bicontinuous PCL core/POSS-MMA shell fibers, to POSS-MMA-rich fibers with a discontinuous PCL inner phase.	polycaprolactone	60-86	PHD finger protein 1	Homo sapiens	88-91
26782272-1	2016	This study reports the structural transition of electrospun poly(epsilon-caprolactone) (PCL)/poly[(propylmethacryl-heptaisobutyl-polyhedral oligomeric silsesquioxane)-co-(methyl meth-acrylate)] (POSS-MMA) blends, from PCL-rich fibers, to bicontinuous PCL core/POSS-MMA shell fibers, to POSS-MMA-rich fibers with a discontinuous PCL inner phase.	polycaprolactone	60-86	PHD finger protein 1	Homo sapiens	218-221
26782272-1	2016	This study reports the structural transition of electrospun poly(epsilon-caprolactone) (PCL)/poly[(propylmethacryl-heptaisobutyl-polyhedral oligomeric silsesquioxane)-co-(methyl meth-acrylate)] (POSS-MMA) blends, from PCL-rich fibers, to bicontinuous PCL core/POSS-MMA shell fibers, to POSS-MMA-rich fibers with a discontinuous PCL inner phase.	polycaprolactone	60-86	PHD finger protein 1	Homo sapiens	218-221
26782272-1	2016	This study reports the structural transition of electrospun poly(epsilon-caprolactone) (PCL)/poly[(propylmethacryl-heptaisobutyl-polyhedral oligomeric silsesquioxane)-co-(methyl meth-acrylate)] (POSS-MMA) blends, from PCL-rich fibers, to bicontinuous PCL core/POSS-MMA shell fibers, to POSS-MMA-rich fibers with a discontinuous PCL inner phase.	polycaprolactone	60-86	PHD finger protein 1	Homo sapiens	218-221
28773427-4	2016	In this study, Vascular Endothelial Growth Factor (VEGF) and High Mobility Group Box 1 (HMGB1) were used for incorporation into poly-epsilon-caprolactone (PCL)-coated porous titanium implants.	polycaprolactone	128-153	vascular endothelial growth factor A	Homo sapiens	15-49
28773427-4	2016	In this study, Vascular Endothelial Growth Factor (VEGF) and High Mobility Group Box 1 (HMGB1) were used for incorporation into poly-epsilon-caprolactone (PCL)-coated porous titanium implants.	polycaprolactone	128-153	vascular endothelial growth factor A	Homo sapiens	51-55
28773427-4	2016	In this study, Vascular Endothelial Growth Factor (VEGF) and High Mobility Group Box 1 (HMGB1) were used for incorporation into poly-epsilon-caprolactone (PCL)-coated porous titanium implants.	polycaprolactone	128-153	high mobility group box 1	Homo sapiens	61-86
28773427-4	2016	In this study, Vascular Endothelial Growth Factor (VEGF) and High Mobility Group Box 1 (HMGB1) were used for incorporation into poly-epsilon-caprolactone (PCL)-coated porous titanium implants.	polycaprolactone	128-153	high mobility group box 1	Homo sapiens	88-93
28773427-4	2016	In this study, Vascular Endothelial Growth Factor (VEGF) and High Mobility Group Box 1 (HMGB1) were used for incorporation into poly-epsilon-caprolactone (PCL)-coated porous titanium implants.	polycaprolactone	155-158	vascular endothelial growth factor A	Homo sapiens	15-49
28773427-4	2016	In this study, Vascular Endothelial Growth Factor (VEGF) and High Mobility Group Box 1 (HMGB1) were used for incorporation into poly-epsilon-caprolactone (PCL)-coated porous titanium implants.	polycaprolactone	155-158	vascular endothelial growth factor A	Homo sapiens	51-55
28773427-4	2016	In this study, Vascular Endothelial Growth Factor (VEGF) and High Mobility Group Box 1 (HMGB1) were used for incorporation into poly-epsilon-caprolactone (PCL)-coated porous titanium implants.	polycaprolactone	155-158	high mobility group box 1	Homo sapiens	61-86
28773427-4	2016	In this study, Vascular Endothelial Growth Factor (VEGF) and High Mobility Group Box 1 (HMGB1) were used for incorporation into poly-epsilon-caprolactone (PCL)-coated porous titanium implants.	polycaprolactone	155-158	high mobility group box 1	Homo sapiens	88-93
28773427-7	2016	Also, VEGF-functionalized PCL-coated titanium implants enhanced angiogenesis in vitro.	polycaprolactone	26-29	vascular endothelial growth factor A	Homo sapiens	6-10
27186292-3	2016	In this study, we hypothesized high concentrations of cardiac nature protein (NP), namely elastin and collagen, in hybrid polycaprolactone (PCL) electrospun nanofibrous sheets could be effective as cardiac-mimicking patch.	polycaprolactone	122-138	elastin	Mus musculus	90-97
27186292-3	2016	In this study, we hypothesized high concentrations of cardiac nature protein (NP), namely elastin and collagen, in hybrid polycaprolactone (PCL) electrospun nanofibrous sheets could be effective as cardiac-mimicking patch.	polycaprolactone	140-143	elastin	Mus musculus	90-97
26791775-2	2016	In this study, we exploited this platform to evaluate the behavior of two biodegradable formulations, poly-epsilon-caprolactone (PCL3) and poly lactic-acid (PLA8), respectively, in cellular and animal models of triple-negative breast cancer (TNBC).	polycaprolactone	102-127	PHD finger protein 19	Homo sapiens	129-133
26914154-3	2016	Here we report a convenient and novel method to produce VIP loaded microspheres in polycaprolactone (PCL) nanofibrous membrane without complicated processes.	polycaprolactone	83-99	vasoactive intestinal polypeptide	Mus musculus	56-59
26914154-3	2016	Here we report a convenient and novel method to produce VIP loaded microspheres in polycaprolactone (PCL) nanofibrous membrane without complicated processes.	polycaprolactone	101-104	vasoactive intestinal polypeptide	Mus musculus	56-59
26660628-3	2016	AIM: The aim of this study has been to investigate the interaction between mesenchymal stem cells with poly (epsilon-caprolactone) (PCL) biomaterials used for obtaining scaffolds through additive manufacturing.	polycaprolactone	103-130	PHD finger protein 1	Homo sapiens	132-135
26896610-2	2016	In the present work, we proposed a multifunctional theranostic micellar drug delivery system utilizing cationic PDMA-block-poly(epsilon-caprolactone) (PDMA-b-PCL) micelles as nanocarriers of SN-38 (7-ethyl-10-hydroxycamptothecin), ultra-small superparamagnetic iron oxide nanoparticles (USPIO), and small interfering RNA (siRNA) that targets human vascular endothelial growth factor (VEGF).	polycaprolactone	123-149	vascular endothelial growth factor A	Homo sapiens	348-382
26896610-2	2016	In the present work, we proposed a multifunctional theranostic micellar drug delivery system utilizing cationic PDMA-block-poly(epsilon-caprolactone) (PDMA-b-PCL) micelles as nanocarriers of SN-38 (7-ethyl-10-hydroxycamptothecin), ultra-small superparamagnetic iron oxide nanoparticles (USPIO), and small interfering RNA (siRNA) that targets human vascular endothelial growth factor (VEGF).	polycaprolactone	123-149	vascular endothelial growth factor A	Homo sapiens	384-388
26012354-7	2016	Additionally, an in vitro cultivation of human skin keratinocytes (HaCaT) and fibroblasts on polycaprolactone/hyaluronan and polycaprolactone/hyaluronan-epidermal growth factor scaffolds showed a significant synergistic effect of hyaluronan and epidermal growth factor on cell proliferation and infiltration.	polycaprolactone	125-141	epidermal growth factor	Homo sapiens	153-176
28042345-3	2016	We found that poly(epsilon-caprolactone) fiber substrates designed to mimic the organized ECM of a non-failing human heart maintained healthy CM phenotype (evidenced by cell morphology, organized actin/myomesin bands and expression of beta-MYH7 and SCN5A.1 and SCN5A.2) compared to both failing heart ECM-mimetic substrates and tissue culture plates.	polycaprolactone	14-40	sodium voltage-gated channel alpha subunit 5	Homo sapiens	249-254
28042345-3	2016	We found that poly(epsilon-caprolactone) fiber substrates designed to mimic the organized ECM of a non-failing human heart maintained healthy CM phenotype (evidenced by cell morphology, organized actin/myomesin bands and expression of beta-MYH7 and SCN5A.1 and SCN5A.2) compared to both failing heart ECM-mimetic substrates and tissue culture plates.	polycaprolactone	14-40	sodium voltage-gated channel alpha subunit 5	Homo sapiens	261-266
30979150-3	2016	In this study, emulsion electrospinning technique was introduced as a flexible and promising technique for the fabrication of random (R) and aligned (A) Poly(epsilon-caprolactone) (PCL)-Nerve Growth Factor (NGF)&amp;amp;Bovine Serum Albumin (BSA) nanofibrous scaffolds [(R/A)-PCL-NGF&amp;amp;BSA], where NGF and BSA were encapsulated in the core while PCL form the shell.	polycaprolactone	181-184	nerve growth factor	Rattus norvegicus	207-210
30979150-3	2016	In this study, emulsion electrospinning technique was introduced as a flexible and promising technique for the fabrication of random (R) and aligned (A) Poly(epsilon-caprolactone) (PCL)-Nerve Growth Factor (NGF)&amp;amp;Bovine Serum Albumin (BSA) nanofibrous scaffolds [(R/A)-PCL-NGF&amp;amp;BSA], where NGF and BSA were encapsulated in the core while PCL form the shell.	polycaprolactone	181-184	albumin	Rattus norvegicus	227-240
30979150-3	2016	In this study, emulsion electrospinning technique was introduced as a flexible and promising technique for the fabrication of random (R) and aligned (A) Poly(epsilon-caprolactone) (PCL)-Nerve Growth Factor (NGF)&amp;amp;Bovine Serum Albumin (BSA) nanofibrous scaffolds [(R/A)-PCL-NGF&amp;amp;BSA], where NGF and BSA were encapsulated in the core while PCL form the shell.	polycaprolactone	181-184	nerve growth factor	Rattus norvegicus	280-283
30979150-3	2016	In this study, emulsion electrospinning technique was introduced as a flexible and promising technique for the fabrication of random (R) and aligned (A) Poly(epsilon-caprolactone) (PCL)-Nerve Growth Factor (NGF)&amp;amp;Bovine Serum Albumin (BSA) nanofibrous scaffolds [(R/A)-PCL-NGF&amp;amp;BSA], where NGF and BSA were encapsulated in the core while PCL form the shell.	polycaprolactone	181-184	nerve growth factor	Rattus norvegicus	280-283
30979150-6	2016	Release study showed that, with the addition of stabilizer BSA, a sustained release of NGF from emulsion electrospun PCL nanofibers was observed over 28 days.	polycaprolactone	117-120	nerve growth factor	Rattus norvegicus	87-90
26889917-3	2016	Here we elaborate on the fabrication of keratin containing poly (epsilon-caprolactone) (PCL) nanofibers (i.e., PCL/keratin composite fiber).	polycaprolactone	59-86	PHD finger protein 1	Homo sapiens	88-91
26889917-3	2016	Here we elaborate on the fabrication of keratin containing poly (epsilon-caprolactone) (PCL) nanofibers (i.e., PCL/keratin composite fiber).	polycaprolactone	59-86	PHD finger protein 1	Homo sapiens	111-114
30979150-3	2016	In this study, emulsion electrospinning technique was introduced as a flexible and promising technique for the fabrication of random (R) and aligned (A) Poly(epsilon-caprolactone) (PCL)-Nerve Growth Factor (NGF)&amp;amp;Bovine Serum Albumin (BSA) nanofibrous scaffolds [(R/A)-PCL-NGF&amp;amp;BSA], where NGF and BSA were encapsulated in the core while PCL form the shell.	polycaprolactone	153-179	nerve growth factor	Rattus norvegicus	207-210
26641134-0	2016	Efficient and Tumor Targeted siRNA Delivery by Polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol)-folate (PEI-PCL-PEG-Fol).	polycaprolactone	70-86	PHD finger protein 1	Homo sapiens	127-130
26012354-8	2016	Furthermore, there was an up-regulation of the wound-healing-related genes collagen I, collagen III and TGF-beta in polycaprolactone/hyaluronan/epidermal growth factor scaffolds compared with control groups.	polycaprolactone	116-132	epidermal growth factor	Homo sapiens	144-167
26689653-2	2016	In this work, we explored Etoricoxib (COX-2 inhibitor)-loaded Poly caprolactone (PCL) microparticles (MPs) as a potential IA-DDS.	polycaprolactone	62-79	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	38-43
26689653-2	2016	In this work, we explored Etoricoxib (COX-2 inhibitor)-loaded Poly caprolactone (PCL) microparticles (MPs) as a potential IA-DDS.	polycaprolactone	81-84	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	38-43
26012354-9	2016	In the full-thickness wound model, the enhanced regeneration of fully functional skin was facilitated by epidermal regeneration in the polycaprolactone/hyaluronan/epidermal growth factor treatment group.	polycaprolactone	135-151	epidermal growth factor	Homo sapiens	163-186
26407651-5	2015	When cardiomyocytes were cultured on the electrically-conductive PPy-PCL, more cells were observed to have peripheral localization of the gap junction protein connexin-43 (Cx43) as compared to cells on NaOH-treated PCL (60.3 +- 4.3% vs. 46.6 +- 5.7%).	polycaprolactone	69-72	gap junction protein alpha 1	Homo sapiens	159-170
26806749-0	2016	[Evaluation of in vitro insulin release from nanoparticles assembled by polyethylene glycol, polycaprolactone and polyethyleneimine].	polycaprolactone	93-109	insulin	Homo sapiens	24-31
26313249-1	2016	In view of their complementary properties, blending polylactide (PLA) with poly (epsilon-caprolactone) (PCL) becomes a good choice to improve PLA"s properties without compromising its biodegradability.	polycaprolactone	75-102	PHD finger protein 1	Homo sapiens	104-107
26703586-7	2015	To improve ingrowth of blood vessels into porous implants, proangiogenic factors like Vascular Endothelial Growth Factor (VEGF) and High Mobility Group Box 1 (HMGB1) were incorporated into PCL coated, porous titanium and magnesium implants.	polycaprolactone	189-192	vascular endothelial growth factor A	Mus musculus	86-120
26703586-7	2015	To improve ingrowth of blood vessels into porous implants, proangiogenic factors like Vascular Endothelial Growth Factor (VEGF) and High Mobility Group Box 1 (HMGB1) were incorporated into PCL coated, porous titanium and magnesium implants.	polycaprolactone	189-192	vascular endothelial growth factor A	Mus musculus	122-126
26703586-7	2015	To improve ingrowth of blood vessels into porous implants, proangiogenic factors like Vascular Endothelial Growth Factor (VEGF) and High Mobility Group Box 1 (HMGB1) were incorporated into PCL coated, porous titanium and magnesium implants.	polycaprolactone	189-192	high mobility group box 1	Mus musculus	132-157
26703586-7	2015	To improve ingrowth of blood vessels into porous implants, proangiogenic factors like Vascular Endothelial Growth Factor (VEGF) and High Mobility Group Box 1 (HMGB1) were incorporated into PCL coated, porous titanium and magnesium implants.	polycaprolactone	189-192	high mobility group box 1	Mus musculus	159-164
26407651-5	2015	When cardiomyocytes were cultured on the electrically-conductive PPy-PCL, more cells were observed to have peripheral localization of the gap junction protein connexin-43 (Cx43) as compared to cells on NaOH-treated PCL (60.3 +- 4.3% vs. 46.6 +- 5.7%).	polycaprolactone	69-72	gap junction protein alpha 1	Homo sapiens	172-176
26432440-3	2015	Here we have screened the ability of such surface-gradients of polycaprolactone to influence the expression of alkaline phosphatase (ALP), collagen type 1 (COL1) and mineralization by hMSCs cultured in dexamethasone (Dex)-deprived osteogenic induction medium (OIM) and in basal growth medium (BGM).	polycaprolactone	63-79	alkaline phosphatase, placental	Homo sapiens	111-131
26432440-3	2015	Here we have screened the ability of such surface-gradients of polycaprolactone to influence the expression of alkaline phosphatase (ALP), collagen type 1 (COL1) and mineralization by hMSCs cultured in dexamethasone (Dex)-deprived osteogenic induction medium (OIM) and in basal growth medium (BGM).	polycaprolactone	63-79	alkaline phosphatase, placental	Homo sapiens	133-136
28793632-8	2015	PGA-alpha-MSH functionalized PCL membranes reduced proliferation of Pg-LPS stimulated EC and FB.	polycaprolactone	29-32	proopiomelanocortin	Homo sapiens	4-13
32262904-4	2015	This work focuses on designing a novel class of encapsulated poly(epsilon-caprolactone) (PCL) nanofiber scaffolds with different topographies (random and aligned) that generate controlled release of GDNF to potentially serve as a suitable substitute for the dura mater during neurosurgical procedures.	polycaprolactone	61-87	glial cell derived neurotrophic factor	Homo sapiens	199-203
32262904-4	2015	This work focuses on designing a novel class of encapsulated poly(epsilon-caprolactone) (PCL) nanofiber scaffolds with different topographies (random and aligned) that generate controlled release of GDNF to potentially serve as a suitable substitute for the dura mater during neurosurgical procedures.	polycaprolactone	89-92	glial cell derived neurotrophic factor	Homo sapiens	199-203
25533304-10	2015	Addition of bioactive glass into the PCL matrix promotes mineralization estimated on the basis of the ALP activity.	polycaprolactone	37-40	ATHS	Homo sapiens	102-105
26335746-0	2015	Three-dimensional poly-(epsilon-caprolactone) nanofibrous scaffolds directly promote the cardiomyocyte differentiation of murine-induced pluripotent stem cells through Wnt/beta-catenin signaling.	polycaprolactone	18-44	catenin (cadherin associated protein), beta 1	Mus musculus	172-184
26423218-7	2015	Janus PLA/PCL (polycaprolactone) particles were produced by solvent evaporation-induced phase separation within organic phase droplets containing 3% (v/v) PLA/PCL (30/70 or 70/30) mixture in dichloromethane.	polycaprolactone	15-31	PHD finger protein 1	Homo sapiens	10-13
26491313-9	2015	The composite film had higher water absorption than the pure PCL, and increasing the concentration of the HAp increased the water absorption.	polycaprolactone	61-64	reticulon 3	Homo sapiens	106-109
25837415-0	2015	Interleukin-10 conjugated electrospun polycaprolactone (PCL) nanofibre scaffolds for promoting alternatively activated (M2) macrophages around the peripheral nerve in vivo.	polycaprolactone	38-54	interleukin 10	Rattus norvegicus	0-14
26255261-5	2015	Herein, the synergistic outcome of co-application of Fn and nHA incorporation into aligned electrospun polycaprolactone (PCL) seeded by mouse mesenchymal stem cells (MSC) was investigated both in vitro and in vivo.	polycaprolactone	103-119	fibronectin 1	Mus musculus	53-55
26255261-5	2015	Herein, the synergistic outcome of co-application of Fn and nHA incorporation into aligned electrospun polycaprolactone (PCL) seeded by mouse mesenchymal stem cells (MSC) was investigated both in vitro and in vivo.	polycaprolactone	121-124	fibronectin 1	Mus musculus	53-55
25842103-0	2015	Nanofibrous yet injectable polycaprolactone-collagen bone tissue scaffold with osteoprogenitor cells and controlled release of bone morphogenetic protein-2.	polycaprolactone	27-43	bone morphogenetic protein 2	Mus musculus	127-155
26036174-7	2015	In vivo study of SCI animal models demonstrated that local delivery of FTY720 with polycaprolactone (PCL) membrane significantly decreased S1P1 expression and glial scarring compared with the control group.	polycaprolactone	83-99	sphingosine-1-phosphate receptor 1	Homo sapiens	139-143
26036174-7	2015	In vivo study of SCI animal models demonstrated that local delivery of FTY720 with polycaprolactone (PCL) membrane significantly decreased S1P1 expression and glial scarring compared with the control group.	polycaprolactone	101-104	sphingosine-1-phosphate receptor 1	Homo sapiens	139-143
26251597-3	2015	In this study, we report the differences in the rate and mechanism of cellular internalization of a biocompatible polycaprolactone (PCL)/maltodextrin (MD) nanocarrier system for intracellular drug delivery in LNCaP, PC3, and DU145 PCa cell lines.	polycaprolactone	114-130	keratin 6A	Homo sapiens	216-219
26251597-3	2015	In this study, we report the differences in the rate and mechanism of cellular internalization of a biocompatible polycaprolactone (PCL)/maltodextrin (MD) nanocarrier system for intracellular drug delivery in LNCaP, PC3, and DU145 PCa cell lines.	polycaprolactone	132-135	keratin 6A	Homo sapiens	216-219
25747407-5	2015	Using poly(epsilon-caprolactone) nanofibers, efficient knockdown of OL differentiation inhibitory regulators were achieved by either nanofiber alone (20-40%, p&lt;0.05) or the synergistic integration with miR-219 and miR-338 (up to 60%, p&lt;0.05).	polycaprolactone	6-31	microRNA 219a-1	Homo sapiens	205-212
25747407-5	2015	Using poly(epsilon-caprolactone) nanofibers, efficient knockdown of OL differentiation inhibitory regulators were achieved by either nanofiber alone (20-40%, p&lt;0.05) or the synergistic integration with miR-219 and miR-338 (up to 60%, p&lt;0.05).	polycaprolactone	6-31	microRNA 338	Homo sapiens	217-224
26020609-1	2015	In this work, fluorescent gold nanocluster (AuNC) decorated polycaprolactone (PCL) nanofibers (AuNC*PCL-NF) for real time visual monitoring of Hg(2+) detection at ppt level in water is demonstrated.	polycaprolactone	60-76	tachykinin precursor 1	Homo sapiens	163-166
26020609-1	2015	In this work, fluorescent gold nanocluster (AuNC) decorated polycaprolactone (PCL) nanofibers (AuNC*PCL-NF) for real time visual monitoring of Hg(2+) detection at ppt level in water is demonstrated.	polycaprolactone	78-81	tachykinin precursor 1	Homo sapiens	163-166
25640312-3	2015	In this study, we investigated the differentiating potential of hiPSCs on poly (epsilon-caprolactone) (PCL) nanofibrous scaffold into DE cells.	polycaprolactone	74-101	PHD finger protein 1	Homo sapiens	103-106
25837415-0	2015	Interleukin-10 conjugated electrospun polycaprolactone (PCL) nanofibre scaffolds for promoting alternatively activated (M2) macrophages around the peripheral nerve in vivo.	polycaprolactone	56-59	interleukin 10	Rattus norvegicus	0-14
25837415-5	2015	IL-10 was adsorbed and covalently bound to electrospun poly(epsilon-caprolactone) (PCL) nanofibrous scaffolds.	polycaprolactone	55-81	interleukin 10	Rattus norvegicus	0-5
25837415-5	2015	IL-10 was adsorbed and covalently bound to electrospun poly(epsilon-caprolactone) (PCL) nanofibrous scaffolds.	polycaprolactone	83-86	interleukin 10	Rattus norvegicus	0-5
25837415-7	2015	IL-10 remained immobilised to PCL scaffolds for more than 120 days when stored in phosphate buffered saline at room temperature and for up to 14d ays when implanted around the sciatic nerve.	polycaprolactone	30-33	interleukin 10	Rattus norvegicus	0-5
25617805-3	2015	Furthermore, a core-shell structure of a biopolymer fiber made of polyethylene oxide/polycaprolactone was introduced to load FGF2, another type of cell proliferative and angiogenic growth factor, safely within the core while releasing it more rapidly than FGF18.	polycaprolactone	85-101	fibroblast growth factor 2	Rattus norvegicus	125-129
25617805-3	2015	Furthermore, a core-shell structure of a biopolymer fiber made of polyethylene oxide/polycaprolactone was introduced to load FGF2, another type of cell proliferative and angiogenic growth factor, safely within the core while releasing it more rapidly than FGF18.	polycaprolactone	85-101	myotrophin	Rattus norvegicus	181-194
25617805-3	2015	Furthermore, a core-shell structure of a biopolymer fiber made of polyethylene oxide/polycaprolactone was introduced to load FGF2, another type of cell proliferative and angiogenic growth factor, safely within the core while releasing it more rapidly than FGF18.	polycaprolactone	85-101	fibroblast growth factor 18	Rattus norvegicus	256-261
25922647-5	2015	MATERIALS AND METHODS: In this study, polycaprolactone (PCL) scaffold coated with fibronectin (3D) is compared to routine cell culture system (two dimensional, 2D) used for cell culture.1x10(4) cord blood CD34+ cells isolated by MACS were seeded on PCL scaffold and allowed to expand for 10  days.	polycaprolactone	38-54	fibronectin 1	Homo sapiens	82-93
25787740-3	2015	In this study, we fabricated polycaprolactone/gelatin composite electrospun nanofibers incorporated with basic fibroblast growth factor (bFGF) to direct bone regeneration.	polycaprolactone	29-45	fibroblast growth factor 2	Homo sapiens	105-135
25787740-3	2015	In this study, we fabricated polycaprolactone/gelatin composite electrospun nanofibers incorporated with basic fibroblast growth factor (bFGF) to direct bone regeneration.	polycaprolactone	29-45	fibroblast growth factor 2	Homo sapiens	137-141
25592048-2	2015	We investigated whether coadministration of autologous myoblasts and bFGF-loaded polycaprolactone beads could improve sphincter recovery in a dog model of fecal incontinence (FI).	polycaprolactone	81-97	fibroblast growth factor 2	Canis lupus familiaris	69-73
25592048-4	2015	One month later, the dogs were randomized to receive either PKH-26-labeled autologous myoblasts alone (M group, five dogs) or autologous myoblasts and bFGF-loaded polycaprolactone beads (MBG group, five dogs).	polycaprolactone	163-179	fibroblast growth factor 2	Canis lupus familiaris	151-155
25502922-0	2015	Fibronectin immobilization on to robotic-dispensed nanobioactive glass/polycaprolactone scaffolds for bone tissue engineering.	polycaprolactone	71-87	fibronectin 1	Homo sapiens	0-11
25502922-2	2015	Fibronectin (FN)-immobilized nanobioactive glass (nBG)/polycaprolactone (PCL) (FN-nBG/PCL) scaffolds with an open pore architecture were generated by a robotic-dispensing technique.	polycaprolactone	55-71	fibronectin 1	Homo sapiens	0-11
25502922-2	2015	Fibronectin (FN)-immobilized nanobioactive glass (nBG)/polycaprolactone (PCL) (FN-nBG/PCL) scaffolds with an open pore architecture were generated by a robotic-dispensing technique.	polycaprolactone	55-71	fibronectin 1	Homo sapiens	13-15
25502922-2	2015	Fibronectin (FN)-immobilized nanobioactive glass (nBG)/polycaprolactone (PCL) (FN-nBG/PCL) scaffolds with an open pore architecture were generated by a robotic-dispensing technique.	polycaprolactone	73-76	fibronectin 1	Homo sapiens	0-11
25502922-2	2015	Fibronectin (FN)-immobilized nanobioactive glass (nBG)/polycaprolactone (PCL) (FN-nBG/PCL) scaffolds with an open pore architecture were generated by a robotic-dispensing technique.	polycaprolactone	73-76	fibronectin 1	Homo sapiens	13-15
25922647-5	2015	MATERIALS AND METHODS: In this study, polycaprolactone (PCL) scaffold coated with fibronectin (3D) is compared to routine cell culture system (two dimensional, 2D) used for cell culture.1x10(4) cord blood CD34+ cells isolated by MACS were seeded on PCL scaffold and allowed to expand for 10  days.	polycaprolactone	56-59	fibronectin 1	Homo sapiens	82-93
25515846-0	2015	Biomineral coating increases bone formation by ex vivo BMP-7 gene therapy in rapid prototyped poly(L-lactic acid) (PLLA) and poly(epsilon-caprolactone) (PCL) porous scaffolds.	polycaprolactone	125-151	bone morphogenetic protein 7	Homo sapiens	55-60
25686988-3	2015	Differential scanning calorimetry, ATR-FTIR spectroscopy and circular dichroic analysis have been employed to substantiate the changes in hydration of gelatin, interacting with polycaprolactone.	polycaprolactone	177-193	ATR serine/threonine kinase	Homo sapiens	35-38
25335965-12	2015	Attenuated expression of AQP-4 in the PCL/TCP group (p&lt;0.05) suggested that PCL/TCP scaffolds altered BBB selectivity to a lower degree as compared with sham and PCL groups, pointing to potential clinical implications in reducing cerebral edema.	polycaprolactone	38-41	aquaporin 4	Homo sapiens	25-30
25579898-1	2015	Outstanding wound healing activity of gum tragacanth (GT) and higher mechanical strength of poly (epsilon-caprolactone) (PCL) may produce an excellent nanofibrous patch for either skin tissue engineering or wound dressing application.	polycaprolactone	92-119	PHD finger protein 1	Homo sapiens	121-124
25513839-5	2015	The identification of the optimal FN density regime for the osteogenic commitment of hBM-MSCs presents a simple and versatile strategy to significantly enhance the surface properties of polycaprolactone as a paradigm for other synthetic polymers intended for bone-related applications.	polycaprolactone	186-202	hemoglobin subunit mu	Homo sapiens	85-88
25709432-3	2015	A thick electrospun poly(epsilon-caprolactone) nanofibrous implant (from 700 mum to 1 cm thick) was functionalized with chitosan and bone morphogenetic protein BMP-7 as growth factor using layer-by-layer technology, producing fish scale-like chitosan/BMP-7 nanoreservoirs.	polycaprolactone	20-45	bone morphogenetic protein 7	Homo sapiens	160-165
25335965-12	2015	Attenuated expression of AQP-4 in the PCL/TCP group (p&lt;0.05) suggested that PCL/TCP scaffolds altered BBB selectivity to a lower degree as compared with sham and PCL groups, pointing to potential clinical implications in reducing cerebral edema.	polycaprolactone	79-82	aquaporin 4	Homo sapiens	25-30
25335965-12	2015	Attenuated expression of AQP-4 in the PCL/TCP group (p&lt;0.05) suggested that PCL/TCP scaffolds altered BBB selectivity to a lower degree as compared with sham and PCL groups, pointing to potential clinical implications in reducing cerebral edema.	polycaprolactone	79-82	aquaporin 4	Homo sapiens	25-30
26198725-4	2015	METHODS: ORM-11984 was mixed with a copolymer of L-lactide and e-caprolactone (PLCL).	polycaprolactone	63-77	orosomucoid 1	Rattus norvegicus	9-12
25462528-4	2015	The PC-miR-148b-SNP conjugates added to hASCs and loaded to either Matrigel or polycaprolactone (PCL) scaffolds resulted in different levels of healing of the defect.	polycaprolactone	79-95	microRNA 148b	Mus musculus	7-15
25462528-4	2015	The PC-miR-148b-SNP conjugates added to hASCs and loaded to either Matrigel or polycaprolactone (PCL) scaffolds resulted in different levels of healing of the defect.	polycaprolactone	97-100	microRNA 148b	Mus musculus	7-15
25531645-2	2015	Herein, electrospun fibrous scaffolds of polycaprolactone-gelatin incorporating mesoporous bioactive glass nanoparticles (mBGn) were proposed to be excellent matrix platforms for bone tissue engineering.	polycaprolactone	41-57	biglycan	Mus musculus	122-126
26090397-1	2015	The purpose of this study was to demonstrate the ability of BMP-2-immobilized polycaprolactone (PCL) fibers modified using the gamma-ray irradiation technique to induce the osteogenic differentiation of MG-63 cells.	polycaprolactone	78-94	bone morphogenetic protein 2	Homo sapiens	60-65
26090397-1	2015	The purpose of this study was to demonstrate the ability of BMP-2-immobilized polycaprolactone (PCL) fibers modified using the gamma-ray irradiation technique to induce the osteogenic differentiation of MG-63 cells.	polycaprolactone	96-99	bone morphogenetic protein 2	Homo sapiens	60-65
25158862-0	2015	Bone morphogenetic protein-2-encapsulated grafted-poly-lactic acid-polycaprolactone nanoparticles promote bone repair.	polycaprolactone	67-83	bone morphogenetic protein 2	Oryctolagus cuniculus	0-28
25145988-0	2015	Hybrid vitronectin-mimicking polycaprolactone scaffolds for human retinal progenitor cell differentiation and transplantation.	polycaprolactone	29-45	vitronectin	Homo sapiens	7-18
25262582-3	2015	We demonstrated that bioactive glass nanoparticles (nBG) incorporated polycaprolactone (PCL) coating on hydroxyapatite/beta-tricalcium phosphate (HA/TCP) scaffold exerted a synergistic effect with 3days of BMP-2 treatment in promoting osteogenic gene expression levels (Runx-2, collagen I, osteopontin and bone sialoprotein) and alkaline phosphatase activity in ASCs.	polycaprolactone	70-86	serine peptidase inhibitor Kazal type 1	Homo sapiens	104-152
26065539-0	2015	Preparation and preliminary in vitro evaluation of a bFGF-releasing heparin-conjugated poly(epsilon-caprolactone) membrane for guided bone regeneration.	polycaprolactone	87-113	fibroblast growth factor 2	Homo sapiens	53-57
26065539-1	2015	In an effort to improve guided bone regeneration (GBR), we successfully fabricated a novel basic fibroblast growth factor (bFGF)-releasing heparin-conjugated poly(epsilon-caprolactone) membrane (hep-PCL/bFGF).	polycaprolactone	158-184	fibroblast growth factor 2	Homo sapiens	123-127
26065539-1	2015	In an effort to improve guided bone regeneration (GBR), we successfully fabricated a novel basic fibroblast growth factor (bFGF)-releasing heparin-conjugated poly(epsilon-caprolactone) membrane (hep-PCL/bFGF).	polycaprolactone	158-184	fibroblast growth factor 2	Homo sapiens	203-207
25262582-3	2015	We demonstrated that bioactive glass nanoparticles (nBG) incorporated polycaprolactone (PCL) coating on hydroxyapatite/beta-tricalcium phosphate (HA/TCP) scaffold exerted a synergistic effect with 3days of BMP-2 treatment in promoting osteogenic gene expression levels (Runx-2, collagen I, osteopontin and bone sialoprotein) and alkaline phosphatase activity in ASCs.	polycaprolactone	70-86	bone morphogenetic protein 2	Homo sapiens	206-211
25262582-3	2015	We demonstrated that bioactive glass nanoparticles (nBG) incorporated polycaprolactone (PCL) coating on hydroxyapatite/beta-tricalcium phosphate (HA/TCP) scaffold exerted a synergistic effect with 3days of BMP-2 treatment in promoting osteogenic gene expression levels (Runx-2, collagen I, osteopontin and bone sialoprotein) and alkaline phosphatase activity in ASCs.	polycaprolactone	70-86	RUNX family transcription factor 2	Homo sapiens	270-276
25262582-3	2015	We demonstrated that bioactive glass nanoparticles (nBG) incorporated polycaprolactone (PCL) coating on hydroxyapatite/beta-tricalcium phosphate (HA/TCP) scaffold exerted a synergistic effect with 3days of BMP-2 treatment in promoting osteogenic gene expression levels (Runx-2, collagen I, osteopontin and bone sialoprotein) and alkaline phosphatase activity in ASCs.	polycaprolactone	70-86	secreted phosphoprotein 1	Homo sapiens	290-301
25262582-3	2015	We demonstrated that bioactive glass nanoparticles (nBG) incorporated polycaprolactone (PCL) coating on hydroxyapatite/beta-tricalcium phosphate (HA/TCP) scaffold exerted a synergistic effect with 3days of BMP-2 treatment in promoting osteogenic gene expression levels (Runx-2, collagen I, osteopontin and bone sialoprotein) and alkaline phosphatase activity in ASCs.	polycaprolactone	88-91	serine peptidase inhibitor Kazal type 1	Homo sapiens	104-152
25262582-3	2015	We demonstrated that bioactive glass nanoparticles (nBG) incorporated polycaprolactone (PCL) coating on hydroxyapatite/beta-tricalcium phosphate (HA/TCP) scaffold exerted a synergistic effect with 3days of BMP-2 treatment in promoting osteogenic gene expression levels (Runx-2, collagen I, osteopontin and bone sialoprotein) and alkaline phosphatase activity in ASCs.	polycaprolactone	88-91	bone morphogenetic protein 2	Homo sapiens	206-211
25262582-3	2015	We demonstrated that bioactive glass nanoparticles (nBG) incorporated polycaprolactone (PCL) coating on hydroxyapatite/beta-tricalcium phosphate (HA/TCP) scaffold exerted a synergistic effect with 3days of BMP-2 treatment in promoting osteogenic gene expression levels (Runx-2, collagen I, osteopontin and bone sialoprotein) and alkaline phosphatase activity in ASCs.	polycaprolactone	88-91	RUNX family transcription factor 2	Homo sapiens	270-276
25262582-3	2015	We demonstrated that bioactive glass nanoparticles (nBG) incorporated polycaprolactone (PCL) coating on hydroxyapatite/beta-tricalcium phosphate (HA/TCP) scaffold exerted a synergistic effect with 3days of BMP-2 treatment in promoting osteogenic gene expression levels (Runx-2, collagen I, osteopontin and bone sialoprotein) and alkaline phosphatase activity in ASCs.	polycaprolactone	88-91	secreted phosphoprotein 1	Homo sapiens	290-301
25139361-12	2014	At the protein level, osteocalcin expression was induced only in the DPSCs on the PCL+FA surfaces at day 21 and then significantly enhanced at day 28.	polycaprolactone	82-85	bone gamma-carboxyglutamate protein	Homo sapiens	22-33
25445519-3	2014	Binary PCL/PD blend nonwovens showed a PD-dependent increase in swelling of up to 30% and of lysozyme burst release of up to 45% associated with changes of the fiber morphology.	polycaprolactone	7-10	lysozyme	Homo sapiens	93-101
25445519-5	2014	Using ternary PCL/PD/PLGA blends, matrix degradation could be significantly improved over PCL/PD blends, resulting in a biphasic release of lysozyme with constant release over 9 weeks, followed by constant release with a reduced rate over additional 4 weeks.	polycaprolactone	14-17	lysozyme	Homo sapiens	140-148
25360086-7	2014	The PCL+MSC group presented a higher number of myelinated fibers and a larger cortical representation of MN inputs in S1 (3,383 +- 390 fibers; 2.3 mm(2), respectively) than the PCL-Only group (2,226 +- 575 fibers; 1.6 mm(2)).	polycaprolactone	4-7	musculin	Rattus norvegicus	8-11
25386942-1	2014	In this content, a small molecular ligand of prostate specific membrane antigen (SMLP) conjugated poly (caprolactone) (PCL)-b-poly (ethylene glycol) (PEG) copolymers with different block lengths were synthesized to construct a satisfactory drug delivery system.	polycaprolactone	98-117	folate hydrolase 1	Homo sapiens	45-79
26000399-3	2014	Here we report a new approach to locally deliver recombinant VEGF from an electrospun poly-epsilon-caprolactone nanofiber mesh and its effect on improving rat liver regeneration after 70% hepatectomy.	polycaprolactone	86-111	vascular endothelial growth factor A	Rattus norvegicus	61-65
24935525-1	2014	To confirm the effect of recombinant human bone morphogenetic protein-2 (BMP-2) for bone regeneration, BMP-2-loaded polycaprolactone (PCL)-gelatin (Gel)-biphasic calcium phosphate (BCP) fibrous scaffolds were fabricated using the electrospinning method.	polycaprolactone	116-132	bone morphogenetic protein 2	Homo sapiens	103-108
24935525-1	2014	To confirm the effect of recombinant human bone morphogenetic protein-2 (BMP-2) for bone regeneration, BMP-2-loaded polycaprolactone (PCL)-gelatin (Gel)-biphasic calcium phosphate (BCP) fibrous scaffolds were fabricated using the electrospinning method.	polycaprolactone	134-137	bone morphogenetic protein 2	Homo sapiens	103-108
24643931-1	2014	PURPOSE: It is hypothesized that docetaxel (Doc)-loaded hyaluronic acid (HA)-polyethylene glycol/poly(epsilon-caprolactone)-grafted oily core nanocapsules (NCs) can enhance the drug cytotoxicity and uptake in CD44 expressing breast cancer (BC) cells (MDA-MB 231).	polycaprolactone	97-123	CD44 molecule (Indian blood group)	Homo sapiens	209-213
25307051-2	2014	Herein, we report the fabrication of a fibrous mesh of polycaprolactone (PCL) incorporating PCL-pluronic (F127) microvesicles through electrospinning, by exploiting the slow dissolution of PCL in glacial acetic acid (g-AA).	polycaprolactone	55-71	glucosidase, alpha, acid	Mus musculus	217-221
25307051-2	2014	Herein, we report the fabrication of a fibrous mesh of polycaprolactone (PCL) incorporating PCL-pluronic (F127) microvesicles through electrospinning, by exploiting the slow dissolution of PCL in glacial acetic acid (g-AA).	polycaprolactone	73-76	glucosidase, alpha, acid	Mus musculus	217-221
24712446-3	2014	This study investigated augmenting PEG hydrogels with polycaprolactone (PCL) as an analog to the fibrosa to improve strength and introduce anisotropic mechanical behavior.	polycaprolactone	54-70	PHD finger protein 1	Homo sapiens	72-75
24657671-0	2014	Umbilical-cord-blood-derived mesenchymal stem cells seeded onto fibronectin-immobilized polycaprolactone nanofiber improve cardiac function.	polycaprolactone	88-104	fibronectin 1	Rattus norvegicus	64-75
24811954-0	2014	Chemical activation and changes in surface morphology of poly(epsilon-caprolactone) modulate VEGF responsiveness of human endothelial cells.	polycaprolactone	57-83	vascular endothelial growth factor A	Homo sapiens	93-97
24751343-2	2014	A hydrophilic drug, salicylic acid (SA), was loaded in the representative poly(epsilon-caprolactone) (PCL)/polyethylene glycol (PEG) core/sheath fibers, performed according to this combined technique.	polycaprolactone	74-100	PHD finger protein 1	Homo sapiens	102-105
24657671-2	2014	We investigated whether umbilical-cord-blood-derived mesenchymal stem cell (UCB-MSC)-seeded fibronectin (FN)-immobilized polycaprolactone (PCL) nanofibers could improve cardiac function and inhibit left ventricle (LV) remodeling in a rat model of myocardial infarction (MI).	polycaprolactone	121-137	fibronectin 1	Rattus norvegicus	92-103
24657671-2	2014	We investigated whether umbilical-cord-blood-derived mesenchymal stem cell (UCB-MSC)-seeded fibronectin (FN)-immobilized polycaprolactone (PCL) nanofibers could improve cardiac function and inhibit left ventricle (LV) remodeling in a rat model of myocardial infarction (MI).	polycaprolactone	121-137	fibronectin 1	Rattus norvegicus	105-107
24657671-2	2014	We investigated whether umbilical-cord-blood-derived mesenchymal stem cell (UCB-MSC)-seeded fibronectin (FN)-immobilized polycaprolactone (PCL) nanofibers could improve cardiac function and inhibit left ventricle (LV) remodeling in a rat model of myocardial infarction (MI).	polycaprolactone	139-142	fibronectin 1	Rattus norvegicus	92-103
24657671-2	2014	We investigated whether umbilical-cord-blood-derived mesenchymal stem cell (UCB-MSC)-seeded fibronectin (FN)-immobilized polycaprolactone (PCL) nanofibers could improve cardiac function and inhibit left ventricle (LV) remodeling in a rat model of myocardial infarction (MI).	polycaprolactone	139-142	fibronectin 1	Rattus norvegicus	105-107
24657671-5	2014	Furthermore, genes related to angiogenesis and mesenchymal differentiations were up-regulated in the FN-immobilized PCL nanofibers in comparison to control PCL nanofibers in vitro.	polycaprolactone	116-119	fibronectin 1	Rattus norvegicus	101-103
24657671-6	2014	4 weeks after the transplantation in the rat MI model, the echocardiogram showed that the UCB-MSC-seeded FN-immobilized PCL nanofiber group increased LV ejection fraction and fraction shortening as compared to the non-treated control and acellular FN-immobilized PCL nanofiber groups.	polycaprolactone	120-123	fibronectin 1	Rattus norvegicus	105-107
24657671-6	2014	4 weeks after the transplantation in the rat MI model, the echocardiogram showed that the UCB-MSC-seeded FN-immobilized PCL nanofiber group increased LV ejection fraction and fraction shortening as compared to the non-treated control and acellular FN-immobilized PCL nanofiber groups.	polycaprolactone	120-123	fibronectin 1	Rattus norvegicus	248-250
24657671-6	2014	4 weeks after the transplantation in the rat MI model, the echocardiogram showed that the UCB-MSC-seeded FN-immobilized PCL nanofiber group increased LV ejection fraction and fraction shortening as compared to the non-treated control and acellular FN-immobilized PCL nanofiber groups.	polycaprolactone	263-266	fibronectin 1	Rattus norvegicus	105-107
24657671-7	2014	Histological analysis indicated that the implantation of UCB-MSCs with FN-immobilized PCL nanofibers induced a decrease in MI size and fibrosis, and an increase in scar thickness.	polycaprolactone	86-89	fibronectin 1	Rattus norvegicus	71-73
24517081-1	2014	In this study, recombinant human bone morphogenetic protein-2 (rhBMP-2) delivery system with slow mode was successfully developed in three-dimensional (3D) printing-based polycaprolactone (PCL)/poly(lactic-co-glycolic acid) (PLGA) scaffolds for bone formation of critical-sized rabbit segmental diaphyseal defect.	polycaprolactone	171-187	bone morphogenetic protein 2	Homo sapiens	33-61
24588462-12	2014	Astrocytes proliferate and extend into poly-epsilon-caprolactone scaffolds displaying 3D stellated morphologies with reduced GFAP expression and actin stress fibres, plus a cytotrophic gene profile.	polycaprolactone	39-64	glial fibrillary acidic protein	Mus musculus	125-129
24517081-1	2014	In this study, recombinant human bone morphogenetic protein-2 (rhBMP-2) delivery system with slow mode was successfully developed in three-dimensional (3D) printing-based polycaprolactone (PCL)/poly(lactic-co-glycolic acid) (PLGA) scaffolds for bone formation of critical-sized rabbit segmental diaphyseal defect.	polycaprolactone	189-192	bone morphogenetic protein 2	Homo sapiens	33-61
24700461-6	2014	Enzyme-linked immunosorbent assays (ELISA) revealed that GDNF, covalently tethered onto polycaprolactone (PCL) electrospun nanofibrous scaffolds, remained present on the scaffold surface for 120 days, with no evidence of protein leaching or degradation.	polycaprolactone	88-104	glial cell derived neurotrophic factor	Homo sapiens	57-61
23775820-0	2014	Fibronectin adsorption on functionalized electrospun polycaprolactone scaffolds: experimental and molecular dynamics studies.	polycaprolactone	53-69	fibronectin 1	Homo sapiens	0-11
23775820-3	2014	The goal of this study is to examine the effect of functionalization on fibronectin adsorption to electrospun polycaprolactone (PCL) scaffolds through experimentation using fluorescently labeled fibronectin and to couple this experimental data with analysis of interaction energies obtained through molecular dynamics (MD) simulations to develop a better understanding of the adsorption process.	polycaprolactone	110-126	fibronectin 1	Homo sapiens	72-83
23775820-3	2014	The goal of this study is to examine the effect of functionalization on fibronectin adsorption to electrospun polycaprolactone (PCL) scaffolds through experimentation using fluorescently labeled fibronectin and to couple this experimental data with analysis of interaction energies obtained through molecular dynamics (MD) simulations to develop a better understanding of the adsorption process.	polycaprolactone	128-131	fibronectin 1	Homo sapiens	72-83
24700461-6	2014	Enzyme-linked immunosorbent assays (ELISA) revealed that GDNF, covalently tethered onto polycaprolactone (PCL) electrospun nanofibrous scaffolds, remained present on the scaffold surface for 120 days, with no evidence of protein leaching or degradation.	polycaprolactone	106-109	glial cell derived neurotrophic factor	Homo sapiens	57-61
23595895-3	2014	METHODS: The APM was fabricated with polycaprolactone (PCL) and pluronic F127 to have nano-size pores at top side, whereas the bottom side had micro-size pores.	polycaprolactone	37-53	aminopeptidase N	Oryctolagus cuniculus	13-16
23595895-3	2014	METHODS: The APM was fabricated with polycaprolactone (PCL) and pluronic F127 to have nano-size pores at top side, whereas the bottom side had micro-size pores.	polycaprolactone	55-58	aminopeptidase N	Oryctolagus cuniculus	13-16
24651872-2	2014	Biodegradable block copolymers of poly(ethylene glycol) (PEG) and poly(epsilon-caprolactone) (PCL) were synthesized by ring opening copolymerization and characterized thoroughly using FTIR, (1)H NMR and GPC.	polycaprolactone	66-92	glycophorin C (Gerbich blood group)	Homo sapiens	203-206
24651872-2	2014	Biodegradable block copolymers of poly(ethylene glycol) (PEG) and poly(epsilon-caprolactone) (PCL) were synthesized by ring opening copolymerization and characterized thoroughly using FTIR, (1)H NMR and GPC.	polycaprolactone	94-97	glycophorin C (Gerbich blood group)	Homo sapiens	203-206
24518200-1	2014	The aim of this study was to develop novel polycaprolactone/poly(lactic-co-glycolic acid) (PCL/PLGA) scaffolds with a heparin-dopamine (Hep-DOPA) conjugate for controlled release of bone morphogenic protein-2 (BMP-2) to enhance osteoblast activity in vitro and also bone formation in vivo.	polycaprolactone	43-59	heparanase	Rattus norvegicus	136-139
24518200-1	2014	The aim of this study was to develop novel polycaprolactone/poly(lactic-co-glycolic acid) (PCL/PLGA) scaffolds with a heparin-dopamine (Hep-DOPA) conjugate for controlled release of bone morphogenic protein-2 (BMP-2) to enhance osteoblast activity in vitro and also bone formation in vivo.	polycaprolactone	43-59	bone morphogenetic protein 2	Rattus norvegicus	182-208
24518200-1	2014	The aim of this study was to develop novel polycaprolactone/poly(lactic-co-glycolic acid) (PCL/PLGA) scaffolds with a heparin-dopamine (Hep-DOPA) conjugate for controlled release of bone morphogenic protein-2 (BMP-2) to enhance osteoblast activity in vitro and also bone formation in vivo.	polycaprolactone	43-59	bone morphogenetic protein 2	Rattus norvegicus	210-215
32261390-5	2014	Further natural proteins Gel and fibrinogen (Fib) solutions were also CXLed using vitamin B2 (riboflavin (Rib)) released from Rib-loaded polycaprolactone (PCL) nanofibers followed by UV treatment.	polycaprolactone	137-153	fibrinogen beta chain	Homo sapiens	45-48
25786730-0	2014	Controlled release of glial cell line-derived neurotrophic factor from poly(epsilon-caprolactone) microspheres.	polycaprolactone	71-97	glial cell derived neurotrophic factor	Homo sapiens	22-65
25786730-3	2014	As a proof of concept, we encapsulated GDNF into poly(epsilon-caprolactone) (PCL) microspheres to enable controlled drug release for 25 days.	polycaprolactone	49-75	glial cell derived neurotrophic factor	Homo sapiens	39-43
25786730-3	2014	As a proof of concept, we encapsulated GDNF into poly(epsilon-caprolactone) (PCL) microspheres to enable controlled drug release for 25 days.	polycaprolactone	77-80	glial cell derived neurotrophic factor	Homo sapiens	39-43
32261390-5	2014	Further natural proteins Gel and fibrinogen (Fib) solutions were also CXLed using vitamin B2 (riboflavin (Rib)) released from Rib-loaded polycaprolactone (PCL) nanofibers followed by UV treatment.	polycaprolactone	155-158	fibrinogen beta chain	Homo sapiens	45-48
25412799-5	2014	Unmodified polycaprolactone scaffolds uniquely demonstrated a total lack of both macrophage adherence to surfaces and a wider foreign body response compared to scaffolds composed of poly(lactic-co-glycolic acid) (PLGA) and polyurethanes (PURs), with those macrophages present having a clear M2 (MR+, CD80-, iNOS-) phenotype.	polycaprolactone	11-27	Cd80 molecule	Rattus norvegicus	300-304
24550481-6	2014	We then demonstrated that scaffold-mediated gene delivery of transforming growth factor beta3 (TGF-beta3), using a 3D woven poly(epsilon-caprolactone) scaffold, induced robust cartilaginous ECM formation by hMSCs.	polycaprolactone	124-150	transforming growth factor beta 3	Homo sapiens	61-93
24550481-6	2014	We then demonstrated that scaffold-mediated gene delivery of transforming growth factor beta3 (TGF-beta3), using a 3D woven poly(epsilon-caprolactone) scaffold, induced robust cartilaginous ECM formation by hMSCs.	polycaprolactone	124-150	transforming growth factor beta 3	Homo sapiens	95-104
24730245-0	2014	Development and characterization of lactoferrin loaded poly(epsilon-caprolactone) nanofibers.	polycaprolactone	55-81	lactotransferrin	Mus musculus	36-47
24730245-1	2014	Lactoferrin loaded poly (epsilon-caprolactone) nanofibers were fabricated using the process of electrospinning and the osteocompatibility of the scaffolds were evaluated using MC3T3-E1 osteoblast-like cells.	polycaprolactone	19-46	lactotransferrin	Mus musculus	0-11
32261618-5	2014	Poly(epsilon-caprolactone) nanoparticles were loaded with VEGF and in turn the release of VEGF from a surface is controlled by a thick layer-by-layer polyelectrolyte film.	polycaprolactone	0-26	vascular endothelial growth factor A	Homo sapiens	58-62
32261618-5	2014	Poly(epsilon-caprolactone) nanoparticles were loaded with VEGF and in turn the release of VEGF from a surface is controlled by a thick layer-by-layer polyelectrolyte film.	polycaprolactone	0-26	vascular endothelial growth factor A	Homo sapiens	90-94
29470669-0	2014	Electrospun poly(caprolactone)-elastin scaffolds for peripheral nerve regeneration.	polycaprolactone	12-29	elastin	Gallus gallus	31-38
32261313-1	2014	Hyperbranched poly(epsilon-caprolactone) with peripheral terminal alkyne groups (HPCL) was synthesized via thiol-yne click reaction among the AB2-type alpha-thiol-omega-alkyne-poly(epsilon-caprolactone) (CH[triple bond, length as m-dash]C-PCL-SH) linear precursors.	polycaprolactone	14-39	2-hydroxyacyl-CoA lyase 1	Homo sapiens	81-85
23887615-1	2014	In this work, antitumor compounds, lactoferrin [recombinant iron-free (Apo-rLf)], cisplatin (Cis) or their combination were embedded within a biodegradable polycaprolactone (PCL) polymer thin film, by a modified approach of a laser-based technique, matrix-assisted pulsed laser evaporation (MAPLE).	polycaprolactone	156-172	lactotransferrin	Mus musculus	35-46
23887615-1	2014	In this work, antitumor compounds, lactoferrin [recombinant iron-free (Apo-rLf)], cisplatin (Cis) or their combination were embedded within a biodegradable polycaprolactone (PCL) polymer thin film, by a modified approach of a laser-based technique, matrix-assisted pulsed laser evaporation (MAPLE).	polycaprolactone	156-172	RLF zinc finger	Rattus norvegicus	75-78
24738337-9	2014	Elevated gene expression profiles of osteogenic markers such as osteocalcin (0CN), osteopontin (OPN) and ALP further corroborate the osteoinductive nature of the collagen functionalized PCL/CS nanofiber matrices.	polycaprolactone	186-189	secreted phosphoprotein 1	Rattus norvegicus	83-94
24738337-9	2014	Elevated gene expression profiles of osteogenic markers such as osteocalcin (0CN), osteopontin (OPN) and ALP further corroborate the osteoinductive nature of the collagen functionalized PCL/CS nanofiber matrices.	polycaprolactone	186-189	secreted phosphoprotein 1	Rattus norvegicus	96-99
24661328-3	2014	We proposed that defined poly(epsilon-caprolactone) (PCL) nanoscaffolds coated with thymosin beta4 could efficiently differentiate murine-derived cardiomyocytes into functioning cardiac tissue.	polycaprolactone	25-51	thymosin, beta 4, X chromosome	Mus musculus	84-98
24661328-3	2014	We proposed that defined poly(epsilon-caprolactone) (PCL) nanoscaffolds coated with thymosin beta4 could efficiently differentiate murine-derived cardiomyocytes into functioning cardiac tissue.	polycaprolactone	53-56	thymosin, beta 4, X chromosome	Mus musculus	84-98
24370639-1	2014	Polycaprolactone (PCL)/Pluronic F127 membrane with reverse gradients of dual platelet-derived growth factor-beta (PDGF-BB) and bone morphogenetic protein 2 (BMP-2) concentrations was fabricated using a diffusion method to investigate the effect of reverse gradients of dual growth factor concentrations on adipose-derived stem cell (ASC) differentiations, such as tenogenesis and osteogenesis.	polycaprolactone	0-16	bone morphogenetic protein 2	Homo sapiens	127-155
24370639-1	2014	Polycaprolactone (PCL)/Pluronic F127 membrane with reverse gradients of dual platelet-derived growth factor-beta (PDGF-BB) and bone morphogenetic protein 2 (BMP-2) concentrations was fabricated using a diffusion method to investigate the effect of reverse gradients of dual growth factor concentrations on adipose-derived stem cell (ASC) differentiations, such as tenogenesis and osteogenesis.	polycaprolactone	0-16	bone morphogenetic protein 2	Homo sapiens	157-162
23839784-5	2014	Mineralized polycaprolactone showed improved cell proliferation, mineralized nodule formation, and expression of odontoblastic marker genes including alkaline phosphatase, osteopontin, osteocalcin, dentin sialophosphoprotein (DSPP), and dentin matrix protein-1, as compared with pure polycaprolactone.	polycaprolactone	12-28	secreted phosphoprotein 1	Homo sapiens	172-183
23839784-5	2014	Mineralized polycaprolactone showed improved cell proliferation, mineralized nodule formation, and expression of odontoblastic marker genes including alkaline phosphatase, osteopontin, osteocalcin, dentin sialophosphoprotein (DSPP), and dentin matrix protein-1, as compared with pure polycaprolactone.	polycaprolactone	12-28	bone gamma-carboxyglutamate protein	Homo sapiens	185-196
23839784-5	2014	Mineralized polycaprolactone showed improved cell proliferation, mineralized nodule formation, and expression of odontoblastic marker genes including alkaline phosphatase, osteopontin, osteocalcin, dentin sialophosphoprotein (DSPP), and dentin matrix protein-1, as compared with pure polycaprolactone.	polycaprolactone	12-28	dentin sialophosphoprotein	Homo sapiens	198-224
23839784-5	2014	Mineralized polycaprolactone showed improved cell proliferation, mineralized nodule formation, and expression of odontoblastic marker genes including alkaline phosphatase, osteopontin, osteocalcin, dentin sialophosphoprotein (DSPP), and dentin matrix protein-1, as compared with pure polycaprolactone.	polycaprolactone	12-28	dentin sialophosphoprotein	Homo sapiens	226-230
23839784-5	2014	Mineralized polycaprolactone showed improved cell proliferation, mineralized nodule formation, and expression of odontoblastic marker genes including alkaline phosphatase, osteopontin, osteocalcin, dentin sialophosphoprotein (DSPP), and dentin matrix protein-1, as compared with pure polycaprolactone.	polycaprolactone	12-28	dentin matrix acidic phosphoprotein 1	Homo sapiens	237-260
23839784-7	2014	Especially, cells seeded onto mineralized polycaprolactone scaffolds showed significantly increased levels of phosphorylated focal adhesion kinase, a marker of integrin activation, and downstream pathways, such as phosphor (p)-Akt, p-extracellular signal regulated kinase, p-c Jun N-terminal kinase, nuclear factor-kappa B, c-fos, and c-jun, compared with pure polycaprolactone.	polycaprolactone	42-58	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	324-329
23839784-7	2014	Especially, cells seeded onto mineralized polycaprolactone scaffolds showed significantly increased levels of phosphorylated focal adhesion kinase, a marker of integrin activation, and downstream pathways, such as phosphor (p)-Akt, p-extracellular signal regulated kinase, p-c Jun N-terminal kinase, nuclear factor-kappa B, c-fos, and c-jun, compared with pure polycaprolactone.	polycaprolactone	42-58	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	335-340
24470402-1	2014	This study demonstrates the growth of long triisopropylsilyethynyl pentacene (TIPS-PEN) nanofibrils in a thin film of a crystalline polymer, poly(epsilon-caprolactone) (PCL).	polycaprolactone	141-167	proprotein convertase subtilisin/kexin type 1 inhibitor	Homo sapiens	83-86
24470402-1	2014	This study demonstrates the growth of long triisopropylsilyethynyl pentacene (TIPS-PEN) nanofibrils in a thin film of a crystalline polymer, poly(epsilon-caprolactone) (PCL).	polycaprolactone	169-172	proprotein convertase subtilisin/kexin type 1 inhibitor	Homo sapiens	83-86
32261529-3	2014	We observed that polycaprolactone (PCL) surfaces functionalized with poly(glycidyl methacrylate) [(P(GMA)] brushes via atom transfer radical polymerization (ATRP) alone resulted in the enhancement of an activated EC profile characterized by low production of nitric oxide (NO), platelet activation and elevated expression levels of von Willebrand factor (vWF) and matrix metalloproteinase-2 (MMP-2).	polycaprolactone	17-33	von Willebrand factor	Homo sapiens	332-353
32261529-3	2014	We observed that polycaprolactone (PCL) surfaces functionalized with poly(glycidyl methacrylate) [(P(GMA)] brushes via atom transfer radical polymerization (ATRP) alone resulted in the enhancement of an activated EC profile characterized by low production of nitric oxide (NO), platelet activation and elevated expression levels of von Willebrand factor (vWF) and matrix metalloproteinase-2 (MMP-2).	polycaprolactone	17-33	von Willebrand factor	Homo sapiens	355-358
32261529-3	2014	We observed that polycaprolactone (PCL) surfaces functionalized with poly(glycidyl methacrylate) [(P(GMA)] brushes via atom transfer radical polymerization (ATRP) alone resulted in the enhancement of an activated EC profile characterized by low production of nitric oxide (NO), platelet activation and elevated expression levels of von Willebrand factor (vWF) and matrix metalloproteinase-2 (MMP-2).	polycaprolactone	17-33	matrix metallopeptidase 2	Homo sapiens	364-390
32261529-3	2014	We observed that polycaprolactone (PCL) surfaces functionalized with poly(glycidyl methacrylate) [(P(GMA)] brushes via atom transfer radical polymerization (ATRP) alone resulted in the enhancement of an activated EC profile characterized by low production of nitric oxide (NO), platelet activation and elevated expression levels of von Willebrand factor (vWF) and matrix metalloproteinase-2 (MMP-2).	polycaprolactone	17-33	matrix metallopeptidase 2	Homo sapiens	392-397
32261529-3	2014	We observed that polycaprolactone (PCL) surfaces functionalized with poly(glycidyl methacrylate) [(P(GMA)] brushes via atom transfer radical polymerization (ATRP) alone resulted in the enhancement of an activated EC profile characterized by low production of nitric oxide (NO), platelet activation and elevated expression levels of von Willebrand factor (vWF) and matrix metalloproteinase-2 (MMP-2).	polycaprolactone	35-38	von Willebrand factor	Homo sapiens	332-353
32261529-3	2014	We observed that polycaprolactone (PCL) surfaces functionalized with poly(glycidyl methacrylate) [(P(GMA)] brushes via atom transfer radical polymerization (ATRP) alone resulted in the enhancement of an activated EC profile characterized by low production of nitric oxide (NO), platelet activation and elevated expression levels of von Willebrand factor (vWF) and matrix metalloproteinase-2 (MMP-2).	polycaprolactone	35-38	von Willebrand factor	Homo sapiens	355-358
32261529-3	2014	We observed that polycaprolactone (PCL) surfaces functionalized with poly(glycidyl methacrylate) [(P(GMA)] brushes via atom transfer radical polymerization (ATRP) alone resulted in the enhancement of an activated EC profile characterized by low production of nitric oxide (NO), platelet activation and elevated expression levels of von Willebrand factor (vWF) and matrix metalloproteinase-2 (MMP-2).	polycaprolactone	35-38	matrix metallopeptidase 2	Homo sapiens	364-390
32261529-3	2014	We observed that polycaprolactone (PCL) surfaces functionalized with poly(glycidyl methacrylate) [(P(GMA)] brushes via atom transfer radical polymerization (ATRP) alone resulted in the enhancement of an activated EC profile characterized by low production of nitric oxide (NO), platelet activation and elevated expression levels of von Willebrand factor (vWF) and matrix metalloproteinase-2 (MMP-2).	polycaprolactone	35-38	matrix metallopeptidase 2	Homo sapiens	392-397
24266740-3	2014	In this study, genipin-cross-linked gelatin entrapped with recombinant human BMP-2 (rhBMP-2) was exploited to decorate the interior surface of three-dimensional porous poly(epsilon-caprolactone) (PCL) scaffolds.	polycaprolactone	168-194	bone morphogenetic protein 2	Homo sapiens	77-82
24266740-3	2014	In this study, genipin-cross-linked gelatin entrapped with recombinant human BMP-2 (rhBMP-2) was exploited to decorate the interior surface of three-dimensional porous poly(epsilon-caprolactone) (PCL) scaffolds.	polycaprolactone	196-199	bone morphogenetic protein 2	Homo sapiens	77-82
24135269-2	2014	Our recent study reported the potential advantages of electrospun gelatin/polycaprolactone (GT/PCL) membranes in regenerating 3-D cartilage.	polycaprolactone	74-90	PHD finger protein 1	Homo sapiens	95-98
25412799-5	2014	Unmodified polycaprolactone scaffolds uniquely demonstrated a total lack of both macrophage adherence to surfaces and a wider foreign body response compared to scaffolds composed of poly(lactic-co-glycolic acid) (PLGA) and polyurethanes (PURs), with those macrophages present having a clear M2 (MR+, CD80-, iNOS-) phenotype.	polycaprolactone	11-27	nitric oxide synthase 2	Rattus norvegicus	307-311
23975280-0	2013	Biodegradable polycaprolactone (PCL) nanosphere encapsulating superoxide dismutase and catalase enzymes.	polycaprolactone	14-30	catalase	Homo sapiens	87-95
24103504-0	2014	Toward one-pot lipase-catalyzed synthesis of poly(epsilon-caprolactone) particles in aqueous dispersion.	polycaprolactone	45-71	PAN0_003d1715	Moesziomyces antarcticus	15-21
24284744-4	2013	Weak expression of the keratinocyte early marker Cytokeratin 14 (CK-14) was observed up to 12 days when MESCs were cultured in a keratinocyte culture medium on tissue culture plastic and on a gelatin/collagen/polycaprolactone (GCP) biocomposite.	polycaprolactone	209-225	keratin 14	Mus musculus	49-63
24284744-4	2013	Weak expression of the keratinocyte early marker Cytokeratin 14 (CK-14) was observed up to 12 days when MESCs were cultured in a keratinocyte culture medium on tissue culture plastic and on a gelatin/collagen/polycaprolactone (GCP) biocomposite.	polycaprolactone	209-225	keratin 14	Mus musculus	65-70
24268280-3	2014	The HAp scaffold was coated with a poly(epsilon-caprolactone) (PCL) using vacuum impregnation technique.	polycaprolactone	35-61	reticulon 3	Homo sapiens	4-7
24268280-3	2014	The HAp scaffold was coated with a poly(epsilon-caprolactone) (PCL) using vacuum impregnation technique.	polycaprolactone	63-66	reticulon 3	Homo sapiens	4-7
23975280-0	2013	Biodegradable polycaprolactone (PCL) nanosphere encapsulating superoxide dismutase and catalase enzymes.	polycaprolactone	32-35	catalase	Homo sapiens	87-95
23975280-1	2013	Biodegradable polycaprolactone (PCL) nanosphere encapsulating superoxide dismutase (SOD) and catalase (CAT) were successfully synthesized using double emulsion (w/o/w) solvent evaporation technique.	polycaprolactone	14-30	catalase	Homo sapiens	93-101
23975280-1	2013	Biodegradable polycaprolactone (PCL) nanosphere encapsulating superoxide dismutase (SOD) and catalase (CAT) were successfully synthesized using double emulsion (w/o/w) solvent evaporation technique.	polycaprolactone	14-30	catalase	Homo sapiens	103-106
23975280-1	2013	Biodegradable polycaprolactone (PCL) nanosphere encapsulating superoxide dismutase (SOD) and catalase (CAT) were successfully synthesized using double emulsion (w/o/w) solvent evaporation technique.	polycaprolactone	32-35	catalase	Homo sapiens	93-101
23975280-1	2013	Biodegradable polycaprolactone (PCL) nanosphere encapsulating superoxide dismutase (SOD) and catalase (CAT) were successfully synthesized using double emulsion (w/o/w) solvent evaporation technique.	polycaprolactone	32-35	catalase	Homo sapiens	103-106
23975280-3	2013	Human skin HaCat cells were used for analyzing antioxidative properties of SOD- and CAT-encapsulated PCL nanospheres.	polycaprolactone	101-104	catalase	Homo sapiens	84-87
23975280-6	2013	Increase in HaCat cells SOD and CAT activities after treatment hints toward uptake of PCL nanosphere into the human skin HaCat cells.	polycaprolactone	86-89	catalase	Homo sapiens	32-35
23975280-7	2013	The result signifies the role of PCL-encapsulating SOD and CAT nanosphere in alleviating oxidative stress.	polycaprolactone	33-36	catalase	Homo sapiens	59-62
24038600-0	2013	Human skin-derived keratinocytes and fibroblasts co-cultured on 3D poly epsilon-caprolactone scaffold support in vitro HSC differentiation into T-lineage committed cells.	polycaprolactone	67-92	fucosyltransferase 1 (H blood group)	Homo sapiens	119-122
24064148-5	2013	Nanofibers composed of poly(DL-lactide-co-glycolide) (PLAGA) and polycaprolactone (PCL) were used to delivery FTY720, a targeted agonist of S1P receptors 1 and 3.	polycaprolactone	65-81	sphingosine-1-phosphate receptor 1	Homo sapiens	140-161
24064148-5	2013	Nanofibers composed of poly(DL-lactide-co-glycolide) (PLAGA) and polycaprolactone (PCL) were used to delivery FTY720, a targeted agonist of S1P receptors 1 and 3.	polycaprolactone	83-86	sphingosine-1-phosphate receptor 1	Homo sapiens	140-161
23629851-5	2013	The solid PETA-co-TMPTMP with and without HA exhibited compressive strength in the range of 7-20 MPa, while the cytotoxicity and biocompatibility results demonstrate higher metabolic activity of hASC on PETA-co-TMPTMP than on a polycaprolactone control.	polycaprolactone	228-244	PYD and CARD domain containing	Homo sapiens	195-199
23530764-3	2013	RESULTS: Results indicate that hMSC differentiation can be enhanced by either culturing in electrically conductive, carbon nanotube-containing composite scaffolds without electrical stimulation in the presence of 5-azacytidine, or extrinsic electrical stimulation in nonconductive poly(epsilon-caprolactone) scaffolds without carbon nanotube and azacytidine.	polycaprolactone	281-307	musculin	Homo sapiens	31-35
24094153-3	2013	In this research, forsterite (Mg2SiO4) nanoparticles was surface esterified by dodecyl alcohol and nanofibrous poly(epsilon-caprolactone)(PCL)/modified forsterite scaffolds were developed through electrospinning technique.	polycaprolactone	111-137	PHD finger protein 1	Homo sapiens	138-141
24094167-7	2013	Optimal results were obtained with 5 wt.% PCL in DMAC solution sprayed within the stable cone-jet mode operating window at a flow rate of 15 mul min(-1) for 300 s at 11.1 kV with a working distance of 60mm.	polycaprolactone	42-45	CD59 molecule (CD59 blood group)	Homo sapiens	145-151
32261065-0	2013	Biodegradable micelles from a hyaluronan-poly(epsilon-caprolactone) graft copolymer as nanocarriers for fibroblast growth factor 1.	polycaprolactone	41-67	fibroblast growth factor 1	Rattus norvegicus	104-130
23584739-6	2013	The in vitro test results revealed that PCL/BFP-1/Alginate had significantly higher ALP activity and calcium deposition than the PCL/BMP-2/Alginate composite.	polycaprolactone	40-43	alkaline phosphatase, placental	Homo sapiens	84-87
23584739-6	2013	The in vitro test results revealed that PCL/BFP-1/Alginate had significantly higher ALP activity and calcium deposition than the PCL/BMP-2/Alginate composite.	polycaprolactone	40-44	alkaline phosphatase, placental	Homo sapiens	84-87
27574631-4	2013	The novel ASC-J9 - loaded porous scafold was fabricated for skin wound repair using electrospun fibers of collagen and polycaprolactone (PCL) blend.	polycaprolactone	119-135	steroid sulfatase	Mus musculus	10-13
27574631-4	2013	The novel ASC-J9 - loaded porous scafold was fabricated for skin wound repair using electrospun fibers of collagen and polycaprolactone (PCL) blend.	polycaprolactone	137-140	steroid sulfatase	Mus musculus	10-13
23545290-3	2013	In this study, plasmid DNA (pDNA; encoding for bFGF) complex-loaded poly(DL-lactic-co-glycolic acid) (PLGA)/Pluronic F127 mixture dispersed with polycaprolactone (PCL) microspheres was prepared as an injectable bioactive bulking agent that may provide bulking effect (by PCL microspheres) and allow stimulation of the defect tissues around urethra (by synthesis of bFGF from cells or tissues transfected by the pDNA complex) for the effective treatment of SUI.	polycaprolactone	163-166	fibroblast growth factor 2	Homo sapiens	47-51
23768780-4	2013	In this study, it has been shown that PCL can encapsulate RAP with high loading efficiencies, and PAsp(DET) can successfully interact with siRNA for efficient transfection/knockdown with negligible cytotoxicity.	polycaprolactone	38-41	regulatory associated protein of MTOR, complex 1	Mus musculus	58-61
23602170-0	2013	Controlled release of metronidazole from composite poly-epsilon-caprolactone/alginate (PCL/alginate) rings for dental implants.	polycaprolactone	51-76	PHD finger protein 1	Homo sapiens	87-90
23545290-3	2013	In this study, plasmid DNA (pDNA; encoding for bFGF) complex-loaded poly(DL-lactic-co-glycolic acid) (PLGA)/Pluronic F127 mixture dispersed with polycaprolactone (PCL) microspheres was prepared as an injectable bioactive bulking agent that may provide bulking effect (by PCL microspheres) and allow stimulation of the defect tissues around urethra (by synthesis of bFGF from cells or tissues transfected by the pDNA complex) for the effective treatment of SUI.	polycaprolactone	145-161	fibroblast growth factor 2	Homo sapiens	47-51
23545290-3	2013	In this study, plasmid DNA (pDNA; encoding for bFGF) complex-loaded poly(DL-lactic-co-glycolic acid) (PLGA)/Pluronic F127 mixture dispersed with polycaprolactone (PCL) microspheres was prepared as an injectable bioactive bulking agent that may provide bulking effect (by PCL microspheres) and allow stimulation of the defect tissues around urethra (by synthesis of bFGF from cells or tissues transfected by the pDNA complex) for the effective treatment of SUI.	polycaprolactone	163-167	fibroblast growth factor 2	Homo sapiens	47-51
32260979-2	2013	Here, we engineered the surface of poly(caprolactone) (PCL) scaffolds, first with bone mineral hydroxyapatite (HA), and then with fibronectin-osteocalcin (FN-OCN) bi-functional protein by means of affinity binding between OCN and HA.	polycaprolactone	35-53	fibronectin 1	Rattus norvegicus	130-141
23602170-4	2013	METHODS: The study involved incorporating a model antibacterial agent (metronidazole) into custom designed poly-epsilon-caprolactone/alginate (PCL/alginate) composite rings to produce the intended controlled release profile.	polycaprolactone	107-132	PHD finger protein 1	Homo sapiens	143-146
23858976-0	2013	Insulin-loaded poly(epsilon-caprolactone) nanoparticles: efficient, sustained and safe insulin delivery system.	polycaprolactone	15-41	insulin	Homo sapiens	0-7
23858976-1	2013	The aim of this work was to develop an efficient, biodegradable, biocompatible and safe controlled release system using insulin-loaded poly(epsilon-caprolactone) (PCL) nanoparticles.	polycaprolactone	135-161	insulin	Homo sapiens	120-127
23858976-7	2013	These results suggest that insulin-loaded PCL nanoparticles prepared by water-in-oil-in-water emulsion method are biocompatible, efficient and safe insulin-delivering system with controlled insulin release, which indicates that it may be a powerful tool for insulin-dependent patients care.	polycaprolactone	42-45	insulin	Homo sapiens	148-155
23858976-1	2013	The aim of this work was to develop an efficient, biodegradable, biocompatible and safe controlled release system using insulin-loaded poly(epsilon-caprolactone) (PCL) nanoparticles.	polycaprolactone	163-166	insulin	Homo sapiens	120-127
23858976-7	2013	These results suggest that insulin-loaded PCL nanoparticles prepared by water-in-oil-in-water emulsion method are biocompatible, efficient and safe insulin-delivering system with controlled insulin release, which indicates that it may be a powerful tool for insulin-dependent patients care.	polycaprolactone	42-45	insulin	Homo sapiens	148-155
23858976-7	2013	These results suggest that insulin-loaded PCL nanoparticles prepared by water-in-oil-in-water emulsion method are biocompatible, efficient and safe insulin-delivering system with controlled insulin release, which indicates that it may be a powerful tool for insulin-dependent patients care.	polycaprolactone	42-45	insulin	Homo sapiens	27-34
23318815-4	2013	To overcome this we prepared HF membranes via phase inversion using blends of PLGA with poly(epsilon-caprolactone) (PCL).	polycaprolactone	88-114	PHD finger protein 1	Homo sapiens	116-119
23164422-0	2013	Effect of BMP-2 and/or BMP-9 on preosteoblasts attached to polycaprolactone functionalized by adhesive peptides derived from bone sialoprotein.	polycaprolactone	59-75	bone morphogenetic protein 2	Homo sapiens	10-15
23576741-4	2013	We observed that Ewing sarcoma cells cultured in porous 3D electrospun poly(epsilon-caprolactone) scaffolds not only were more resistant to traditional cytotoxic drugs than were cells in 2D monolayer culture but also exhibited remarkable differences in the expression pattern of the insulin-like growth factor-1 receptor/mammalian target of rapamycin pathway.	polycaprolactone	71-97	insulin like growth factor 1 receptor	Homo sapiens	283-320
23576741-4	2013	We observed that Ewing sarcoma cells cultured in porous 3D electrospun poly(epsilon-caprolactone) scaffolds not only were more resistant to traditional cytotoxic drugs than were cells in 2D monolayer culture but also exhibited remarkable differences in the expression pattern of the insulin-like growth factor-1 receptor/mammalian target of rapamycin pathway.	polycaprolactone	71-97	mechanistic target of rapamycin kinase	Homo sapiens	321-350
22965926-1	2013	In this article, the plasma surface modification effects on the chemical, mechanical, and biological properties of electrospun poly (epsilon-caprolactone) (PCL) random nanofiber meshes (NFMs) were investigated by adjusting plasma chemistry, that is, using glow discharges of N(2) +H(2), NH(3) +O(2), and Ar+O(2) gas mixtures.	polycaprolactone	127-154	polycystic kidney disease 2-like 1	Mus musculus	156-159
23544568-1	2013	An ionic liquid, 1-ethyl-3-methylimidazolium acetate (EMIMAc), was synthesized and employed as a homogeneous and green reaction media to prepare chitosan-graft-polycaprolactone (CS-g-PCL) via ring-opening polymerization, using stannous octoate (Sn(Oct)2) as a catalyst.	polycaprolactone	160-176	POU class 2 homeobox 2	Homo sapiens	248-253
23178191-4	2013	In this study, an electrospun nanofibrous scaffold of polycaprolactone (PCL) was investigated with respect to its topographic effects on astrocyte behavior and expression of GFAP.	polycaprolactone	54-70	glial fibrillary acidic protein	Rattus norvegicus	174-178
23178191-4	2013	In this study, an electrospun nanofibrous scaffold of polycaprolactone (PCL) was investigated with respect to its topographic effects on astrocyte behavior and expression of GFAP.	polycaprolactone	72-75	glial fibrillary acidic protein	Rattus norvegicus	174-178
23164422-0	2013	Effect of BMP-2 and/or BMP-9 on preosteoblasts attached to polycaprolactone functionalized by adhesive peptides derived from bone sialoprotein.	polycaprolactone	59-75	growth differentiation factor 2	Homo sapiens	23-28
23164422-3	2013	We have shown that bone morphogenetic protein (BMP) 2 activates the Smad pathway only in murine MC3T3-E1 preosteoblasts attached to polycaprolactone (PCL) film functionalized by RGD peptides derived from bone sialoprotein (pRGD).	polycaprolactone	132-148	bone morphogenetic protein 2	Mus musculus	19-53
23164422-3	2013	We have shown that bone morphogenetic protein (BMP) 2 activates the Smad pathway only in murine MC3T3-E1 preosteoblasts attached to polycaprolactone (PCL) film functionalized by RGD peptides derived from bone sialoprotein (pRGD).	polycaprolactone	132-148	SMAD family member 1	Homo sapiens	68-72
23164422-3	2013	We have shown that bone morphogenetic protein (BMP) 2 activates the Smad pathway only in murine MC3T3-E1 preosteoblasts attached to polycaprolactone (PCL) film functionalized by RGD peptides derived from bone sialoprotein (pRGD).	polycaprolactone	150-153	bone morphogenetic protein 2	Mus musculus	19-53
23164422-3	2013	We have shown that bone morphogenetic protein (BMP) 2 activates the Smad pathway only in murine MC3T3-E1 preosteoblasts attached to polycaprolactone (PCL) film functionalized by RGD peptides derived from bone sialoprotein (pRGD).	polycaprolactone	150-153	SMAD family member 1	Homo sapiens	68-72
23493403-2	2013	In this work, biodegradable micelles made from star-shaped poly(epsilon-caprolactone)/poly(ethylene glycol) (PCL/PEG) copolymer were prepared and used to deliver doxorubicin (Dox) in vitro and in vivo.	polycaprolactone	59-85	polycystic kidney disease 2-like 1	Mus musculus	109-112
24751081-9	2012	In addition, cell viability (at 5 wt% phlorotannin), total protein content, ALP activity, and calcium deposition were higher with PCL/phlorotannin mats than with pure PCL mats.	polycaprolactone	130-133	alkaline phosphatase, placental	Homo sapiens	76-79
23746285-2	2013	Previous studies have demonstrated that continuous delivery of 50 ng/ml TNF-alpha to mesenchymal stem cells (MSCs) cultured on three-dimensional (3D) biodegradable electrospun poly(epsilon-caprolactone) (PCL) microfiber meshes stimulates mineralized matrix deposition, a marker of osteogenic differentiation.	polycaprolactone	176-202	tumor necrosis factor	Homo sapiens	72-81
23746285-2	2013	Previous studies have demonstrated that continuous delivery of 50 ng/ml TNF-alpha to mesenchymal stem cells (MSCs) cultured on three-dimensional (3D) biodegradable electrospun poly(epsilon-caprolactone) (PCL) microfiber meshes stimulates mineralized matrix deposition, a marker of osteogenic differentiation.	polycaprolactone	204-207	tumor necrosis factor	Homo sapiens	72-81
23022345-4	2012	Here we examine the capacity of fibrous poly epsilon-caprolactone (PCL) scaffolds, biofunctionalised with immobilised glial cell-derived neurotrophic factor (GDNF), to influence primary cortical neural stem cells/progenitors in vitro and enhance integration of these cells following transplantation into the brain parenchyma.	polycaprolactone	67-70	glial cell derived neurotrophic factor	Homo sapiens	118-156
23022345-6	2012	In vitro, we demonstrate that PCL with immobilised GDNF (iGDNF) significantly enhances cell viability and neural stem cell/progenitor proliferation compared to conventional 2-dimensional cultureware.	polycaprolactone	30-33	glial cell derived neurotrophic factor	Homo sapiens	51-55
22973579-0	2004	Indotricarbocyanine-loaded AS1411 DNA aptamer- and TGN peptide-modified poly(ethylene glycol)-poly(epsilon-caprolactone) nanoparticles Indotricarbocyanine (DiR)-loaded AS1411 DNA aptamer- and TGN peptide-modified poly(ethylene glycol)-poly(epsilon-caprolactone) (PEG-PCL) nanoparticles, abbreviated as DiR-AsTNP, is a cascade delivery system synthesized by Gao et al.	polycaprolactone	94-120	arginine vasopressin receptor 2	Homo sapiens	156-159
22973579-0	2004	Indotricarbocyanine-loaded AS1411 DNA aptamer- and TGN peptide-modified poly(ethylene glycol)-poly(epsilon-caprolactone) nanoparticles Indotricarbocyanine (DiR)-loaded AS1411 DNA aptamer- and TGN peptide-modified poly(ethylene glycol)-poly(epsilon-caprolactone) (PEG-PCL) nanoparticles, abbreviated as DiR-AsTNP, is a cascade delivery system synthesized by Gao et al.	polycaprolactone	94-120	arginine vasopressin receptor 2	Homo sapiens	302-305
23630420-4	2013	Thiolated GRP78 binding peptide (GRP78BP) was first labeled with maleimide-terminated poly(ethylene glycol)- poly(e-caprolactone) and then mixed with diethylenetriaminepentaacetic acid (DTPA)-linked poly(ethylene glycol)-poly(e-caprolactone) to form DTPA/GRP78BP-conjugated micelles.	polycaprolactone	114-128	heat shock protein 5	Mus musculus	10-15
23212298-4	2012	Here, we present evidence that some HCT116-19, bearing an integrated, mutated enhanced green fluorescent protein (eGFP) gene and corrected by gene editing, proliferate on polylysine or fibronectin-coated polycaprolactone (PCL) nanofiber scaffolds.	polycaprolactone	204-220	fibronectin 1	Homo sapiens	185-196
23003680-3	2012	We studied the ability of dapivirine-loaded polycaprolactone (PCL)-based nanoparticles (NPs) to interact with a simulated vaginal fluid (SVF) incorporating mucin.	polycaprolactone	44-60	LOC100508689	Homo sapiens	156-161
23003680-3	2012	We studied the ability of dapivirine-loaded polycaprolactone (PCL)-based nanoparticles (NPs) to interact with a simulated vaginal fluid (SVF) incorporating mucin.	polycaprolactone	62-65	LOC100508689	Homo sapiens	156-161
22875607-6	2012	Moreover, the expression of several genes, including ANX-V, type I collagen and OCN, ALP activity, the deposition of calcium, and the BSP protein, were also significantly higher on 10 M-PCL than PCL.	polycaprolactone	186-189	bone gamma-carboxyglutamate protein	Homo sapiens	53-83
22615065-0	2012	Three-dimensional polycaprolactone scaffold-conjugated bone morphogenetic protein-2 promotes cartilage regeneration from primary chondrocytes in vitro and in vivo without accelerated endochondral ossification.	polycaprolactone	18-34	bone morphogenetic protein 2	Homo sapiens	55-83
22569737-1	2012	This study covers the quantification of the covalent attachment of gelatin type B (GelB) and the subsequent adsorption of Fibronectin (Fn) on poly-epsilon-caprolactone (PCL) surfaces, functionalised with 2-aminoethyl methacrylate (AEMA) by means of post-plasma UV-irradiation grafting.	polycaprolactone	142-167	fibronectin 1	Homo sapiens	122-133
22569737-1	2012	This study covers the quantification of the covalent attachment of gelatin type B (GelB) and the subsequent adsorption of Fibronectin (Fn) on poly-epsilon-caprolactone (PCL) surfaces, functionalised with 2-aminoethyl methacrylate (AEMA) by means of post-plasma UV-irradiation grafting.	polycaprolactone	142-167	fibronectin 1	Homo sapiens	135-137
22569737-1	2012	This study covers the quantification of the covalent attachment of gelatin type B (GelB) and the subsequent adsorption of Fibronectin (Fn) on poly-epsilon-caprolactone (PCL) surfaces, functionalised with 2-aminoethyl methacrylate (AEMA) by means of post-plasma UV-irradiation grafting.	polycaprolactone	169-172	fibronectin 1	Homo sapiens	122-133
22488989-5	2012	In the present work, we therefore report on possible biological effects originating from the transfer of a double protein coating protocol, involving gelatin type B and fibronectin, from 2D poly-epsilon-caprolactone (PCL) films to 3D PCL scaffolds produced by rapid prototyping.	polycaprolactone	190-215	fibronectin 1	Homo sapiens	169-180
22569737-1	2012	This study covers the quantification of the covalent attachment of gelatin type B (GelB) and the subsequent adsorption of Fibronectin (Fn) on poly-epsilon-caprolactone (PCL) surfaces, functionalised with 2-aminoethyl methacrylate (AEMA) by means of post-plasma UV-irradiation grafting.	polycaprolactone	169-172	fibronectin 1	Homo sapiens	135-137
22488989-5	2012	In the present work, we therefore report on possible biological effects originating from the transfer of a double protein coating protocol, involving gelatin type B and fibronectin, from 2D poly-epsilon-caprolactone (PCL) films to 3D PCL scaffolds produced by rapid prototyping.	polycaprolactone	217-220	fibronectin 1	Homo sapiens	169-180
22364710-1	2012	Hydroxyapatite (HAp) nanoparticle-armored poly(epsilon-caprolactone) (PCL) microspheres were fabricated via a "Pickering-type" emulsion solvent evaporation method in the absence of any molecular surfactants.	polycaprolactone	42-68	retinoic acid receptor beta	Homo sapiens	16-19
22646162-4	2012	It was found that a high surface area leads to significantly higher amount of grafted PCL in the substrates when Sn(Oct)2 was utilized as a catalyst.	polycaprolactone	86-89	POU class 2 homeobox 2	Homo sapiens	116-121
22364710-1	2012	Hydroxyapatite (HAp) nanoparticle-armored poly(epsilon-caprolactone) (PCL) microspheres were fabricated via a "Pickering-type" emulsion solvent evaporation method in the absence of any molecular surfactants.	polycaprolactone	70-73	retinoic acid receptor beta	Homo sapiens	16-19
22364710-2	2012	It was clarified that the interaction between carbonyl/carboxylic acid groups of PCL and the HAp nanoparticles at an oil-water interface played a crucial role in the preparation of the stable Pickering-type emulsions and the HAp nanoparticle-armored microspheres.	polycaprolactone	81-84	retinoic acid receptor beta	Homo sapiens	93-96
22364710-2	2012	It was clarified that the interaction between carbonyl/carboxylic acid groups of PCL and the HAp nanoparticles at an oil-water interface played a crucial role in the preparation of the stable Pickering-type emulsions and the HAp nanoparticle-armored microspheres.	polycaprolactone	81-84	retinoic acid receptor beta	Homo sapiens	225-228
22248526-12	2012	MC3T3-E1 preosteoblasts seeded onto PCL-PGF grew up to day 7 in culture.	polycaprolactone	36-39	placental growth factor	Homo sapiens	40-43
21839050-4	2012	Moreover, we found that BCP/PCL-nHA scaffolds induced early osteogenic differentiation of ASCs through integrin-alpha2 and an extracellular signal-regulated kinase (ERK) signaling pathway.	polycaprolactone	28-31	integrin subunit alpha 2	Homo sapiens	103-118
21839050-4	2012	Moreover, we found that BCP/PCL-nHA scaffolds induced early osteogenic differentiation of ASCs through integrin-alpha2 and an extracellular signal-regulated kinase (ERK) signaling pathway.	polycaprolactone	28-31	mitogen-activated protein kinase 1	Homo sapiens	126-163
21839050-4	2012	Moreover, we found that BCP/PCL-nHA scaffolds induced early osteogenic differentiation of ASCs through integrin-alpha2 and an extracellular signal-regulated kinase (ERK) signaling pathway.	polycaprolactone	28-31	mitogen-activated protein kinase 1	Homo sapiens	165-168
22169927-1	2012	In this study we investigated the blend electrospinning of poly(epsilon-caprolactone) (PCL) and silk fibroin (SF) to improve the biodegradability and biocompatibility of PCL-based nanofibrous scaffolds.	polycaprolactone	59-85	PHD finger protein 1	Homo sapiens	87-90
22169927-1	2012	In this study we investigated the blend electrospinning of poly(epsilon-caprolactone) (PCL) and silk fibroin (SF) to improve the biodegradability and biocompatibility of PCL-based nanofibrous scaffolds.	polycaprolactone	59-85	PHD finger protein 1	Homo sapiens	170-173
22322196-9	2012	Furthermore, the percentage of CD68 positive cells in the E7-conjugated PCL electrospun meshes was much lower than that in the RGD-conjugated PCL electrospun meshes (5.57% vs. 53.43%).	polycaprolactone	72-75	Cd68 molecule	Rattus norvegicus	31-35
22322196-0	2012	Polycaprolactone electrospun mesh conjugated with an MSC affinity peptide for MSC homing in vivo.	polycaprolactone	0-16	musculin	Rattus norvegicus	53-56
22213643-0	2012	Delivery of VEGF using collagen-coated polycaprolactone scaffolds stimulates angiogenesis.	polycaprolactone	39-55	vascular endothelial growth factor A	Homo sapiens	12-16
22322196-0	2012	Polycaprolactone electrospun mesh conjugated with an MSC affinity peptide for MSC homing in vivo.	polycaprolactone	0-16	musculin	Rattus norvegicus	78-81
22322196-6	2012	Thereafter, E7 was covalently conjugated onto polycaprolactone (PCL) electrospun meshes to construct an "MSC-homing device" for the recruitment of MSCs both in vitro and in vivo.	polycaprolactone	64-67	musculin	Rattus norvegicus	105-108
22322196-8	2012	After 7 d of implantation, immunofluorescence staining showed that the cells grown into the E7-conjugated PCL electrospun meshes yielded a high positive rate for specific MSC surface markers (CD44, CD90, and CD105) compared with those in arginine-glycine-aspartic acid (RGD)-conjugated PCL electrospun meshes (63.67% vs. 3.03%; 59.37% vs. 2.98%; and 61.45% vs. 3.82%, respectively).	polycaprolactone	106-109	musculin	Rattus norvegicus	171-174
22322196-8	2012	After 7 d of implantation, immunofluorescence staining showed that the cells grown into the E7-conjugated PCL electrospun meshes yielded a high positive rate for specific MSC surface markers (CD44, CD90, and CD105) compared with those in arginine-glycine-aspartic acid (RGD)-conjugated PCL electrospun meshes (63.67% vs. 3.03%; 59.37% vs. 2.98%; and 61.45% vs. 3.82%, respectively).	polycaprolactone	106-109	CD44 molecule (Indian blood group)	Rattus norvegicus	192-196
22322196-8	2012	After 7 d of implantation, immunofluorescence staining showed that the cells grown into the E7-conjugated PCL electrospun meshes yielded a high positive rate for specific MSC surface markers (CD44, CD90, and CD105) compared with those in arginine-glycine-aspartic acid (RGD)-conjugated PCL electrospun meshes (63.67% vs. 3.03%; 59.37% vs. 2.98%; and 61.45% vs. 3.82%, respectively).	polycaprolactone	106-109	Thy-1 cell surface antigen	Rattus norvegicus	198-202
22143907-2	2012	Hydroxyapatite (HA)/poly (epsilon-caprolactone) (PCL) fibrous scaffolds were successfully prepared by electrospinning dopes containing HA and PCL in this work.	polycaprolactone	20-47	PHD finger protein 1	Homo sapiens	49-52
22143907-2	2012	Hydroxyapatite (HA)/poly (epsilon-caprolactone) (PCL) fibrous scaffolds were successfully prepared by electrospinning dopes containing HA and PCL in this work.	polycaprolactone	20-47	PHD finger protein 1	Homo sapiens	142-145
21762547-0	2012	The correlation between fibronectin adsorption and fibroblast cell behaviors on chitosan/poly(epsilon-caprolactone) blend films.	polycaprolactone	89-115	fibronectin 1	Mus musculus	24-35
21903260-0	2011	The effect of hydrophilic chain length and iRGD on drug delivery from poly(epsilon-caprolactone)-poly(N-vinylpyrrolidone) nanoparticles.	polycaprolactone	70-96	interferon gamma inducible protein 47	Mus musculus	43-47
22583129-1	2012	This article describes enhanced skin permeation and UV/thermal stability of retinol emulsions by the co-stabilisation of Tween20 and biodegradable poly(ethylene oxide)-block-poly(epsilon-caprolactone)-block-poly(ethylene oxide) (PEO-PCL-PEO) triblock copolymers having different lengths of hydrophobic PCL block.	polycaprolactone	173-200	PHD finger protein 1	Homo sapiens	233-236
22186500-4	2012	METHODS: Incorporation of glial cell line-derived, neurotrophic factor, double-walled microspheres into polycaprolactone nerve guides has demonstrated an off-the-shelf product alternative to promote nerve regeneration, and this conduit was filled with keratin gel and examined in a rat 15-mm sciatic nerve defect model.	polycaprolactone	104-120	glial cell derived neurotrophic factor	Rattus norvegicus	26-70
22186500-8	2012	CONCLUSION: From their studies, the authors conclude that polycaprolactone nerve guides with glial cell line-derived, neurotrophic factor-loaded, double-walled microspheres filled with keratin gel represent a potentially viable guiding material for Schwann cell and axon migration and proliferation in the treatment of peripheral nerve regeneration.	polycaprolactone	58-74	glial cell derived neurotrophic factor	Rattus norvegicus	93-137
22808271-2	2012	Previously we determined that bone-mimetic electrospun scaffolds composed of polycaprolactone, collagen I and nanohydroxyapatite (PCL/col/HA) supported greater MSC adhesion, proliferation and activation of integrin-related signaling cascades than scaffolds composed of PCL or collagen I alone.	polycaprolactone	77-93	PHD finger protein 1	Homo sapiens	269-272
22040511-5	2012	Ibuprofen (IBU), a popular non-steroidal anti-inflammatory drug, was co-valently (ester) bonded to the PAMAM/PCL molecules using the DCC/DMAP coupling method (DCC, N,N"-dicyclohexylcarbodiimide; DMAP, 4-(dimethylamino)pyridine).	polycaprolactone	109-112	DCC netrin 1 receptor	Homo sapiens	133-136
21732529-2	2011	In this study, novel poly(epsilon-caprolactone)/biphasic calcium phosphate (70/30) composite microspheres (PCL/BCP MPs) were prepared using the emulsion solvent-evaporation method.	polycaprolactone	21-47	PHD finger protein 1	Homo sapiens	107-110
21682591-2	2011	We have selected a three-dimensional polycaprolactone (PCL) scaffold with an interconnected honeycomb-like porous structure to provide a conduit for vasculature ingrowth as well as an osteoconductive pathway to guide recruited cells responding to a unique triphasic release of osteoinductive bone morphogenetic proteins (BMP) from these PCL scaffolds.	polycaprolactone	37-53	bone morphogenetic protein 2	Homo sapiens	321-324
21682591-2	2011	We have selected a three-dimensional polycaprolactone (PCL) scaffold with an interconnected honeycomb-like porous structure to provide a conduit for vasculature ingrowth as well as an osteoconductive pathway to guide recruited cells responding to a unique triphasic release of osteoinductive bone morphogenetic proteins (BMP) from these PCL scaffolds.	polycaprolactone	55-58	bone morphogenetic protein 2	Homo sapiens	321-324
21679895-6	2011	Relative peri-infarct zone was calculated as the difference in hyperenhanced regions between ECE and LCE, normalized to the individual infarct size.	polycaprolactone	93-96	perilipin 1	Homo sapiens	9-13
22103127-0	2011	Biodegradable particulate delivery of vascular endothelial growth factor plasmid from polycaprolactone/polyethylenimine electrospun nanofibers for the treatment of myocardial infarction.	polycaprolactone	86-102	vascular endothelial growth factor A	Homo sapiens	38-72
21563304-7	2011	Release studies showed that the immobilization of ASA and VEGF on the modified PCL surface via DSC is greatly improved compared to the adsorption-only reference.	polycaprolactone	79-82	vascular endothelial growth factor A	Mus musculus	58-62
21284956-0	2011	Integrity characterization of myoglobin released from poly(epsilon-caprolactone) microspheres using two analytical methods: UV/Vis spectrometry and conductometric bi-enzymatic biosensor.	polycaprolactone	54-80	myoglobin	Homo sapiens	30-39
21284956-1	2011	Myoglobin (Mb)-loaded poly(epsilon-caprolactone) (PCL) microparticles were prepared by multiple emulsion with solvent extraction/evaporation method under more or less deleterious operating conditions.	polycaprolactone	22-48	myoglobin	Homo sapiens	0-9
21284956-1	2011	Myoglobin (Mb)-loaded poly(epsilon-caprolactone) (PCL) microparticles were prepared by multiple emulsion with solvent extraction/evaporation method under more or less deleterious operating conditions.	polycaprolactone	50-53	myoglobin	Homo sapiens	0-9
22103127-2	2011	Branched polyethylenimine cross-linked via disulfide bonds (ssPEI) complexed with vascular endothelial growth factor (VEGF) were immobilized on electrospun polycaprolactone (PCL)/polyethylenimine (PEI) nanofibers for the local expression of VEGF angiogenic factor.	polycaprolactone	156-172	vascular endothelial growth factor A	Homo sapiens	82-116
22103127-2	2011	Branched polyethylenimine cross-linked via disulfide bonds (ssPEI) complexed with vascular endothelial growth factor (VEGF) were immobilized on electrospun polycaprolactone (PCL)/polyethylenimine (PEI) nanofibers for the local expression of VEGF angiogenic factor.	polycaprolactone	156-172	vascular endothelial growth factor A	Homo sapiens	118-122
20827712-4	2011	As the first step, this study sought to determine the optimal dosage of TGF-beta1 on polycaprolactone (PCL) scaffolds cultured with primary human osteoblasts (HOBs) to effectively induce in vitro calcification.	polycaprolactone	85-101	transforming growth factor beta 1	Homo sapiens	72-81
21275847-1	2011	In our previous study, growth factor (basic fibroblast growth factor [bFGF] or vascular endothelial growth factor)-immobilized polycaprolactone (PCL)/Pluronic F127 porous beads were fabricated by an isolated particle-melting/melt-molding particulate-leaching method.	polycaprolactone	127-143	myotrophin	Rattus norvegicus	23-36
21275847-1	2011	In our previous study, growth factor (basic fibroblast growth factor [bFGF] or vascular endothelial growth factor)-immobilized polycaprolactone (PCL)/Pluronic F127 porous beads were fabricated by an isolated particle-melting/melt-molding particulate-leaching method.	polycaprolactone	127-143	myotrophin	Rattus norvegicus	55-68
21275847-1	2011	In our previous study, growth factor (basic fibroblast growth factor [bFGF] or vascular endothelial growth factor)-immobilized polycaprolactone (PCL)/Pluronic F127 porous beads were fabricated by an isolated particle-melting/melt-molding particulate-leaching method.	polycaprolactone	127-143	myotrophin	Rattus norvegicus	55-68
21275847-1	2011	In our previous study, growth factor (basic fibroblast growth factor [bFGF] or vascular endothelial growth factor)-immobilized polycaprolactone (PCL)/Pluronic F127 porous beads were fabricated by an isolated particle-melting/melt-molding particulate-leaching method.	polycaprolactone	145-148	myotrophin	Rattus norvegicus	23-36
21702366-2	2011	In this paper, anti-CD40 antibody modified magnetic poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) (PCL-PEG-PCL, PCEC) microspheres were prepared.	polycaprolactone	52-78	CD40 molecule	Homo sapiens	20-24
21702366-2	2011	In this paper, anti-CD40 antibody modified magnetic poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) (PCL-PEG-PCL, PCEC) microspheres were prepared.	polycaprolactone	101-127	CD40 molecule	Homo sapiens	20-24
20827712-4	2011	As the first step, this study sought to determine the optimal dosage of TGF-beta1 on polycaprolactone (PCL) scaffolds cultured with primary human osteoblasts (HOBs) to effectively induce in vitro calcification.	polycaprolactone	103-106	transforming growth factor beta 1	Homo sapiens	72-81
21186059-1	2011	Diblock copolymers (PEI-PCL) of poly(epsilon-caprolactone) (PCL) and linear poly(ethylene imine) (PEI) were synthesized and assembled to biodegradable nano-carriers for co-delivery of BCL-2 siRNA and doxorubicin (DOX).	polycaprolactone	24-27	BCL2 apoptosis regulator	Homo sapiens	184-189
21292355-2	2011	Linear PUR conjugates were prepared by the reaction between oligo(e-caprolactone) (PCL), oligolactide (PLA), copolymers of e-caprolactone (CL) and rac-lactide (rac-LA), dihydroxy(polyethylene adipate) (OEDA) with 1,6-diisocyanatohexane (HDI).	polycaprolactone	66-80	PHD finger protein 1	Homo sapiens	83-86
21147501-1	2011	This study investigates the effect of surface cross-linked heparin on vascular endothelial growth factor (VEGF)-mediated angiogenesis in porous polycaprolactone (PCL) scaffolds in vivo.	polycaprolactone	144-160	vascular endothelial growth factor A	Mus musculus	70-104
21147501-1	2011	This study investigates the effect of surface cross-linked heparin on vascular endothelial growth factor (VEGF)-mediated angiogenesis in porous polycaprolactone (PCL) scaffolds in vivo.	polycaprolactone	144-160	vascular endothelial growth factor A	Mus musculus	106-110
21147501-0	2011	The enhancement of VEGF-mediated angiogenesis by polycaprolactone scaffolds with surface cross-linked heparin.	polycaprolactone	49-65	vascular endothelial growth factor A	Mus musculus	19-23